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 SUMMARY 
Multiple myeloma remains an incurable disease due to the failure of currently available chemotherapies 
to eradicate all the tumour cells from bone. Tumour cells alter the processes of bone resorption and 
bone formation to promote the development of osteolytic bone disease. Targeting osteoclastic bone 
resorption with bisphosphonates, including zoledronic acid has been shown to be effective in 
preventing tumour-induced bone disease. In addition to preventing bone disease, there is increasing 
evidence to suggest that altering the bone microenvironment by inhibiting osteoclastic bone resorption 
reduces tumour burden in bone. However, the mechanisms responsible are not clear. In order to 
develop effective therapeutic strategies, it is essential to understand the interactions between tumour 
cells and the bone microenvironment during disease progression from single tumour cells that home to 
the bone to the development of overt tumour colonies. 
In order to characterise the interactions between tumour cells and the bone microenvironment, an in 
vivo murine model of myeloma was utilised by injecting 5TGM1 murine myeloma cells expressing 
eGFP and labelled with DID into C57BL/KaLwRij mice. Data presented in this thesis show myeloma 
cells engrafted in the bone as early as 3 days and formed colonies after 10 days post tumour cell 
injection. Tumour-induced alterations in bone remodelling occurred only at the end-stage of the 
disease when the mice showed signs of clinical illness. However, development of osteolytic lesions 
occurred as early as 10 days post tumour cell injection prior to an increase in osteoclast numbers and 
serum TRACP5b levels or a decrease in osteoblast numbers and serum P1NP levels. Furthermore, this is 
the first study to identify a subpopulation of quiescent myeloma cells in proximity to bone which 
suggests the existence of specific niches, which may render cells dormant. However, this warrants 
further investigation. 
Treatment studies showed that early initiation of zoledronic acid treatment (125 µg/kg, subcutaneously, 
twice-weekly) prior to tumour cell injection is effective not only at inhibiting the development of 
osteolytic lesions but also at inhibiting the late stage tumour burden in bone. Interestingly, ZA 
treatment started prior or after tumour cell injection did not affect the early stages of myeloma colony 
formation suggesting that the process of expansion from single cells to colonies is not reliant on a so 
called ‗vicious cycle‘ in the 5TGM1 murine model of myeloma. In a separate experiment, zoledronic 
acid treatment started prior or at the time of tumour cell injection demonstrated a significant increase 
in disease-free survival when compared with untreated controls (24 vs. 21 days). 
Taken together, the data presented in this thesis demonstrate that zoledronic acid treatment, in the 
5TGM1 murine model of myeloma started prior to tumour cell arrival in bone is not only able to 
prevent the development of bone disease but also reduce tumour burden and increase disease-free 
survival. 
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1 . 1  M U L T I PLE  M Y E LO M A ( M M )  
Multiple myeloma (also known as myeloma, Kahlers‘disease or myelomatosis) is an incurable 
malignancy of antibody producing plasma cells. It is the second most common cancer of the blood and 
accounts for 1-2% of all cancers excluding non-melanoma skin cancer and 10-15% of all haematological 
malignancies (Becker 2011). Plasma cells are terminally differentiated B lymphocytes which reside in the 
bone marrow (BM), the soft and spongy tissue found inside the bone. Malignant transformation occurs 
in a plasma cell and this result in uncontrolled proliferation of a single clone that goes on to form 
tumours in multiple locations in the BM. MM cells, like the normal plasma cells, also produce 
immunoglobulins (Ig) but in excessive quantities of homogenous forms. MM is characterised by multi-
organ damage and dysfunction which includes bone pain, pathological bone fractures, anaemia and 
pancytopenia resulting in increased susceptibility to infections, clotting abnormalities, hypercalcaemia, 
renal failure and hyperviscosity syndrome. 
There are 5 different types of myeloma based on the type of immunoglobulin that is produced by the 
malignant plasma cells. The immunoglobulins are G, A, M, D and E. But in each patient, there is only 
one type of immunoglobulin that is produced excessively with IgG being the commonest and IgE being 
the rarest. In about 20% of myeloma patients only a part of the immunoglobulin will be produced 
known as light chain as they lack the heavy chain component of a complete immunoglobulin. This type 
of myeloma is known as light chain myeloma. The free light chains are excreted in the urine where 
they are called Bence Jones protein and hence this type of myeloma is also called Bence Jones 
myeloma. This type of myeloma is diagnosed by urine protein electrophoresis for Bence Jones proteins. 
Non-secretory myeloma is another type seen in about 2% of the myeloma patients where is no 
detectable levels of M proteins in blood or light chains in urine. As there is no detectable level of M 
proteins in the serum or urine, it is difficult to diagnose this type of myeloma. Non-secretory myeloma 
is diagnosed using a free light chain test (Freelite test) for the initial diagnosis which can be used to 
measure very small levels of free light chains in the serum. 
Although archaeological evidence suggests the existence of MM from skeletal defects observed from 
dinosaur skeletons of the Mesozoic era (Capasso 2005), the first well-documented case of myeloma 
was recorded by Solly in 1844 as a case of ‗mollities ossium‘ (pathological softness and fragility of 
bones) (figure 1.1-1) (Solly 1844). Currently, there are 86000 new cases of myeloma diagnosed annually 
and it is responsible for 63000 deaths worldwide (Becker 2011). Although a relatively rare cancer, it is 
estimated that there are lifetime risks of 1 in 115 for men and 1 in 155 for women of developing 
myeloma in the UK. MM is primarily a disease of the elderly with incidence rates increasing with age 
and currently the median age at diagnosis is 65 years although it remains rare under the age of 40 
(Myeloma incidence statistics 2011, Cancer Research UK). 
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Figure 1.1-1: First recorded case of MM - Sarah Newbury with fractured femur and humerus. 
The first well-documented case of MM, Sarah Newbury a 39 yr. old female described by Dr. Samuel Solly in his 
―Remarks on the Pathology of Mollities Ossium with cases‖ published in 1843. (A) Diseased sternum from the 
myeloma patient where there is patchy replacement of the red marrow substance. (B) Sarah Newbury showing 
MM fractures in both femurs and the right humerus. (C) Extensive bone destruction in the femur following 
advanced MM. Adapted from (Solly 1844) with permission. 
1 . 1 . 1   M Y E LO M A  AE T IO P AT HO GE N E S I S  &  C L IN I C A L  M AN IF E ST A T IO N S  
The aetiology of MM is not known. Multiple chromosomal abnormalities have been identified in MM 
patients and in some monoclonal gamopathy of undetermined significance (MGUS) patients, an 
asymptomatic premalignant condition that may progress to myeloma (Drach et al., 1995, Zandecki et 
al., 1995, Winter et al., 2008). Karyotypic abnormalities include chromosomal gain (in about 30% of 
cases) such as trisomy‘s in 1q, 3q, 9q, 11q and 15q and chromosomal loss (about 50% of cases) with the 
most common being a deletion in 13q (monosomy 13) (Hallek et al., 1998). Reciprocal translocations 
involving the immunoglobulin locus that affect B-cell specific DNA remodelling mechanisms has been 
identified in both the early and the late stages of MM. Reciprocal translocations that put an oncogene 
next to an immunoglobulin loci (Ch. 14q32) may result in defective DNA modification mechanisms like 
VDJ recombination, somatic hypermutation of B lymphocytes in the germinal centres (GC) and 
immunoglobulin heavy chain (IgH) recombination. The most frequent oncogene translocation sites 
include the cyclin D loci (11q13 and 6p21), multiple myeloma SET domain containing protein (MMSET) 
and fibroblast growth factor receptor 3 (4p16), c-MAF (16q23) and c-MYC (8q24) (Gutierrez et al., 
2007, Anderson 2011). 
Although several karyotypic abnormalities were identified in myeloma patients, the precise aetiological 
factors responsible for the development of the disease remain unknown. No significant association was 
found between MM and common cancer risk factors like smoking, alcohol, dietary habits and physical 
activity. However, studies have shown an increased incidence of MM in people exposed to ionising 
radiations, agricultural workers, miners, farmers, wood and metal workers (Dittel et al., 1993). 
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Furthermore, there is also evidence suggesting a genetic predisposition to the condition with an 
increased incidence in the first-degree relatives of myeloma patients (Vachon et al., 2009). 
The clinical signs and symptoms seen in MM are due to the infiltration of the BM with myeloma cells, 
secretions of the myeloma cell and their interaction with the host cells in the BM environment. As 
myeloma cells are malignant and clonally identical, they grow extensively in the BM (figure 1.1-2) 
which produces excessive levels of monoclonal immunoglobulin. Bone pain and pathological fractures 
are the most common clinical manifestation of MM. The expanding myeloma cells inside the BM 
activate osteoclasts, the bone destroying cells resulting in multiple osteolytic lesions causing bone pain 
and fractures. Infiltration and expansion of the neoplastic plasma cells in the BM also causes 
haemolysis, decreased erythropoietin levels and reduced red cell production which causes anaemia and 
fatigue. Furthermore, increased synthesis of monoclonal immunoglobulin results in low levels of 
normal antibodies due to decreased production and increased destruction of normal antibodies (Pilarski 
et al., 1986). This results in an immunocompromised state causing recurrent infections. In addition, the 
accumulations of immunoblobulin in the kidneys result in amyloidosis and renal failure. Patients also 
have hypercalcaemia due to excessive bone damage. A small proportion of patients also show signs of 
bleeding or clotting disorders due to myeloma cell induced damage to platelets, clotting factors and 
endothelial cells (Fauci  et al., 2008). 
 
 
Figure 1.1-2: Normal and myeloma BM aspirate. 
(A) A normal BM aspirate showing erythroid and granulocytic precursors. (B) A BM aspirate from a patient with 
MM showing numerous myeloma cells (black arrows) with eccentric nuclei and perinuclear halos of clearer 
cytoplasm. Reproduced with permission from The Internet Pathology Laboratory for Medical Education, Mercer 
University School of Medicine, The University of Utah Eccles Health Sciences Library©. 
  
A. NORMAL B. MULTIPLE MYELOMA 
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1 . 2  B I O L O G Y  O F  M U LT IP L E  M YE L O M A  
Myeloma cells are malignant clones of terminally differentiated post-GC long-lived memory B cells that 
home and grow inside the BM. 
1 . 2 . 1  N O RM A L  PL A S M A  C E L L  A N D  M Y E L O M A  C E L L  D E V E LO P ME N T  
Pre-B cells and naïve B lymphoblasts migrate from the BM to peripheral lymphoid tissues like the 
spleen, lymph nodes and Peyer‘s patches where they transform into mature lymphoblasts upon 
antigenic recognition and stimulation. Terminal plasmacytic differentiation of mature B cells is 
dependent on the temporo-spatial arrangement within the B cell compartment inside the lymphoid 
tissue. Marginal zone B cells (MZB) of the lymphoid follicles correspond to the first wave of the 
immune response following antigenic stimulation. MZB cells migrate to the extra-follicular region 
where they proliferate and provide ―T cell independent immune response‖ by producing IgM 
antibodies to fight infection. MZB are short-lived plasma cells and usually die after 3 days undergoing 
apoptosis. However, B cells located in the follicular zone (follicular B cells) migrate into the GCs of the 
spleen and undergo ―T cell dependent antigen recognition and stimulation‖. Inside the GCs the 
follicular B cells proliferate, undergo extensive somatic hypermutation, antigenic selection and VDJ 
recombination to produce long-lived IgG antibody secreting plasmablasts and non-secreting memory B 
cells. These plasmablasts migrate from the GCs into the circulation where they terminally mature into 
plasma cells. Some non-secreting plasma cells migrate to the BM where they reside as memory B cells 
or as the BM immunoglobulin secreting plasma cells (figure 1.2-1) (Hallek et al., 1998, Rogers et al., 
1999). However, in MM, malignant transformation occurs in the post GC phase following damage to 
the B cell specific DNA remodelling mechanisms. As mentioned earlier, several chromosomal 
abnormalities have been identified in MM which damages genes within immunoglobulin loci which 
regulates the sequential DNA modification processes such as VDJ recombination, somatic 
hypermutation and isotype switching that are involved in the terminal differentiation of mature plasma 
cell (Hallek et al., 1998). 
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Figure 1.2-1: Biology of plasma cell development. 
Immature B cells from the BM migrate to the site of infection and upon antigenic stimulation transform to mature 
B cells: the plasmablasts and memory B cells. Plasmablasts transform to short-lived plasma cells where they 
eventually terminate, while memory B cells migrate to the GC and upon antigenic stimulation undergo isotype-
switching to become long-lived plasma cells. In MM, mutations of certain oncogenes cause malignant 
transformation (isotype-switching and extensive somatic hypermutation of the VH gene) of the long-lived plasma 
cells which mature into myeloma cells that home to the BM (Hallek et al., 1998). 
1 . 3  S T A GE S  O F  M UL T I PLE  M Y E LO M A  D E V E LO P M E N T  
Unlike other haematological malignancies, the early stages of MM development are strictly confined to 
the intramedullary compartments of the bone where the disease becomes symptomatic. Recently 
studies have shown that all MM patients are preceded by MGUS, a premalignant asymptomatic 
condition characterised by elevated serum monoclonal protein levels (<3g/dl), elevated plasma cells 
(<10%) and no end-organ damage (Uchiyama et al., 1992, Van Driel et al., 2002). Smouldering MM 
(SMM) is the next stage of progression where the disease still remains asymptomatic although there are 
elevated levels of serum monoclonal protein (>3g/dl) and elevated plasma cells (>10%) (Menu et al., 
2004). Following an increase in the proportion of the BM plasma cells and serum M protein the 
disease becomes clinically evident with tissue and organ involvement known as symptomatic myeloma. 
Diagnostic criteria for symptomatic myeloma include elevation of clonal plasma cells > 10% in BM 
biopsy, presence of M protein in serum or urine and presence of myeloma related organ or tissue 
impairment (ROTI). Components of the myeloma-related ROTI published by the International 
Myeloma Working Group (2003) include elevated serum calcium levels (>0.25 mmol/l above normal 
or >2.75 mmol/l), impairment in renal functions (serum creatinine >175 mmol/l), anaemia (<2 g/dl of 
the normal level or <10g/dl) and bone involvement (lytic lesions or fracture) (CRAB acronym) or 
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symptomatic hypervisocsity, amyloidosis or recurrent infections. In some MM patients, there is 
extension of myeloma cell growth outside the BM either by local extension through cortical damage or 
by haematogenous spread where it is called extramedullary disease (EMD) in MM. EMD can involve 
organs such as skin, lungs, liver, lymph nodes and breast resulting in multi-organ damage (Varettoni et 
al., 2010). Figure 1.3-1 shows the different stages of myeloma development. 
 
Figure 1.3-1: Stages of myeloma development. 
1 . 3 . 1  M G U S  A N D  S M O LD E R I N G  M UL T I PLE  M Y E L O M A  ( S M M)  
Both MGUS and SMM are asymptomatic, premalignant plasma cell dyscrasias characterised by 
continuous monoclonal plasma cell expansion with no associated end-organ damage. MGUS is 
prevalent in 3% of the population above 50 years of age (with an age associated increase in 
prevalence) whereas SMM accounts for 15% of newly diagnosed cases of MM (Rajkumar 2005). 
Currently, as these conditions remain asymptomatic, no specific treatment is recommended until 
symptoms develop. These patients are at a life-time risk for progression to overt MM or other 
malignancies and require life-long monitoring. However, a number of clinical trials are currently 
underway, testing the effects of early administration of anti-myeloma chemotherapy to these patients. 
Rajkumar and colleagues (2003) showed that thalidomide treatment in SMM or indolent myeloma 
patients delayed progression to overt disease. Moreover, Mateos and colleagues (2013) recently 
showed that a combination of lenalidomide and dexamethasone in patients with high risk SMM 
successfully delayed the onset of symptomatic MM and also improved their overall survival (OS). In 
another phase III randomised trial, it was showed that a combination of thalidomide and zoledronic 
acid (ZA) prolonged the development time to symptomatic MM when compared with a ZA only 
treatment group (Witzig et al., 2013). Taken together, these studies support the early intervention of 
myeloma using newer chemotherapeutic agents with tolerable toxicity compared to older alkylating 
agents which were either ineffective or led to long-term toxicity. 
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1 . 3 . 2  I N T R AM E D U LL A R Y  M Y E LO M A 
The interaction between the myeloma cell and the BM microenvironment has been implicated in the 
homing and survival of myeloma cells in the BM. Stromal dependency of myeloma cells is seen during 
the early and the main course of the disease. In the later stages of the disease, myeloma cells may 
become stromal-independent and may migrate to extramedullary sites (Van Riet et al., 1998, Damaj et 
al., 2004). Several studies have indicated that myeloma cells show immunophenotypic and histological 
similarities to normal B lymphocytes at a particular stage of differentiation (Kubagawa et al., 1979). It is 
the intrinsic feature of B cells to migrate to the BM following maturation to long-lived plasma cells. B 
cells express a diverse range of adhesion molecules during their maturation phase allowing them to 
migrate into different compartments. This is coordinated by various cytokines and chemokines which 
play a critical role in guiding plasma cells to specific BM niches (Dittel et al., 1993, Kaisho et al., 1994, 
Koenig et al., 2002). As myeloma cells are malignant clones of normal plasma cells, the BM stromal 
dependency for survival might be a feature acquired from their non-malignant counterpart.  
Chemokines like stromal cell-derived factor 1 (SDF-1, also known as CXCL-12) and monocyte chemo-
attractant protein-1 (MCP-1) play a critical role in the initial attraction of myeloma cells to the BM. 
MCP-1 expression by the BM endothelial cells (BMEC) causes the initial attraction of the circulating 
myeloma cell which express CXCR-2 receptors to adhere to the vascular endothelium of the BM while 
SDF-1 secreted by the BMSCs binds with the CXCR-4 receptor expressed on the myeloma cell (Lee et al., 
2001, Sanz-Rodriguez et al., 2001, Vanderkerken et al., 2002, Alsayed et al., 2007). CXCR-4 is a 
chemokine receptor expressed by haematopoietic progenitor cells (HPC) and plasma cells that play a 
critical role in the homing of cells to the BM (Aiuti et al., 1997, Aparicio et al., 1998, Shipman et al., 
1998, Kawabata et al., 1999, Fooksman et al., 2010). Studies have shown there is enhanced expression 
of CXCR-4 by the terminally differentiated post GC phase plasma cells (Iguchi et al., 2003). CXCR-4 
expressing cells migrate in response to CXCL-12, the unique ligand to CXCR-4. Erickson and colleagues 
(2003) demonstrated the selective inability of plasma cells to home to the BM in CXCL-12 deficient 
New Zealand Mixed (NZM) lupus mice. Myeloma cells express various adhesion molecules like very 
late antigen 4 and 5 (VLA-4 and VLA-5), CD44v, intercellular adhesion molecule 1 (ICAM-1), leukocyte 
function associated antigen (LFA-1), syndecan 1 (also known as CD138) and cadherins which promote 
the binding of the myeloma cells to the BM mileu (Diel 2000, Asosingh et al., 2001, Van Driel et al., 
2002, Guenther et al., 2010). Studies have demonstrated that SDF-1/CXCR-4 interaction results in an 
up-regulation of VLA-4 expression in MM cells, which promotes adhesion to fibronectin and VCAM-1 
(Sanz-Rodriguez et al., 2001, Parmo-Cabañas et al., 2004). 
Several groups have reported a diverse expression of matrix metalloproteinases (MMPs) in various 
myeloma cell lines and patient cells. MMPs are zinc-dependent end peptidases that are involved in 
tissue degradation. MM cells were shown to produce MMP-8, 9 and 13 (Barille et al., 1997, Wahlgren 
et al., 2001, Parmo-Cabañas et al., 2006) while BMSCs produce MMP-1 and 2 (Barille et al., 1997). 
MMP expression and activation in MM BM mileu is regulated by several cytokines and the interaction 
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of the MM cells with cells of the BM microenvironment. Syndecan-1, a trans-membrane heparin 
sulphate glycoprotein plays a critical role in binding the MM cells to the collagen thereby activating the 
production of MMP-1 (Catlett-Falcone et al., 1999). Urokinase-type plasminogen activator (uPA) is 
another serine protease, which converts plasminogen to its active form plasmin. Plasmin plays a very 
important role in activating MMPs and induces extracellular matrix degradation (Wong et al., 1992, 
Carmeliet et al., 1997, Noel et al., 1997, Lijnen et al., 1998). Primary myeloma cells and certain 
myeloma cell lines were also shown to express both uPA and uPAR (Hjertner et al., 2000). 
1 . 3 . 3  M U L T I PLE  M Y E LO M A A N D  T HE  BO N E  M AR R O W  M I C RO E N V I RO N ME N T   
The interactions between MM cells and the BM microenvironment are thought to provide necessary 
survival signals for the proliferation of myeloma cells. Invasion of myeloma cells through BMECs and 
the basement membrane exposes myeloma cells to the BM microenvironment. The term BM 
microenvironment includes both the extracellular matrix proteins and the stromal components which 
include BMSCs, osteoclasts, osteoblasts, sinusoidal endothelial cells, macrophages and adipocytes. The 
tumour-host interactions influence several elements in the development of intramedullary myeloma: 
homing and survival of the myeloma cells in the BM; colonisation and intramedullary spread of 
tumour cells; paracrine secretions that ascertain survival advantage and drug resistance of the myeloma 
cells; osteoclastogenesis, inhibited osteogenesis and development of lytic lesions and tumour-induced 
angiogenesis (Thomas et al., 2004).  
Interactions of the myeloma cells with the bone microenvironment are mediated by direct cell to cell 
contact or paracrine secretions. Myeloma cells express various adhesion molecules and integrins which 
mediates their interactions with ECM proteins and BMSCs (Komori 2010). Subsequently, the BM 
microenvironment produces several cytokines and chemokines after interacting with myeloma cells 
which helps tumour cell growth and protects them from apoptosis. Tumour cells interact with BMSCs 
or extracellular matrix proteins by direct cell to cell or cell to matrix contact through the expression of 
adhesion molecules such as VLA-4, VLA-5 and CD40 (figure 1.3-2). 
The interactions of myeloma cells with BMSCs 
The BM microenvironment produces several cytokines and chemokines after interacting with the 
myeloma cells which helps their growth and protects them from apoptosis. Various adhesion molecules 
including VLA-4 and ICAM-1 mediate the adhesion of the myeloma cell to the BMSCs (Uchiyama et al., 
1992, Uchiyama et al., 1993). Studies have shown that the adhesion of myeloma cells to BMSCs results 
in enhanced expression of IL-6 by both cell types, which supplies survival and proliferative signals and 
confers drug resistance to myeloma cells by paracrine and autocrine mechanisms (Uchiyama et al., 
1993, Chauhan et al., 1996). Adhesion of myeloma cells to BMSCs triggers the activation of the nuclear 
factor kappa B (NF-kB) pathway which further enhances adhesion by upregulating more adhesion 
molecules in both cell types (Uchiyama et al., 1993, Chauhan et al., 1996). Moreover, IL-6 expression 
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in BMSCs is also up-regulated via an NF-kB dependent pathway (Hideshima et al., 2001). IL-6 was 
shown to trigger phosphorylation of the signal transducer and activation of transcription 3 (STAT3) 
pathway via Janus-kinase 1 (JK-1), activation of Ras/mitogen-activated protein kinase (MAPK) pathway 
and the phosphatidylinositol-3 kinase (PI-3K) pathway which results in the production of anti-apoptotic 
and proliferative signals for myeloma cells (Ogata et al., 1997, Hideshima et al., 2001, Brocke-Heidrich 
et al., 2004, Van De Donk et al., 2005). However, IL-6 blockade did not evoke a substantial anti-
myeloma effect and myeloma cells were found to survive when co-cultured with BMSCs (Trikha et al., 
2003, Chatterjee et al., 2004). This suggests that interactions between the myeloma cells and the BM 
microenvironment additionally stimulate IL-6 independent mechanisms for the survival of the myeloma 
cell. Chatterjee and colleagues (2004) demonstrated that the interactions of BMSC with myeloma cells 
stimulates Ras/MAPK pathway in myeloma cells which is independent of IL-6R blockade. 
Insulin like growth factor-I (IGF-1) is another important chemokine produced by BMSCs upon 
interacting with myeloma cells. It was shown to have a synergistic effect on myeloma cell survival and 
proliferation through an IL-6 independent mechanism by activating both MAPK and PI-3K pathways 
(Ferlin et al., 2000). Various other cytokines have been identified that play an important role in the 
anti-apoptotic effects which include interleukin IL-1α, IL-1β, basic fibroblast growth factor (bFGF), 
hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) (Mitsiades et al., 
2007). Although myeloma cell interaction with the BMSCs, either by direct adhesion mediated 
interaction or production of chemokines and cytokines, was shown to activate a number of different 
pathways in the myeloma cell, they all converged to a common downstream event enhancing anti-
apoptotic signals and degrading pro-apoptotic signals giving a survival advantage to the myeloma cell 
in the BM microenvironment. 
The interactions of myeloma cells with BMECs & neovascularisation 
Tumour angiogenesis is an important event responsible for the growth and expansion in solid tumours. 
Myeloma cells produce several pro-angiogenic and angiogenic molecules like VEGF, b-FGF, 
transforming growth factor-β (TGF-β), platelet derived growth factor (PDGF), HGF and IL-1 both by 
autocrine and paracrine mechanisms upon interaction with BMSCs and BMECs (Vacca et al., 1999, 
Gupta et al., 2001, Ria et al., 2003, Hideshima et al., 2007). All these factors are involved in the 
growth and differentiation of vascular endothelial cells and the recruitment of new vessels in the BM. 
Vacca and colleagues (2003) demonstrated that myeloma BMECs express various adhesion molecules 
and receptors which confers them to have high angiogenic and vasculogenic ability compared to 
human umbilical vein endothelial cells (HUVEC). Furthermore, adhesive interaction of BMECs with the 
myeloma cells enhance the invasiveness of myeloma cells by stimulating the production of MMP-2 and 
MMP-9 which in turn release bone growth factors favouring myeloma growth (Vande Broek et al., 
2004). 
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The interactions of myeloma cells with osteoblasts  
Studies showed that certain myeloma cell lines upon interaction with osteoblasts via direct cell to cell 
contact release IL-6 which in turn enhances the survival potential of myeloma cells (Barille et al., 1995, 
Franchimont et al., 2000). However, at present the direct role of osteoblasts on myeloma cell survival 
is not known. Interestingly, myeloma cells have an inhibitory effect on osteoblastogenesis both by 
direct adhesive interaction with osteoblast progenitors, causing down regulation of RUNX2 
transcription factor which plays an important role in osteoblast differentiation, and by the production 
of soluble Wnt inhibitory factors like dickkopf 1 (DKK1) and frizzled ring protein 2 (FRP2) (Tian et al., 
2003, Thomas et al., 2004, Oshima et al., 2005, Abe et al., 2006, Giuliani et al., 2006a, Chim et al., 
2007, Komori 2010). Osteoblasts also regulate the expression of the receptor for activation of nuclear 
factor kappa B ligand (RANKL) and osteoprotogerin (OPG), which are positive and negative mediators 
of osteoclast differentiation respectively. Therefore, myeloma cells, in addition to their direct effect on 
osteoclastogenesis, also regulate osteoclasts indirectly through osteoblast inhibition (Glass Ii et al., 
2005, Spencer et al., 2006). 
The interactions of myeloma cells with osteoclasts 
MM cells produce several cytokines and growth factors for the activation and maturation of osteoclasts 
in the BM microenvironment. Studies have shown that the interaction of myeloma cells with BMSCs 
and osteoclasts results in a coordinated increase in osteoclastogenic factors such as IL-6, IL-1β, 
macrophage-colony stimulating factor (M-CSF), tumour necrosis factor- α(TNF-α), VEGF, and MIP-1
α, 1β (Sati et al., 1999, Oyajobi et al., 2003, Mitsiades et al., 2007) and suppression of negative 
regulators of osteoclastogenesis such as OPG (Qiang et al., 2008) resulting in uncontrolled 
osteoclastogenesis and bone resorption. Hecht et al., (2008) using an in vitro coculture system 
demonstrated that interactions of myeloma cells with osteoclasts resulted in activation of p44/p42 
MAPK STAT3 and Akt signalling and promoted the growth of the myeloma cell. Furthermore, they 
also showed that these interactions also resulted in an up-regulation of p38 MAPK and NF-kB signalling 
pathways which are involved in osteoclastogenesis. Another group showed that the interactions 
between myeloma cells and osteoclasts resulted in an increased secretion of chondroitin synthase 1, a 
soluble protein prominently seen in myeloma cells and osteoclast cocultures which support myeloma 
cell survival by stimulating notch-2 signalling (Yin 2005). Abe et al., (2004) demonstrated that the 
binding of myeloma cells to osteoclasts through cell surface receptors promoted myeloma cell growth 
and also enhanced the release of IL-6 and osteopontin which in turn promoted myeloma cell survival. 
Anti-IL-6 and anti-OPN neutralising antibodies were not able to fully abrogate the osteoclast mediated 
survival of the myeloma as it was suggested to be more dependent on a direct physical contact with 
the osteoclasts. Furthermore, the same group also showed that myeloma-osteoclast interactions had a 
more potent growth promoting effect than myeloma-BMSC interactions (Vanderkerken et al., 2003b). 
Two other molecules, B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL), 
produced by osteoclasts were shown to promote growth and anti-apoptosis in certain myeloma cell 
J Gurubalan|Page|12  
 
lines (Moreaux et al., 2004, Abe et al., 2006). In addition, Tanaka et al., (2007) showed that the 
interactions between myeloma cells and osteoclasts resulted in enhanced angiogenesis by secreting 
proangiogenic factors, VEGF and osteopontin. 
 
Figure 1.3-2: Interactions of the myeloma cells with the BM 
Myeloma cells interact with the BMSCs via expression of molecules such as VLA-4, CD40, and LFA-1. Close cell to 
cell contact with the BMSC results in the secretion of RANKL which binds to RANK receptors resulting in the 
maturation of osteoclasts.  Myeloma cell interaction with the BMSCs also releases osteoblast inhibitors such as 
DKK-1 which in turn suppresses OPG production, a soluble decoy receptor for RANK. This in turn also promotes 
osteoclastogenesis. Following osteoclast maturation bone resorption ensues resulting in the release of bone matrix 
derived growth factor such as IL-6 and TGF-β which supports myeloma cell proliferation and survival inside the 
BM. This establishes a ‘vicious‘ cycle between myeloma cells and osteoclast. RANK= receptor for activation of 
nuclear factor kappa B, RANKL= receptor for activation of nuclear factor kappa B ligand, DKK-1=Dickkops-1,VLA-
1=Very late antigen-1, LFA= leukocyte function associated antigen. 
Bone derived growth factors 
During osteoclastic bone resorption several growth factors and cytokines are released from the bone 
tissue into the surrounding BM microenvironment. These include factors like IGF, TGF-β, b-FGF and 
PDGF (Mohan and Baylink 1991). Additionally, there is also release of calcium (Ca
2+
) and phosphate 
(PO4) due to the breakdown of hydroxyapatite crystals, a major component of the bone mineral 
matrix (Yoneda and Hiraga 2005). The role of IGF, TGF-β, b-FGF and PDGF in myeloma cell survival, 
proliferation and drug resistance has already been discussed above. Following resorption there is 
abundant release of bone derived factors into the resorption pit under the osteoclast and into the BM. 
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This makes the BM niche a very fertile environment for cells to grow. Yamaguchi and colleagues 
(2002) showed that certain myeloma cells express calcium sensing receptors (Ca
2+
R). These cells 
showed proliferative effects when stimulated with Ca
2+
. The copious release of growth factors supports 
the survival and proliferation of myeloma cells which in turn activates more osteoclasts thereby 
establishing a ‗vicious cycle‘ leading to uninterrupted bone damage and subsequent tumour expansion. 
Furthermore, anti-resorptive agents such as bisphosphonates (BPs) and human anti-RANKL antibody 
(Denosumab) have been shown to reduce tumour burden in in vivo preclinical models of myeloma 
and in clinical trials (Rogers et al., 2000, Sordillo and Pearse 2003, Vanderkerken et al., 2003b, Avilés 
et al., 2007, Morgan et al., 2010a, Iqbal et al., 2011). However, the mechanisms responsible are not 
clearly understood yet. 
1 . 3 . 4  M Y E LO M A  B O N E  D I S E A SE   
Myeloma bone disease (MBD) is not merely a functional consequence of the disease progression on the 
BM microenvironment; it is an ongoing process which promotes MM cell survival and tumour growth. 
Interactions of myeloma cells with BMSCs results in the production of several osteoclast activating 
factors (OAFs) which include RANKL, macrophage inflammatory protein-1α (MIP), VEGF, IL-6 and 
TNF-α (Lacey et al., 1998, Fuller et al., 2002, Henriksen et al., 2003, Heider et al., 2004). RANKL is a 
TNF-related activation-induced cytokine which binds to the RANK receptor on osteoclasts and is 
involved in the activation and differentiation of precursor osteoclasts into mature and functionally 
active osteoclasts (Lacey et al., 1998). In normal conditions, RANKL is secreted by osteoblasts, BMSCs 
and BMECs. The extent of osteoclast activation and consequent bone resorption is limited by the 
production of OPG, a soluble decoy receptor antagonist for RANKL, mainly produced by osteoblasts 
and BMSCs (Kong et al., 1999). However, in MM there is an up-regulation of RANKL expression by 
both myeloma cells and the BMSCs (Croucher et al., 2001, Giuliani et al., 2001). Moreover, myeloma 
cells were shown to inhibit OPG synthesis by osteoblasts and BMSCs both in vitro and in vivo (Pearse 
et al., 2001). Additionally, Standal and colleagues (2002) showed MM cells, by their transmembrane 
heparin sulphate proteoglycan syndecan-I, binds, internalises and degrades circulating OPG. Thus in 
MM, the RANKL/OPG balance is disrupted resulting in enhanced osteoclastic activity and a subsequent 
increase in osteoclastic bone resorption.  
Myeloma cells also produce MIP-1αthat directly acts through the receptors CCR1, CCR5 and CCR9 
expressed on osteoclasts. They promote osteoclast maturation and differentiation both independently 
of RANKL as well as supporting RANKL and IL-6 induced osteoclast activation (Dunford et al., 2001). 
Studies have shown that MIP-1αmRNA levels from the BM plasma and serum levels of the protein 
correspond to the severity of the bone disease in myeloma patients (Choi et al., 2000, Terpos et al., 
2003). Furthermore, a neutralising antibody to MIP-1α and anti-sense blocking showed inhibition of 
osteoclast activation and reduction of MBD in a murine model of myeloma (Choi et al., 2000, Choi et 
al., 2001). VEGF is another angiogenic cytokine produced by myeloma cells, BMSCs and BMECs and it 
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plays a critical role in osteoclast activation, maturation and migration (Henriksen et al., 2003, Yang et 
al., 2008). Lee and colleagues (2004) showed IL-3 produced by myeloma cells activates osteoclasts 
along with RANKL and MIP-1α and was consistently found elevated in MM patients. Recently, T 
lymphocytes in the BM plasma of myeloma patients were shown to produce IL-3 and were involved in 
osteoclastogenesis (Giuliani et al., 2006a). A number of other cytokines such as IL-6, TNF-α, IL-1β 
were also shown to be regularly elevated in patients with MBD. 
1 . 3 . 5  M U L T I PLE  M Y E LO M A W I T H  E X T R A M E D U LL A R Y  D I S E ASE  ( E M D )  
EMD is a condition where there is spread of MM from bone to extraskeletal sites such as kidneys, liver, 
skin and central nervous system during disease progression. Varettoni et al., (2010), in a longitudinal 
study involving 1003 MM patients showed that 7 to 18% of newly diagnosed patients had EMD and 6 
to 20% developed the disease later during follow-up. Extramedullary spread occurs either as a result of 
direct extension from intramedullary tumour to the local soft tissues through disrupted cortical bone or 
via metastatic haematogenous spread to distant sites. Disruption in the normal homing mechanisms of 
the myeloma cells to bone has been attributed to the development of EMD. Studies have suggested 
that decreased expression of adhesion molecules such as CD44, CD56 and VLA-4 and down regulation 
of chemokine receptors such as CXCR-4 and CXCL-12 to be responsible for the dissemination of tumour 
cells from the primary site (Blade et al., 2012). It has been shown that myeloma patients who develop 
EMD have been consistently associated with aggressive disease and poorer prognosis (Damaj et al., 
2004, Ping Wu 2009). Studies have also shown that the extramedullary plasmacytoma varies 
characteristically from the medullary disease even in the same patient such as p53 deletion which was 
seen only in the extramedullary clone and remained refractory to conservative treatments that were 
used for the systemic disease (Lopez-Anglada et al., 2010).    
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1 . 4  T HE  U SE  O F  B I S P HO S P H O N AT E S  I N  M Y E L O M A  M A N A GE ME N T  
Approximately 70-80% of myeloma patients develop MBD characterised by development of bone 
pain, bone fracture and hypercalcaemia. Currently, BPs are used as osteo-protective agents for the 
symptomatic management of cancer-induced bone disease in conditions such as MM, breast and 
prostate cancer. BP‘s improve bone health by reducing tumour cell induced bone damage and cancer-
induced hypercalcaemia. BPs are a class of compounds that are synthetic analogues of the inorganic 
pyrophosphates where the central oxygen atom (P-O-P) is replaced by a carbon atom (P-C-P) (figure 
1.4-1 A and B). The substitution of the central O2 moiety to the backbone of the naturally occurring 
inorganic pyrophosphate has made BPs more stable, resistant to degradation, biologically active and 
water soluble compounds (Green 2005). The P-C-P backbone motif of the BP acts as a bone-hook 
binding it to the hydroxyapatite of the bone. This affinity of the BPs is because of their intrinsic 
property to bind divalent cations such as Ca
2+
. Substitution of the R1 side chain with a hydroxyl (-OH) 
or primary amino (-NH2) group increases its binding affinity to bone as it permits a tridentate 
conformation (figure 1.4-1 C) which binds with Ca
2+
 ions more effectively than substitutions with 
chlorine (Cl
-
) or hydrogen (H
+
) ions which allows only a bidentate conformation (Van Beek et al., 
1998, Rogers et al., 2000, Reszka and Rodan 2003, Papapoulos 2006). Although the entire molecular 
structure is essential for the biological potency of these drugs, the structure of the R2 side chains 
significantly alters their anti-resorptive potency (Van Beek et al., 1998, Winter et al., 2008). 
 
Figure 1.4-1: Tridentate configuration of bone binding by bisphosphonates. 
The chemical structure of a pyrophosphate (A), BP (B) and the tridentate configuration of a BP with Ca
2+
 ion (C). 
The substitution of the OH group at R1 allows a tight binding with the exposed Ca
2+
 ion at sites of active 
resorption. The presence of an additional OH group at R1 contributes to one more covalent bond between the BP 
and Ca
2+
 in the hydroxyapatite bone matrix. 
A. PYROPHOSPHATE B. BISPHOSPHONATE 
C. TRIDENTATE 
CONFIGURATION 
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1 . 4 . 1  Z O L E D RO N IC  AC I D  (Z A )  
ZA (manufactured and marketed by Novartis pharma in the name of Zometa/ Aclasta/ Reclast) is a 
nitrogen-containing bisphosphonate (NBP) that has been widely used over the past 10 years as an 
osteotrophic agent in the treatment of Paget‘s disease, osteoporosis and also in malignancy associated 
osteolysis and hypercalcaemia. ZA is a heterocyclic imidazole ring with two nitrogen atoms at its R2 
moiety and a hydroxyl (–OH) group at its R1. It is currently the most potent BP commercially available 
with the highest osteoclast inhibitory effect and the broadest clinical application (Green 2005). It was 
initially approved for the treatment of bone disease in MM and other solid tumour. Currently, due to 
increasing evidence of reduction in skeletal related events and improvement in OS and progression free 
survival (PFS) in phase III MM clinical trials, it is included for the management of symptomatic 
myeloma along with standard chemotherapy (Morgan et al., 2010a). 
1 . 4 . 2  A N T I - RE SO R PT IV E  ME C H A N IS M  O F  Z A  
ZA is an effective anti-resorptive agent inhibiting osteoclastic bone resorption thereby preventing bone 
damage. Although all classes of BPs target osteoclasts, their selective activity differs between the group 
of compounds classified as Non-NBPs (e.g. Clodronate & Etidronate) and the NBPs (e.g. ZA & 
Risedronate) (Rogers et al., 2000). The intrinsic property of BPs to have a high affinity to mineralized 
bone matrix, favours the rapid relocation of these molecules from the circulation to areas of active 
bone remodelling, which has rendered them to have a very short plasma half-life and hence low-
plasma circulating levels (Sato et al., 1991, Masarachia et al., 1996, Chen et al., 2002, Green 2003). 
NBPs are internalised into osteoclasts during bone resorption by fluid phase endocytosis (Thompson et 
al., 2006). In agreement, Sato et al., (1991) also showed evidence of intracellular accumulation of 
radio-labelled alendronate (ALN) in various subcellular compartments in rat osteoclasts in vivo. 
NBP inhibits an enzyme in the mevalonate pathway in the osteoclast and other cells that can actively 
uptake them (Amin et al., 1992, Luckman et al., 1998). NBPs inhibits geranyl diphosphate and farnesyl 
diphosphate synthase (FPPS) which plays a critical role in the conversion of isopentenyl diphosphate 
(IPP) into farnesyl diphosphate (FPP) of the mevalonate pathway (Van Beek et al., 1999, Bergstrom et 
al., 2000, Dunford et al., 2001) (figure 1.4-2). Inhibition of FPPS results in loss of prenylation of 
important signalling proteins like Ras, Rho, Rac and hence defective cell signalling, cellular functioning 
and osteoclast inactivation and apoptosis (Rogers et al., 1999, Mönkkönen et al., 2007, Russell et al., 
2008). 
Recently, evidence suggests potent NBPs like ZA produce a cytotoxic analogue of ATP known as ApppI 
(triphosphoric acid 1-adenosin- 5‘–yl ester 3-(3-methyl-but-3-enyl) ester). ApppI in both in vitro and in 
vivo conditions can induce osteoclast apoptosis by blocking mitochondrial ATP/ADP translocase 
(Monkkonen et al., 2006, Mönkkönen et al., 2007). 
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Figure 1.4-2: The inhibition of the mevalonate pathway in osteoclasts by ZA. 
ZA binds to the bone and is released into the resorption pit (A) as a result of substances released by the osteoclast. 
The released ZA is internalised by the osteoclast by fluid phase endocytosis. Inside the osteoclast, ZA inhibits the 
enzyme farnesyl diphosphate synthase (FPPS), an enzyme which plays a key role in the mevalonate pathway (B). 
This in turn inhibits the synthesis of geranyl diphosphate and farnesyl diphosphate which are necessary for protein 
prenylation and the production of intracellular signaling proteins like Ras, Rac & Rho. Further the accumulation of 
Isopentyl diphosphate also results in production of ApppI, a cytotoxic analogue of ATP which is toxic to the 
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1 . 5  T HE  A N T I - M Y E LO M A E F F E C T  O F  Z O LE D RO N IC  AC I D  
Several preclinical studies have established BPs as therapeutic agents for the treatment of tumour-
induced bone diseases, but emerging evidence suggest that BPs may have a role well beyond being a 
mere osteolysis inhibitor. In addition to inhibiting tumour-induced osteolysis, BPs were shown to have 
a remarkable effect on skeletal tumour burden and survival in several preclinical cancer models and 
clinical trials of bone metastasis (Green 2003, Clezardin 2005, Clezardin et al., 2005, Green 2005, 
Avilés et al., 2007, Saad 2008, Morgan and Lipton 2010). 
1 . 5 . 1  I N  V IT RO  E V ID E N C E  O F  AN  A N T I - M YE LO M A  E F F E C T  O F  Z A  
In vitro evidences suggest that BPs have both cytostatic and apoptotic effect not only on osteoclasts but 
also on a variety of tumour cells such as MM, breast cancer, prostate cancer, renal cell carcinoma, 
pancreatic cancer and osteosarcoma (Shipman et al., 1997, Shipman et al., 1998, Senaratne et al., 2000, 
Lee et al., 2001, Kubista et al., 2006, Horie et al., 2007, Ullén et al., 2008). Baulch-Brown and 
colleagues (2007) showed that ZA had a dose and time-dependent apoptotic effect on NCI-H929, 
RPMI8226, LP-1, OPM-2 cells and induced cell cycle arrest in the NCI-H929 cell line. Shipman et al., 
(1997) demonstrated that NBPs such as pamidronate (PAM) and incadronate has a dose and time-
dependent inhibitory effect on cell proliferation in U226-B1, JJN-3 & HS Sultan myeloma cell lines by 
inducing cell cycle arrest and apoptotic changes in culture. There was no evidence of anti-tumour 
effects observed in any cell lines using non-NBPs such as clodronate (CLO). In addition, studies by 
Tassone et al., (2000) and Ural et al., (2003) showed in vitro synergistic cytoreductive effects on 
myeloma cell growth when ZA was combined with simvastatin, dexamethasone and thalidomide. 
Loss of protein isoprenylation in tumour cells by NBPs has been suggested to be responsible for both 
the reduction in cell proliferation and induction of apoptosis (Shipman et al., 1998). Aparicio and 
colleagues (1998) demonstrated that ZA has more potent cytoreductive effects compared to PAM in 
human myeloma cell lines such as RPMI 8226. ZA induced apoptosis on tumour cells was shown by 
DNA fragmentation and cytoplasmic blebbing. Minodronate, another NBP was reported to exhibit 
cytoreductive effects on the myeloma cell lines HS Sultan, RPMI8226 and U266 is (Iguchi et al., 2003). 
Recently, it has been demonstrated that ZA had inhibitory effects on the growth of plasma cell lines 
such as RPMI8226, INA-6, JK-6E, L363 and JK-6L with maximum inhibitory concentration (IC50) 
ranging from 23-204 µM. The inhibitory effect was shown to be due to induction of apoptosis using 
annexin-V and actinomycin D apoptotic assay. No evidence of cytotoxic effects was observed in 
peripheral blood mononuclear cell (PBMC) even at a concentration as high as 300 µM (Guenther et al., 
2010). Despite its direct apoptotic effects, NBPs also have an indirect inhibitory effect on myeloma cells 
by inhibiting IL-6 synthesis by the BMSCs and osteoblasts. Kawano et al., (1988) and Catlett-Falcone et 
al., (1999) showed that IL-6 produced by BMSC and osteoblasts plays a very important role in the 
development of myeloma in the BM microenvironment. However, the mechanisms of apoptotic 
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induction by NBPs on myeloma cells were independent of IL-6 production, as exogenous IL-6 did not 
abrogate the apoptotic effects of ZA or PAM (Aparicio et al., 1998, Derenne et al., 1999).    
1 . 5 . 2  P R E - C L IN I C AL  E V ID E N C E  O F  AN  A N T I - MY E LO M A  E F F E C T  O F  Z A  
Yaccoby and colleagues (2002) demonstrated that ZA or PAM treatment resulted in the reduction of 
tumour burden in human bones implanted in SCID-hu mice (severe combined immune-deficient mice 
implanted with human bone) when compared with untreated controls. The reduction in tumour 
burden was shown as a reduction in serum levels of human-paraprotein (hIg). However, no effect was 
seen either with PAM or ZA when the tumour was induced by injecting myeloma cells from patients 
with extramedullary disease. This shows that the extramedullary tumour growth in myeloma were 
insensitive to the inhibitory effects of BPs which suggests that the anti-tumour effect mediated by ZA 
was indirectly through modification of the BM (Yaccoby et al., 2002). In the 5T2MM murine model of 
myeloma, ZA (120 µg/kg) treatment of established tumours resulted in a reduction of tumour-induced 
osteolytic lesions. In addition, ZA treated mice exhibited reduced tumour area, reduction in micro-
vessel density in areas of tumour development in bone, reduction in serum paraprotein levels and 
prolongation of disease-free survival when compared to untreated controls (Croucher et al., 2003a). In 
another preclinical study, ZA treatment was shown to prolong survival in SCID mice injected with INA-
6.Tu1 human myeloma cells. Here, ZA treatment was shown to induce apoptosis in extraskeletal sites. 
Presence of unprenylated forms of Rap1A in tumour homogenates suggests a direct inhibitory effect on 
myeloma cells in vivo via inhibition of mevalonate pathway (Guenther et al., 2010). In another study, 
ZA treatment in the 5TGM1 murine model of myeloma showed significant reduction in tumour burden 
as assessed by changes in serum paraprotein level (Dairaghi et al., 2012). 
1 . 5 . 3  E V ID E N C E  O F  AN  AN T I - M YE LO M A  E F F E C T  O F  Z A  I N  C L I N IC A L  T R A I L S  
A number of clinical trials have suggested that ZA treatment added to standard chemotherapy may 
exert survival benefits in multiple myeloma (MM). The first clinical evidence of anti-myeloma effects in 
BPs was demonstrated by Berenson et al., (1998) who showed that in 198 stage III myeloma patients 
treated with intravenous PAM 2 patients lived longer compared to placebo (14 vs. 21 months, 
P=0.041). Similarly, McCloskey et al., (2001), in a double-blind placebo controlled trial in patients 
without skeletal fractures at the time of treatment showed a significant improvement in survival using 
oral CLO along with standard chemotherapy (59 vs. 37 months; P=0.006). However, in a systematic 
Cochrane Review published in 2002, which included 11 placebo controlled clinical trial involving 2183 
patients using bisphosphonates such as CLO, PAM, etidronate (ETI) and ibandronate (IBN) showed 
reduced vertebral fractures but no mortality benefits in MM patients (Djulbegovic et al., 2002). 
However, in a recently updated network meta-analysis published by Cochran Collaboration including 
6692 patients from 20 randomized clinical trials, addition of ZA along with standard chemotherapy 
showed improved OS when compared with ETI or placebo (Mhaskar et al., 2012). Avilés et al., (2007) 
showed ZA treatment with standard chemotherapy (cyclophosphamide, vincristine, melphalan, and 
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prednisone) improved the event-free survival (EFS) and OS in advanced myeloma patients up to 80% 
compared to 52% and 48% respectively in chemotherapy alone treated control group. In a recently 
conducted phase III clinical trial (myeloma IX study) involving 1960 patients, addition of ZA treatment 
to standard anti-myeloma chemotherapy showed a 16% increase in the OS (50 vs 44.5 months, 
P=0.0118) and a 12% increase in the progression-free survival (PFS) (19.5 vs 17.5 months, P=0.0179) 
when compared to patients treated with oral CLO (Morgan et al., 2010a). More recently, in a single-
centered double blind randomized placebo-controlled study involving 308 previously untreated 
symptomatic myeloma patients using intravenous ZA along with chemotherapy (dexamethasone, all- 
trans- retinoic acid, and interferon alpha 2b) followed by ASCT resulted in a significant prolongation of 
10-year PFS (60.4 vs. 38.4 months; P<0.001) and 10-year OS (67 vs. 48 months; P<0.001) when 
compared with placebo-treated control groups (Avilés et al., 2013). The survival benefit associated 
with ZA treatment with standard chemotherapy was seen only in patients with symptomatic myeloma 
and not in asymptomatic myeloma. Mutso et al., (2008) showed intravenous ZA treatment (4mg, 
monthly) administered for a year in asymptomatic patients did not delay the progression to 
symptomatic disease when compared with untreated control groups over a median follow-up for 64.7 
person-months (67 vs. 59 months; P=0.8312). Despite evidences from clinical trials that CLO or ZA 
addition to chemotherapy prolongs survival in patients with symptomatic myeloma, the exact 
mechanism in which these drugs prolong survival is not clearly known.  It is clear from the MRC 
Myeloma IX study that ZA is superior to CLO in improving OS and PFS in symptomatic myeloma 
patients. Furthermore, the improvement in survival was also shown to be independent of the SRE. 
Therefore, the anti-myeloma effect observed with ZA is either due to a direct cytotoxic effect on the 
tumour cell or an indirect effect associated with modifying the local BM microenvironment remains to 
be established. 
1 . 5 . 4  T HE  ME C H AN IS M S  O F  A N  AN T I - M YE L O MA  E F F E C T  B Y  Z A  
There is clear evidence that ZA either independently or in combination with other chemotherapeutic 
agents, in addition to its anti-resorptive property, also exhibits anti-tumour activity in MM and in other 
solid tumour with bone involvement. ZA exhibits their anti-myeloma effect in several possible ways 
(figure 1.5-1). 
Mechanisms responsible for the inhibitory effect of ZA on myeloma cell  
Several in vitro studies have shown that ZA and certain NBPs have a cytostatic and pro-apoptotic effect 
on primary human myeloma cells and various myeloma cell lines by inhibiting proliferation and 
inducing apoptosis (Croucher et al., 2003b). ZA was shown to achieve maximum inhibitory effect on 
myeloma cell lines in vitro between 10 to 100 µM (Shipman et al., 1997, Aparicio et al., 1998, Derenne 
et al., 1999, Croucher et al., 2003b, Baulch-Brown et al., 2007). Accumulating evidence suggests that 
NBPs induce inhibitory and apoptotic effects in tumour cell lines by inhibiting the mevalonate pathway 
similar to the effect on osteoclasts (Diel 2000). Loss of protein prenylation of small GTPases such as 
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Ras, Rap1A and Rho results in defective downstream signalling which causes the apoptotic effects in 
tumour cells. The administrations of farnesol and geranylgeraniol have been shown to partially prevent 
the inhibitory effects of BPs (Shipman et al., 1998, Iguchi et al., 2003). In a study reported by Benford 
et al., (2001), the NBP induced apoptotic effect on osteoclasts was due to caspase-3 activation which 
caused loss of mitochondrial membrane potential. Down-regulation of anti-apoptotic proteins of the 
bcl-2 family of apoptotic genes (Bcl-xL, Bcl-W) has been attributed to mitochondrial release of 
cytochrome c which activates caspase 3 (Senaratne et al., 2002).  Studies by Senaratne et al., (2002) 
demonstrated that NBPs down regulate bcl-2 induced apoptosis in breast cancer cell lines. Similar 
results were produced by Aparicio et al., (1998) when forced bcl-2 expression protected IM-9 cells from 
the ZA induced apoptotic effects but not the cytostatic effect. Interestingly, inhibiting the mevalonate 
pathway using a HMG CoA reductase inhibitor (fluvastatin) did not affect the Bcl-2 family protein; 
instead it inhibited anti-apoptotic Mcl-1 and phosphor-Rb (Baulch-Brown et al., 2007). However, the 
in vivo BM microenvironment is far more complicated with complex cellular interactions and cell 
signalling. Moreover, the concentration at which the cytoreductive effects of BPs described in the in 
vitro settings are much higher to the peak plasma concentration of the drug. BPs owing to their high 
bone binding affinity rapidly translocate from the plasma and concentrates into areas of active bone 
resorption. ALN, another NBP has been shown to reach a local concentration in the range of 0.1-1 mM. 
Although, the local concentration of ZA at the osteoclast-bone interface was shown to be well above 
the anti-tumour threshold, it still remains unclear whether it would reach the myeloma tumour cells in 
the BM (Sato et al., 1991, Clezardin 2005). 
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Figure 1.5-1: Possible anti-tumour mechanisms of ZA in MM. 
Schematic representation of different possible mechanisms by which ZA mediates an anti-tumour effect in MM. As 
HMG CoA inhibitor ZA can directly inhibit cell proliferation and induce apoptosis in osteoclasts as well as 
myeloma cells. Inhibition of osteoclastic activity suppresses the release of bone derived growth factor which may in 
turn affect myeloma cell survival. Myeloma cell also inhibits tumour associated macrophages which were shown to 
support and promote tumour growth. ZA treatment improves the antigen recognition of the tumour cells to the 
Vɤ2/Vɤ9 T cells thereby causing cancer cell death. ZA also inhibits tumour induced neovasculogenesis. 
The indirect anti-myeloma effect of ZA by inhibition of osteoclastic bone resorption 
The anti-tumour effects of BPs on most cancer-induced bone metastases suggests that the anti-tumour 
effect observed may be due to osteoclast inactivation and subsequent suppression of bone resorption. 
Bone is a complex environment rich in various growth factors including IGF, TGF-β, PDGF, b-FGF, IL-6 
and bone morphogenetic protein (BMP) which makes it a fertile environment (niche) for tumour cells 
to survive and colonise. Following cancer-induced osteoclastic bone resorption, these growth factors 
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tumour cells in turn stimulates the production of factors such as RANKL which promotes 
osteoclastogenesis and thereby bone resorption, establishing a ‗vicious cycle‘ between the tumour cells 
and the cellular components of the bone (Yoneda and Hiraga 2005). BPs are potent inhibitors of bone 
resorption and they inhibit the release of these factors which facilitates tumour cell survival thereby 
reducing tumour cell colonisation and eventually skeletal tumour burden. Specific osteoclastogenesis 
inhibitors such as Fc.OPG and recombinant RANK-Fc were also shown to exhibit anti-tumour effects in 
bone similar to the BPs (Sordillo and Pearse 2003, Iqbal et al., 2011). This suggests that the anti-tumour 
effect seen with ZA may be an indirect effect mediated by inhibition of osteoclastic bone resorption 
(Croucher et al., 2003a, Vanderkerken et al., 2003b). 
The anti-angiogenic effect of ZA 
ZA has been shown to inhibit angiogenesis in both in vitro and in vivo models. Wood and colleagues 
(2002) demonstrated that ZA inhibited foetal calf serum (FCS) and bFGF induced HUVEC proliferation 
in a dose-dependent fashion at a concentration of 4-5 μM. It also induces cell cycle arrest and prevents 
HUVEC cell adhesion and migration at concentrations >30 µM. ZA also dose-dependently inhibited 





addition, ZA was also shown to inhibit angiogenesis induced by subcutaneous implants impregnated 
with bFGF in murine models. Revascularisation of castrated rat prostate was inhibited by NBPs when 
vascularisation was promoted using testosterone (Fournier et al., 2002). ZA was shown to reduce 
microvessel density in the tibiae and femora developing tumours in 5T2 models of myeloma (Croucher 
et al., 2003a). Similar results were demonstrated with Neridronate, another NBP on HUVEC cell 
proliferation, matrigel assay and CAM assays (Ribatti et al., 2007). There is also evidence suggesting 
BPs reduce serum concentration of VEGF in cancer patients, ZA induced prolonged inhibition of VEGF 
(up to 21 days), whereas the effect was observed only for 7 days in PAM (Santini et al., 2002, Santini 
et al., 2003). Recently, ZA has been shown to induce apoptosis in endothelial progenitor cells by 
altering the expression of VEGFR2 and VE cadherin. Inhibitory effect of ZA were almost rescued by the 
addition of GGOH suggesting that inhibition of protein prenylation was the main mechanism 
responsible for these effects (Yamada et al., 2009). 
The immunomodulatory effect of ZA 
In addition to direct and indirect anti-tumour effects, BPs exhibits immunomodulatory effects 
(Kunzmann et al., 2000, Das et al., 2001, Mariani et al., 2005). NBPs cause expansion of γδ T cells 
(Vγ9Vδ2 T cells) in PBMC cultures which is dependent on IL-2 and also causes dose-dependent 
inhibition of plasma cell proliferation in MM patient BM mononuclear cells (BMMC) (γδ+) cultures, 
whereas no effects were observed in γδ- BMMC cultures (Kunzmann et al., 2000). NBPs owing to their 
structural similarities with prenyl phosphate metabolites such as isopentyl pyrophosphate and geranyl 
pyrophosphate can bind to the tumour cell surface, acting as a γδ T cell antigen leading to activation 
and proliferation of Vγ9Vδ2 T cells through γδTCR mediated signalling (Bukowski et al., 1998, 
J Gurubalan|Page|24  
 
Kunzmann et al., 2000, Mariani et al., 2005). Mature Vγ9Vδ2 T cells were shown to induce tumour 
lysis by cell mediated cytotoxicity in a variety of tumour cells by the secretion of cytokines especially 
IFN-γ (Fisch et al., 1990, Haas et al., 1993, Kunzmann et al., 2000). No evidence of an immune 
response was observed with non-NBP like CLO or etidronate. Treatment of cancer patients with bone 
metastases with ZA also has showed evidence of an increase in the percentage of effector γδ T cells 
which produced IFN-γ (Dieli et al., 2003). 
The effect of ZA on tumour associated macrophages 
Studies have shown that tumour associated macrophages (TAMs) play a critical role in the tumour 
progression and metastases. Macrophages are derived from monocytes and play an important role in 
the immune system. Based on cell polarisation and functional heterogeneity, macrophages are classified 
into the M1 (classically activated) which are immunostimulatory (defend the host organism) and the 
M2 (alternately activated) which are immunosuppressive (Berardi et al., 2013). TAMS, which include 
MM associated macrophages possess pro-tumorigenic property by producing IL-6, IL-10 and VEGF 
which were shown support and promote myeloma cell survival and proliferation (Kim et al., 2012). 
Scavelli et al., (2008) showed that macrophages form myeloma patients promote tumour 
vasculogenesis and produce capillary-like network (vasculogenic mimicry) upon interaction with VEGF 
and FGF-2 released by the myeloma cells. Moreover, TAMS were also shown to contribute to 
myeloma development by immunosuppressive mechanism and chemoresistance to the tumour cells 
(Berardi et al., 2013). Studies have shown that N-BPs such as ZA inhibit proliferation and induce 
apoptosis in macrophages by inhibiting the mevalonate pathway (Moreau et al., 2007). Furthermore, 
Mönkkönen et al., (2006) showed N-BPs in addition to inhibiting FPP synthase also produces cytotoxic 
ApppI analogue which induces macrophage apoptosis. In addition, Coscia et al., (2010) showed that 
ZA also has the ability to repolarise M2 phenotype TAMS to M1 types which are tumouricidal in in 
vivo ZA treated macrophages.  
The effect of ZA on tumour cell adhesion and invasion 
BPs in addition to their cytoreductive properties also inhibits adhesion of tumour cells to bone matrices. 
BP mediated inhibition of adhesion on both mineralised and unmineralised bone matrices was 
demonstrated in breast and prostate cancer cells (Van Der Pluijm et al., 1996, Boissier et al., 1997, 
Magnetto et al., 1999). A dose-dependent increase in inhibition of adhesion was observed at a 




 M in ibandronate (IBN), ALN and PAM in order of potency 
which is parallel to their osteoclastic resorptive potency. Little or no effect was observed with non-
NBPs such as CLO or etidronate (Van Der Pluijm et al., 1996). The mechanism underlying this effect is 
not clearly understood. The interference of NBPs with membrane bound adhesion molecules may be a 
reason for this effect. Increasing evidence suggests that BP mediated inhibition of geranylgeranylation 
could inhibit integrin activation (Coxon et al., 2004, Clezardin et al., 2005). 
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BP treatment was also shown to inhibit tumour cell invasion in vitro (Magnetto et al., 1999, Boissier et 
al., 2000, Virtanen et al., 2002, Denoyelle et al., 2003). Tumour invasion is a complex process which 
involves digestion of the basement membrane followed by cell migration (Magnetto et al., 1999). NBPs 
were shown to inhibit tumour cell invasion at a concentration as low as 10
-12 
M (Boissier et al., 2000, 
Virtanen et al., 2002). ZA at a concentration of 0.1 μM and ALN and CLO at a concentration of 10 μM 
were shown to inhibit tumour cell migration. Inhibition of the mevalonate pathway especially 
geranylgeranylation has been attributed to be responsible for this inhibitory effect as this was rescued 
by addition of GGOH and not by FOH.  Inactivation of the small GTPase RhoA (protein prenylation) 
and inhibition of SDF-1/CXCR-4 prevented tumour cell migration. No evidence of a reduction in matrix 
metalloproteinase (MMP) -2 and MMP-9 was shown at the indicated concentrations (Virtanen et al., 
2002, Denoyelle et al., 2003). However, ZA at 100μM was shown to inhibit both MMP-2,-9 and -12 
activity in MDA-MB-231 breast cancer cell line. The mechanism of MMP inactivation appears to be 
chelation of divalent cations necessary for MMP activation as the inhibitory activity was completely 
rescued by exogenous zinc addition (Boissier et al., 2000). Interestingly, CLO at 0.1 μM inhibited 
tumour cell invasion which is not protected by GGOH or FOH suggesting that it acts through a 
completely unknown mechanism which warrants investigation (Boissier et al., 2000).   
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1 . 6  A I M S ,  O BJE C T IV E S  AN D  H Y P O T HE S I S  
Myeloma cell development in bone depends on the bone microenvironment for colonisation and 
survival. Evidence that ZA delays the incidence of MBD and EFS in myeloma patients suggests that it 
may interfere with early cell colonisation events. Blocking the release of bone derived growth factors 
by inhibiting osteoclastic resorption may therefore alter the BM niche to be unfavourable for the 
colonisation and survival of myeloma cells.  
Based on these observations, I hypothesised 
1. Blocking bone resorption with ZA will prevent the colonisation of myeloma cells   
2. Blocking bone resorption with ZA will stop the initiation of growing lesions or colonies from 
myeloma cells that resides in bone thereby preventing development of overt myeloma‘. 
The main aims were: 
1. To determine whether blocking bone resorption with ZA inhibits the initial colonisation of 
bone by myeloma cells. 
2. To determine whether blocking bone resorption with ZA prevents the development of overt 
myeloma colonies. 
3. To determine whether blocking bone resorption with ZA delays the onset of morbidity (hind 
limb paralysis or sickness). 
The objectives were: 
1. To determine the time taken by ZA to effectively suppress osteoclastic bone resorption in 
C57BL/KaLwRij mice. 
2. To establish the different developmental stages of myeloma using the 5TGM1 murine model of 
myeloma.  
3. To determine the effect of ZA treatment on the early stages of myeloma development in bone. 
4. To determine the effect of ZA treatment on the late stages of myeloma development in bone. 
5. To determine the effect of ZA treatment on the bone disease free survival (hind limb paralysis). 
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2 . 1  M A T E R I A L S  
2 . 1 . 1  Z O L E D RO N IC  AC I D  (Z A )  
CAS number: 118072-93-8 
Zoledronic Acid or Zoledronate (ZA) [1-hydroxy-2-(1H-imidazol-1-yl) ethane-1,1-diyl] bisphosphonic 
acid was supplied as a disodium hydrate salt (4.5 H2O) by Novartis Pharma, Basel, Switzerland. 
2 . 1 . 2  T HE  5 T G M 1  M U R IN E  M Y E LO M A  C E L L  L IN E  
The 5TGM1 murine myeloma cell line stably transfected to express eGFP (hereafter referred as 5TGM1-
eGFP) was a kind gift from Dr Claire Edwards (University of Oxford, United Kingdom). The 5TGM1 
myeloma cells were derived from repeated in vivo passaging of 5T33MM murine myeloma cells in 
young syngeneic C57BLKalwRij mice and the tumour cells from bone of 5T33 tumour-bearing mice 
were extracted and cultured in Iscove's Modified Dulbecco's Media (IMDM) with 10% FCS and 10% 
murine stromal cell-conditioned media (Garrett et al., 1997). 
2 . 1 . 3  C 5 7 BL /K aL w R i j  M I C E  
C57BL/KaLwRij mice were purchased from Harlan, Harlan laboratories, UK and St. James‘s Biomedical 
Services, St. James University Hospital, Leeds, UK and was housed in the University of Sheffield 
Biological Services located in Royal Hallamshire Hospital, Sheffield, UK. In vivo work was approved by 
UK Home Office under the project licence PPL No: 40/2901 held by Prof. Peter Croucher and PPL No:  
40/3462 held by Dr Colby L Eaton, University of Sheffield, UK. All animal work was performed by me 
under UK Home Office Personal licence (PPL No 40/9809, J Gurubalan) 
The C57BL/KaLwRij strain was developed in 1921 by Little from a brother and sister pair (57 x 52) of 
Miss Abby Lathrop‘s stock. In 1947, they were transferred from Strong, Cold Spring Harbor, New York, 
to Kaplan, Stanford, California, USA, to Law, National Cancer Institute, Bethesda, MD, USA. In 1965, 
they were transferred to the Radiobiological Institute TNO, Rijswijk, the Netherlands and transferred 
to Harlan Laboratories in 1994 through the acquisition of ITRI-TNO, Rijswijk – Harlan Laboratories. 
The C57BL/KaLwRij strains of mice are the most widely used strain for studies on human idiopathic 
paraproteinemia and MM. The 5TGM1 murine myeloma model is a variant of the 5TMM series of 
spontaneously developing murine model of myeloma in aged C57BL/KaLwRij mice in which rapidly 
proliferating, non-adherent 5T33 cells from BM aspirates of 5T33 tumour-bearing mice were 
repeatedly cultured in Iscove's Modified Dulbecco's Media (IMDM) with 10% FCS and 10% murine 
stromal cell-conditioned media (Radl et al., 1978, Garrett et al., 1997).  
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2 . 2  G E N E R A L  ME T HO D S  
2 . 2 . 1  C E LL  C UL T U RE  
Cells were passaged in RPMI 1640 media with Glutamax (GIBCO-Invitrogen 1870-010) supplemented 
with 10% foetal calf serum (FCS), 1% Penicillin-streptomycin (Pen-strep) (100 units/ml of penicillin and 
100 μg/ml of streptomycin), 1 mM sodium pyruvate and 100 mM non-essential amino acid (NEAA). 
The cells were incubated in a 5% CO2 incubator at 37°C with 95% humidity and passaged every 3-4 
day in T75 flasks under sterile conditions in a cell culture hood. Hereafter, the cell culture media with 
the fore mentioned additives will be referred to as ‗complete media‘. 
2 . 2 . 2  C R Y O PR E S E R V AT IO N  A N D  RE S U SC I T AT IO N  O F  C E L L  L IN E S  
All cell lines were frozen in liquid nitrogen (N2) for long term storage in cryo-vials. Cells were pelleted 
by centrifuging at RCF 1509.3 X g for 5 min and suspended in the freezing medium (Foetal calf serum 
(FCS) + 10% DMSO) at the rate of 2 X 10
6
 cells per ml. The cell suspensions were then transferred to 
cryo-vials and frozen at the rate of -1˚C/min using Nalgene 5100-0001 PC/HDPE Mr. Frosty 1 Degree C 
left overnight in -80˚C freezer. The cryo-vials were transferred to liquid N2 dewars for long-term 
storage. 
Cell lines preserved in liquid N2 were thawed rapidly using a 37˚C water bath. The cells along with the 
freezing medium were mixed gently in 19 ml of pre-warmed complete media. The contents were 
centrifuged at RCF 1509.3 X g for 5 min to obtain cell pellets. Cell pellets were then washed twice in 
10 ml of complete media and resuspended in complete media in a sterile flask. 
2 . 2 . 3  C E LL  C O U N T IN G  U S IN G  A  H AE MO C YT O M E T E R  
Cell counting was done using a Neubaeur haemocytometer. Cells were stained with 0.4% trypan blue 
(TP) dye (1:1 ratio). 10 μl of a single cell suspension was mixed with 10 μl of TP and loaded in to the 
capillary space between the cover slip and the counting chamber of the haemocytometer (figure 2.2-1). 
Using an inverted light microscope the number of cells in the four corner squares was counted. Cells 
inside the grid and cells touching the bottom and left lines of each square were counted normally, 
while cells touching the upper and right lines of the square were not counted. 
The volume held under a single corner square is 0.1 mm
3
 (0.0001 ml), so the number of cells (n) in a 
single square is the number of cells in 10
-4
 ml. The number of cells per ml can be calculated using the 
formula  
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Figure 2.2-1: Cell counting using a Neubaeur haemocytometer. 
A Neubaeur haemocytometer has a laser etched grid on the slide inside a capillary chamber and is used to measure 
cell density.  The numbers of cells in the four corner squares (A, B, C & D) were counted by visualising under a 
light microscope and the average cell number per ml was measured using the formula average cell count (n/4) X 
dilution factor (D.F) X 10
4
. 
2 . 2 . 4  D I D  L A BE L L IN G  O F  5T M M  C E LL S  
5TGM1-eGFP murine myeloma cells were labelled with 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DID dye) for identification of cells by 
flow cytometry and multiphoton microscopy. DID is a lipophilic carbocyanine dye that inserts into the 
phospholipid bilayer of the cell membrane (figure 2.2-2). 
Vybrant® DiD Cell-Labelling Solution (Catalogue No. V-22887; Life Technologies) was used for 
labelling 5TGM1-eGFP murine myeloma cells. The amount of myeloma cells to be labelled was 
suspended in RPMI 1640 with Glutamax (no additives) at concentration of 1 X 10
6
 cells per ml of 
media.  DID vybrant labelling solution was added to the cell at the rate of 10 µl per 1 X 106 cells per ml 
of serum free media and mixed gently by pipetting (addition of DID dye should be done in dark as 
light exposure will result in photo bleaching) and  incubated for 30 min in a 5% CO2 incubator. After 
incubation, FCS (10% of the volume) was added to the mixture and centrifuged at RCF 1509.3 X g for 
5 min at RT. Addition of FCS prevented the cell pellet to be lost during centrifugation. Cell pellets was 
then washed twice using complete media and resuspended in the required volume of sterile PBS (2 X 
10
6
 cells in 100 µl of PBS per mouse).  
A B 
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Figure 2.2-2: DID dye labelling cell membrane. 
DID belongs to the class of amphiphilic carbocyanine dyes with charged fluorescent head groups and long 
lipophilic aliphatic tail groups that conveniently inserts into the phospho-lipid bilayer of the cell membrane. A 
study using fluorescent polarization microscopy has shown that DID dye inserts into the cell membrane using their 
long lipophilic aliphatic tail chains which anchors into the membrane perpendicularly with the fluorescent heads 
lying parallel on the cell surface membrane (Axelrod 1979). 
2 . 2 . 5  D E T E C T IO N  O F  F L U O R E SC E N T L Y  L AB E L LE D  5 T G M 1  M U R I N E  M Y E LO MA 
C E L L S  ( IN  V I T RO )  US I N G  F L O W  C YT O M E T R Y  




 labelled myeloma cells were determined by flow cytometry in 
order to achieve maximum labelling of the cells prior to injection into the mice. Flow cytometry 
analysis was done using FACS Calibur flow cytometer (Becton Dickinson, Oxford, UK) with CellQuest 
software. FACS Calibur is a dual-laser (488 nm - blue laser; 635 nm - red-diode laser) multi-parameter 
system designed for multi-colour analysis. 1 X 10
6
 cells were washed twice in PBS by centrifuging at RCF 
1509.3 X g for 5 min at RT and resuspended in 1 ml of PBS into FACS tubes. Samples were then run 




 labelled cells for up to 1 X 10
6
 cells. 
Unlabelled cells were used as negative control for setting up the flow cytometer. 488 nm laser was 
used to detect eGFP
+
 signals (em: 507-510 nm) in the FL1 channel and 635 nm laser was used to detect 
DID
+
 (em: 675-710 nm) in the FL4 channel (figure 2.2-3). 
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Figure 2.2-3: eGFP and DID excitation and emission spectra. 
2 . 2 . 6  D E T E C T IO N  O F  F L U O R E SC E N T L Y  L AB E L LE D  5 T G M 1  M U R I N E  M Y E LO MA 
C E L L S  IN  BO N E  M A RR O W  (E X  V IV O )  U S IN G  F LO W  C Y T O ME T R Y  
In order to quantitate the percentage of 5TGM1-eGFP-DID cells in the BM using flow cytometry,  the 
BM cells were flushed out in a 1 ml eppendorf with 500 µl of 1 X PBS using an insulin syringe. BM cells 
were centrifuged at RCF 1509.3 X g for 3-4 min at RT and the supernatant removed. The BM cells 
were suspended and incubated in 1 X H-lyse buffer (Whole blood erythrocyte kit, Catalogue No: 
WL1000 R&D systems) for 10 min at RT until red blood cell lysis was complete. When red blood cell 
lysis was complete, the supernatant was removed by centrifuging at RCF 1509.3 X g RT for 3-4 min. 
The cell pellets were then washed twice in 1 ml of 1 X wash buffer (Whole blood erythrocyte kit, 
Catalogue No: WL1000 R&D systems) by wash centrifuging. Once the cells were washed they were 
resuspended in 100 µl of 1 X PBS and samples were run through flow cytometer (FACS Calibur, Becton 
Dickinson, Oxford UK) for up to 10
5









 cells in the BM. BM cells from naïve tumour-free C57BL/KaLwRij were used as negative 
control for setting up the flow cytometer. 488 nm laser was used to detect eGFP
+
 signals (em: 507-510 
nm) in the FL1 channel and 635 nm laser was used to detect DID
+
 (em: 675-710 nm) in the FL4 
channel. 
2 . 2 . 7  S O RT IN G  O F  5T G M1 - e G F P - D I D  L A BE L LE D  C E L L S  
Enrichment of 5TGM1-eGFP murine myeloma cell population in culture was achieved by fluorescent 
activated cell sorting (FACS) using FACS Aria cell sorter (Becton Dickson Biosciences). Cells were sorted 
for eGFP
+
 population using 488 nm blue laser into 1 ml of complete media. These cells were then 
washed twice in PBS or complete media and resuspended in complete media in T75 flask and 
incubated at 5% CO2 incubator at 37˚C. 
 
GFP (ex 488 nm, em 507-510 nm) 
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2 . 2 . 8  I N JE C T IO N  O F  5T GM 1  C E L L S  I N T O  M I C E  U N D E R  LO C A L  AN A E ST HE S I A  
5TGM1-eGFP-DID murine myeloma cells were injected via the lateral tail vein using 1 ml insulin 
syringe. For the purpose of intravenous injection, the tail was anesthetized by topical application of a 
local anaesthetic agent. EMLA cream 5% (active ingredient, lidocaine & prilocaine) was applied 
throughout the tail 60 min prior to the injections. 5TGM1-eGFP murine myeloma cells were labelled 
with DID dye prior to injection (section 2.2.4). Mice were placed in a 37 ˚C incubator for 
approximately 5-10 min in order to dilate the vein. Mice were then restrained using a bench top 
restrainer and 2 X 10
6
 5TGM1-eGFP-DID cells suspended in 0.1 ml of sterile PBS were injected slowly 
through the tail vein. 
2 . 2 . 9  B LO O D  C O LLE C T IO N  V I A  C A R D I AC  P U N C T U R E  W IT H  M IC E  U N D E R  
G E N E R A L  AN A E ST H E S I A  
For the purpose of cardiac puncture to obtain blood samples for serum extraction, the mice were 
sedated using intra-peritoneal injection of sodium pentothal (approx. 0.05-0.1 ml) using insulin 
syringes. All animals were starved 6 hr prior to the sacrifice in order to eliminate the circadian variation 
in the serum bone biomarkers (Christgau 2000, Clowes et al., 2002). Pinch reflex was practised to 
assess the depth of anaesthesia before commencing the procedure.  
Cardiac blood collection was done using 1 ml syringe with a 27 gauge needle after anaesthetizing the 
mice using 0.5 ml/kg of pentobarbitone. Blood was withdrawn from the left ventricle by gently 
inserting the needle perpendicular to the chest wall through the left lateral chest wall for about 5-10 
mm. The plunger was withdrawn gently to allow blood to fill the syringe. The blood was then 
transferred to 1.5 ml eppendorf tube and was allowed to clot at RT for about 60 min and stored at 
4˚C or ice until processing. Following cardiac bleeding, the mice were euthanized humanely. 
2 . 2 . 1 0  S E R U M  C O LLE C T IO N  &  S A M P LE  ST O R A GE  
After blood collection the mice were sacrificed by cervical dislocation. Femora and tibiae were stripped 
of soft tissues and stored appropriately. Storage conditions for the different samples are discussed in 
detail in the appropriate chapters.   
Serum was obtained from blood samples by centrifuging the blood samples in an eppendorf at RCF 
1509.3 X g for 10 min at 4˚C so that the blood clots and settles at the bottom and serum on the top. 
The serum was carefully removed without disturbing the blood clot and stored appropriate aliquots at 
-80˚C.  
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2 . 2 . 1 1  A D M I N I ST R A T IO N  O F  ZO LE D R O N IC  A C ID  T O  M IC E  
500 µg/ml stock solution of ZA was prepared in PBS and stored in -20˚C. Prior to injection, a working 
concentration of ZA (125µg/kg) was prepared by dissolving 1 ml of stock solution in 19 ml of sterile 
PBS. The ZA solution was filter sterilised using a 0.2 µm pore filter and 0.1 ml was injected 
subcutaneously into the scruff over the neck of the mouse. 
2 . 2 . 1 2  M I C RO - C O M P U T E D  T O M O GR A P H Y  
Micro-computed tomography (MicroCT) was performed using SkyScan 1172 Desktop X-ray 
tomographer manufactured by SkyScan N.V. Aartsalaar, Belgium. This equipment is a modified hospital 
CAT scan where high resolution cross-section and 3D virtual models can be produced of objects non-
destructively. The pixel size of the cross-section images are in micro meter range, hence the high 
resolution. The system allows quantitative and 3D morphometric analysis of the bone samples. 
Micro CT works on the simple principle of x-ray projection, where multiple angular x-ray projection of 
a 3D object is performed using a cone beam micro focus x-ray source. A planar (2D) x-ray detector is 
used to capture magnified projection images which are fed to a computer to build 3D virtual cross-
section images of the whole object (figure 2.2-4). Complete quantitative analysis on the morphology of 
the trabecular and cortical component of the long bones were done using a medium sized 2000 X 
1048 pixel camera and an x-ray source powered by 50 kV and 200 μA electric current. A 0.5 mm 
aluminium filter was used to filter out the low energy radiations. The proximal end of tibia was 
scanned at 4.3 μm pixels for every 0.7° rotation of 180˚. 
 
Figure 2.2-4: Principle of micro-computed tomography imaging. 
Micro-computed tomography imaging is based on collection of magnified 2D image projection of the 3D object 
from a micro focus X-ray source. The micro focus source produces a cone X-ray beam which illuminates the object 
area. The object is placed on a rotatory turntable and planar projection images at multiple angles are collected by 
the detectors (A). As a cone beam x-ray sources are not able to produce parallel beam geometry, tomographic 
reconstruction is done by reordering the shadow information. A ‗Feldkamp 3D cone beam reconstruction 
algorithm‘ is used to reconstruct the slices to form virtual 3D models of the object scanned (B). 
DETECTOR OBJECT X-RAY 
SOURCE 
A B 
DETECTOR TURN-TABLE X-RAY 
SOURCE 
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The scanned images were reconstructed using NRecon software ver. 1.6.1.1 within a dynamic range of 0 
to 0.16 and a ring artefact reduction factor of 1 %. Reconstructed images were then analysed using 
CTAn ver. 1.9.1.1. Analysis was done on the cross-sectional images of the tibiae at a fixed distance 1.2 
mm from the growth plate (reference point). The proximal break in the growth plate was used as a 
standard reference point for both cortical and trabecular analysis. The analysis was done on a fixed 
region extending for 1 mm (figure 2.2-5 A). For trabecular analysis, the trabecular bone was carefully 
traced on all cross-sectional images of the tibia, not to include cortical bone for the entire region of 
interest (ROI). Similarly, cortical bone was also analysed. Figure 2.2-5 B shows the trabecular and 
cortical bone traced out in the cross-section of tibia. Analysis was done in batches using Batch Manager 
(BatMan) software and the following parameters were measured: trabecular bone volume (% BV/TV), 
trabecular thickness (Tb. Th), trabecular number (Tb. N), trabecular pattern factor (Tb. Pf), structural 
model index (SMI) and cortical bone volume (Ct.V). For trabecular analysis the binarised images were 
thresholded between 80 and 255 and for cortical bones between 90 and 255. 
 
Figure 2.2-5: MicroCT image analysis and quantification. 
A longitudinal cross-section of the proximal tibial metaphysis, offset (arrow) 1.2 mm from the distal end of the 
growth plate, 1 mm ROI for the analysis of cortical and trabecular bone (A). Cortical and trabecular bone were 
analysed by tracing out boundaries (red) in the ROI and the amount of bone (Ct. V & % BV/TV) and structural 
parameters were analyzed using CTAn software (B).  
2 . 2 . 1 3  C D 1 3 8  I M M UN O H IST O C HE M IS T R Y  ( I H C )  
CD138 is a 30 kDa trans-membrane heparan sulphate proteoglycan expressed by normal plasma cells 
and malignant myeloma cells. CD138 immunohistochemistry (IHC) was done by ‗sandwich‘ or ‗bridge‘ 
IHC where biotinylated secondary antibody was used for antigen amplification and biotin-streptavidin 
system (antibody-enzyme complex) used for antigen detection (figure 2.2-6). CD138 IHC was done 
using purified rat anti-mouse CD138 (BD Pharmingen Catalogue No. 553712). Slides were incubated at 
37˚C overnight prior to the day of staining. Slides were dewaxed and rehydrated by dipping them 
REGION OF INTEREST (1 mm) 
TRABECULAR REGION CORTICAL REGION 
OFFSET (1.2 mm) 
A 
B 
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sequentially in xylene 99%, 95% and 70% ethanol 4 min in each followed by water and 1 X PBS. 
Slides were then incubated with pre-warmed trypsin (A.Menarini Diagnostics MP-955K25) for 10 min 
at RT for antigen retrieval to break the protein bonds due to formalin fixation and paraffin embedding. 
After incubation, the slides were washed in 1 X PBS for 5 min. To prevent non-specific binding the 
tissue samples were incubated in 10% FCS and 10% normal goat serum (Vector Laboratories Catalogue 
No.S-1000) for 60 min at RT. Serum block was tapped off and the tissues were incubated in 1:100 
purified rat anti-mouse CD138 antibody for 60 min at RT. As Streptavidin-horseradish peroxidase 
conjugate (SA-HRP) was used for antibody-enzyme detection complex, endogenous peroxide blocking 
was done by incubating the tissues with 3% H2O2 for 30 min at RT. The samples were then washed in 
PBS and re-incubated in 1:300 dilution of biotinylated goat anti-rat IgG F(ab)2 for 30 min at RT. After 
washing in 1 X PBS, the slides were incubated in SA-HRP conjugate for 30 min at RT for the formation 
of antibody-enzyme detection complex. Slides were then washed in PBS and developed with 3, 3'-
diaminobenzidine tetrahydrochloride (DAB) substrate chromogen system (Vector kit SK-4105). After 
chromogen developing, slides were washed in PBS to remove excess DAB and counter stained with 
Gills II Haematoxylin (for 20 sec) followed by washing in running tap water for 2-3 min. Slides were 
then dehydrated  and coversliped using DPX mountant (Sigma-Aldrich, Catalogue No. 44581). 
 
Figure 2.2-6: Principles of ‗sandwich‘ or ‗bridge‘ immunohistochemical staining of CD138. 
CD138 IHC was based on sandwich or bridge immunoassay which depends on biotin binding to avidin. Here, rat 
anti-mouse CD138 antibody was used as primary antibody to bind to the CD138 expressed by the plasma cells. 
Biotinylated goat anti-rat IgG F(ab)2 was used as secondary antibody which binds to the primary antibody. Horse-
radish peroxidase (enzyme) conjugated to streptavidin was added which binds to the ‗multiple binding sites‘ on 
the biotin. The main advantage of using a biotin-streptavidin system for antibody-enzyme detection is the 
potential for amplification due to multiple binding sites for the conjugated strept-avidin (antibody-enzyme 
complex). Finally addition of chromogen results in oxidation of DAB in the presence of horse-radish peroxidase 
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2 . 2 . 1 4  S C O R IN G  S Y ST E M  F O R  T HE  Q U A N T IF IC A T IO N  O F  C D 1 3 8  P O S IT I V E  
C E L L S  
In tibial biopsies, scoring of CD138
+
 plasma cell was based on the microscopic evaluation of CD138 IHC 
stained slides using a ScanScope CS digital slide scanner, Aperio Technologies® and quantitation was 
done using Aperio ImageScope software Ver 11.1.2.760, Aperio Technologies®. CD138
+
 cells were 
identified as brown (DAB) staining around the plasma membrane surrounded by a haematoxylin 
(blue/purple) stained nucleus. Both individual number of CD138
+





 colonies were quantified (figure 2.2-7). CD138 IHC was performed on both tumour-free naïve 
control and tumour-bearing animal to investigate the levels of CD138
+
 cells in the BM.  
 
 
Figure 2.2-7: Scoring system for CD138 IHC. 
CD138 IHC stained slides were scanned using an Aperio Slide scanner and the images were loaded on the 




 colonies were visually identified and manually traced using 
ScanScope software. Results were exported as excel files for analysis. 
2 . 2 . 1 5  H I S T O L O G Y  
DECALCIFICATION  
After MicroCT analysis, bones were decalcified for histomorphometric analysis. Decalcification was 
done using ethylenediamine tetra acetic acid (EDTA, Fischer Scientific) at RT for a period of 4 weeks. 
BM AREA (ROI) 
CD138
+




J Gurubalan|Page|38  
 
The bones were decalcified in volumes of EDTA approximately 20 times the volume of the bones with 
the solution changed once a week. Once decalcified, the bone tissues were loaded onto labelled tissue 
cassettes and washed in running tap water for 60 min. 
PROCESSING AND WAX EMBEDDING 
Tissue processing was done using a Leica TP1020 automated carousel tissue processor, Leica Biosystems. 
The bones were dehydrated using gradients of alcohol and infiltrated with paraffin wax (Surgipath). 
Processed tissues were then embedded in paraffin wax using metal moulds where the tibiae samples 
were placed diagonally with the crest facing down, and then warm melted paraffin was added to the 
moulds and was allowed to cool.  
SECTION CUTTING AND STAINING 
Wax embedded tissue blocks were cut using Leica RM2135 rotary microtome which was set to cut 
sections at a thickness of 3 μm. The wax moulds were slowly trimmed until the BM was exposed. 
Chattering was prevented by pre-cooling the exposed tissue surface on ice. Two 3 μm serial sections 
were cut and floated onto a water bath maintained at 45°C, these were mounted on Superfrost Plus 
slide labelled appropriately and then dried overnight in a 37°C incubator. The slides were stored at 4°C 
until required.  
2 . 2 . 1 6  H A E M AT O X YL I N  &  E O S IN  ST A I N IN G  
Slides were dewaxed and hydrated by sequentially dipping into xylene 99%, 95% and 70% ethanol 
followed by washing in running tap water for 5 min. The slides were then dipped in Gills II 
Haematoxylin (VWR code: 1.05175.0500) for 90 sec and washed again in running tap water for 5 min. 
Eosin staining was done by dipping the slides in 1% aqueous solution of eosin containing 1% calcium 
carbonate  for 5 min and washed in running tap water for 2-3 min. The slides were then dehydrated 
by sequential dipping in 70%, 95% and 99% ethanol followed by Xylene for 3 min and coversliped 
(VWR codes 36029/36125) with DPX mountant (Sigma-Aldrich, Catalogue No. 44581). 
2 . 2 . 1 7  T R A P  ST A IN I N G  
Before staining the slides were dewaxed and dried. The slides were submerged in 2 containers of 
xylene for 5 min in each to remove the paraffin. After dewaxing, they were dipped consecutively in 
two jars containing 99% and one jar each containing 95% and 70% industrial methylated spirit (IMS) 
for 5 min in each for removing the xylene. The slides were then cleared of IMS and rehydrated by 
rinsing them in tap water. 
A standard Napthol AS-BI phosphate post-coupling method was used for TRAP staining using 
hexazonium pararosaniline. To prepare 1.2% acetic acid solution 6 ml of absolute acetic acid (Analar 
Chemicals) was dissolved in 494 ml of distilled water. Acetate buffer (0.2M) was made by dissolving 
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sodium acetate trihydrate salt (Sigma S-9513) in 200 ml of distilled water and the pH was corrected to 
5.2 by adding 50 ml of 1.2% acetic acid. Sodium tartrate (4.6 gm Sigma S-4797) was added to produce 
acetate tartrate buffer and warmed to 37°C for 2-4 hrs. The dewaxed slides were incubated in the 
warm buffer for 5 min at RT. 
Solution A was prepared by dissolving 0.02 g of Napthol AS-BI phosphate (Sigma N-2250) in 1 ml of 
dimethyl formamide and the resultant solution mixed with 50 ml of acetate tartrate buffer. The slides 
were then incubated in solution A for 30 min at RT. 
4% sodium nitrate solution was prepared by adding 80 mg of sodium nitrate (Sigma S-2252) in 2 ml of 
distilled water. 2 ml of pararosaniline (Sigma P-3750) was added to this 4% sodium nitrate solution to 
form hexazonium pararosaniline. Solution B was prepared by adding 2.5 ml of hexazonium 
pararosaniline/sodium nitrate to 50 ml of pre-warmed acetate tartrate buffer. Solution B had to be 
prepared fresh and the slides were incubated for 15 min in solution B at RT. The slides were then rinsed 
and counterstained with Gills II (VW code 1.05175.0500) haematoxylin for 20 sec. The slides were 
then washed using IMS and dehydrated by xylene and then coversliped over 2-3 drops of DPX 
mountant.  
2 . 2 . 1 8  S C O R IN G  S Y ST E M  F O R  T HE  Q U A N T IF IC A T IO N  O F  O ST E O C L AS T S  &  
O ST E O B L AS T S  
A Leica LEITZ DMRB upright microscope connected to a Sony colour video camera and Osteomeasure 
software (Osteometrics Inc., USA Ver 4.10) was used to quantify the H&E and TRACP stained slides. 
Cells were analysed at 10X magnification. Bone static histomorphometry was performed in accordance 
with the guidelines established by ABSMR Histomorphometry Nomenclature Committee (Parfitt et al., 
1987). TRAP stained slides were used to quantify osteoclasts (Oc) and H&E stained slides were used to 
quantify osteoblasts (Ob). Trabecular analysis was made on a field size of 0.5625 mm
2 
and 0.5 mm 
from the proximal margin (resting zone) of the growth plate. Histomorphometric assessment on the 
cortico-endosteal side was determined on 1.5 mm on each endosteal side 0.5 mm from the growth 
plate (figure 2.2-8). 
The following static variables were measured: total number of Oc per unit area of trabecular bone (i.e., 
osteoclast index, 1/mm
2
) and total number of Ob per unit area of trabecular bone (i.e., osteoblast 
index, 1/mm
2
) were measured on the trabecular region; total number of Oc and Ob per mm of cortico-
endosteal (endocortical) bone surface (1/mm) were measured on the endocortical region. Oc and Ob 
were identified based on their distinctive morphological features in TRAP and H&E staining 
respectively. TRAP
+
 cell on the bone surfaces was identified as Oc while Ob was identified by their 
cuboidal shape and eosin stain with eccentrically placed haematoxylin stained nucleus. A potential 
limitation in the scoring system used in the current study was that the samples were not blinded during 
analysis. However, the morphological changes associated with ZA treatment on the tibial metaphysis 
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was so evident that for a well-trained analyst, it was possible to identify the treatment based on 
microscopic observation of the slides. So, although adequate caution was taken while analysing the 
slides, chances of an over or underestimation in the number of osteoclasts could not be ruled out. 
 
Figure 2.2-8: Scoring of Ocs and Obs in TRAP and H&E stained slides 
Osteomeasure software was used to quantify the number of osteoclasts and osteoblasts in the BM. Analysis was 
done in the proximal tibial metaphysis 0.5 mm below the growth plate using a 10X objective. For trabecular 
region, a 3 X grid tile fashion each measuring 250 X 250 µm was used. For the endocortical analysis, 6 tiles were 
traced along the endocortical surface on both sides. 
2 . 2 . 1 9  Q U A N T I F IC AT I O N  O F  O S T E O L YT IC  BO N E  L E S I O N S  
Computerised image analysis (CIA) system using ‗Image J‘ software (NIH) was developed by Ms Holly 
Evans Research Technician, Mellanby Centre for Bone Research, Sheffield to quantify defects on cortical 
bone surfaces from 3D models built in ex-vivo microCT imaging as an index of osteolytic bone lesion. 
This technology allowed a cost effective method for the measurement of quantifiable lesion on bone 
surfaces using in-house microCT images and open source ‗Image J‘ software. 3D models of proximal 
tibial metaphysis were built from microCT images using CTAn software. Prior to 3D model making the 
microCT images were resized smaller 3X (smaller image size allowed better processing of the images on 
the software) and ROI was drawn to include the cortical bone and exclude the trabecular bone. 3D 
images were then loaded onto CTVol software, SkyScan N.V. Aartsalaar, Belgium and cross-sectional 
cut planes showing the posterior and lateral side were saved as bit map images. 
Using ImageJ software the BMP files were converted to 8-bit images for processing. Images were then 
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image showing proximal tibial metaphysis (posterior side) respectively. Following image conversion (8 
bit, grayscale, black and white image) and binary thresholding the black background is converted to 
red colour showing defects on the surface of cortical bone. Using ‗analyse particle‘ module, defects of 
all shapes and sizes (circularity between 0.0-1.0) were quantitated on the cortical bone surfaces (ImageJ 
basics Ver 1.38). 
 
Figure 2.2-9: Quantification of cortical defects using Image J software. 
(A) An example raw image of the proximal tibial metaphysis (longitudinal cut-section) showing multiple defects on 
the surface of the cortical bone. (B) 8-bit grayscale processed image of the same section with background in red, 
bone in grayscale and cortical defects in blue. 
2 . 2 . 2 0  E N Z Y M E  L IN KE D  I M M U O SO RB E N T  A S S A Y  ( E L I S A )  –  S E RU M  B O N E  
M A R KE R S  
ELISA assay was performed on serum for quantitating serum levels of bone turnover markers.  Tartrate 
resistant acid phosphatase 5b (TRACP5b) was done for osteoclastic bone resorption and Pro-collagen 1 
N-terminal propeptide (P1NP) was done for osteoblastic bone formation.  
TRACP5B ELISA 
Mouse TRACP5b Assay™ (Catalogue no. SB-TR103, Immunodiagnosticsystem, UK Ltd) was used to 
determine the serum levels of the enzyme TRACP5b expressed by bone resorbing osteoclasts. Mouse 
TRACP5b is a solid-phase immunofixed enzyme activity assay in which polyclonal anti-TRACP5b 
capture antibody is bound to anti-rabbit IgG coated microtitre plate (solid phase) upon which antigen 
(TRACP5b) from the serum is bound thereby forming a sandwich of antibody-antibody-antigen. As 
TRACP5b is a phosphatase, a chromogenic substrate para-nitrophenyl phosphate (pNPP) is used to 
produce a soluble yellow colour product para-nitrophenol whose absorbance can be read using a 
spectrophotometer (figure 2.2-10).  
A B 
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Figure 2.2-10: Principles of the TRACP5b immunoassay. 
TRACP5b immunoassay is a ‗sandwich‘ type ELISA where polyclonal anti-TRACP5b capture antibody (red) is 
attached to anti-rabbit IgG solid phase support (orange antibody in the microtitre plate). Addition of serum sample 
(TRACP5b) results in binding of the antigen (TRACP5b) with the polyclonal anti-TRAP5b capture antibody. Para-
nitrophenyl phosphate (pNPP) is a chromogenic substrate for phosphatases which on addition to phosphatases will 
yield para-nitrophenol which is yellow in colour and absorbance can be measured using a spectrophotometer with 
405 nm light. 
The assay was performed according to the manufacturer‘s protocol. 100 μl of reconstituted polyclonal 
anti-TRACP5b antibody was added to appropriate wells in an anti-rabbit IgG coated microtitre plate 
and incubated for 1 hr at RT on a shaker (950 RPM). The plate was manually washed 3 times using a 
wash buffer to remove excess unbound antibody. 100 μl of calibrators and controls were added to 
appropriate wells, 75 μl of 0.9% Nacl followed by 25 μl of each sample were added in duplicates. 25 
μl of releasing reagent was then added to all wells and incubated for 1 hr at RT on a shaker. The 
release reagent was added to dissociate the TRACP5b from the binding proteins. The plates were 
washed 3 times in wash buffer and 100μl of freshly prepared p-nitrophenyl phosphate (pNPP), a 
colorimetric, soluble substrate for protein, acid or alkaline phosphatase was added. The plates were 
then incubated for 2 hr at 37° C. 25 μl of NaOH was used to stop the reaction and the plate was read 
at 405 nm using a SpectraMax M5e automated plate reader (Molecular Devices). 
MURINE P1NP ENZYME IMMUNOASSAY 
Pro-Collagen Type 1 N-terminal propeptide (P1NP) is a major component required for the synthesis of 
bone matrix. During the process of active bone formation and collagen synthesis, propeptides are 
secreted into the circulation from the pro-collagen molecule from the ‗C‘ (carboxy) and ‗N‘ (amino) 
terminal. Therefore, quantification of serum levels of P1NP reflects the bone formation rates. 
Rat/Mouse P1NP EIA (Immunodiagnosticsystem, Catalogue No: AC-33F1) a competitive enzyme 
immunoassay was used for the quantification of N terminal propeptides in the serum (figure 2.2-11).  
The P1NP assay was performed according to the manufacturer‘s protocol. 50 μl of calibrators, controls 
and 5 μl of each sample were added in duplicate to the polyclonal rabbit anti-mouse P1NP antibody 
coated microtitre plate. 45 μl of sample diluents was added to each well containing sample. 50 μl of 
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controls) and the plate was incubated on a shaker for 60 min at RT. The plates were washed 3 times in 
250 μl of wash buffer. 150 μl of horseradish peroxidase enzyme labelled with avidin (this binds with 
the biotin) was then added to all wells and incubated for 30 min at RT.  The plates were washed and 
150 μl of chromogenic TMB substrate was added to all wells and incubated for 30 min. Finally 50 μl of 
HCl (Stop Solution) was used to stop the reaction. The plate was read at 450 nm with a reference 
range 0f 650 nm using SpectraMax M5
e
 automated plate reader (Molecular Devices). 
 
Figure 2.2-11: Principles of P1NP competitive immunoassay. 
Competitive enzyme immunoassay works on the principle of competitive binding of the anylate (antigen in the 
sample to be tested) or the enzyme conjugated antigen (bound enzyme reacts with the substrate) to the available 
antibody sites in the antibody coated plate/well. After the binding, the plates/well is washed to remove excess 
unbound anylate or antigen molecule. Substrate is added which can bind to enzyme component of the antigen 
molecular yielding colour. The more anylate is present in the sample the less will be the available sites for the 
enzyme conjugate antigen molecule to bind yielding less colour or vice versa. 
2 . 2 . 2 1  O P T I M AL  C U T T I N G  T E M P E R AT U RE  ( O C T )  E M BE D D IN G  A N D  
C R Y O ST A T  S E C T I O N I N G  
OCT embedding of the bone samples was done for longitudinal sectioning of the bone. Embedding of 
the bone samples was done using a Hexane - methanol freezing bath which was set 20 min prior to the 
embedding. Bones were placed in plastic moulds with the ventral side of the bone facing downwards. 
The moulds were filled with OCT; placed on a brass chuck until the OCT froze and stored at -80˚C 
until processing (figure 2.2-12). 
Moulds were attached to a pre-cooled metal chuck (-20˚C) using OCT. Metal chucks along with OCT 
embedded bone was mounted on the Cryostat 5030 (Bright Instrument Company, UK) and cut 4-10 
µm sections until the BM was exposed over the entire length of the bone (usually 900 µm depth from 
the surface of the bone). The cut samples were covered in clean foil to prevent contamination of the 
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Figure 2.2-12: Design of Hexane-methanol freezing bath 
2 . 2 . 2 2  M U L T I PH O T O N  M IC R O SC O P Y  
A Zeiss LSM 510 META inverted microscope (Carl Zeiss), equipped with Chameleon™ Compact OPO-Vis 
(Coherent®) Ti: Sapphire laser for multiphoton imaging was used for scanning the exposed BM of long 
bones. Multiphoton laser was used to excite the fluorescently labelled myeloma cells present in the BM. 
The ‗chameleon‘ laser module was tuned to deliver mode-locked pulsed near infrared (NIR) laser. 
Bone samples were cleared of the residual OCT by wash dissolving in 1 X PBS and the flat cut exposed 
surface was placed onto a 0.35 mm glass bottom petridish (MatTek Corporation, USA). The sample in 
the petridish was covered with PBS to prevent the BM from drying out during the prolonged scanning 
procedure. The longitudinal cut surface was focused using a 20X dry piece Plan-Apochromat objective 
lens and a low resolution (128 X 128 pixel sixe) pilot image was taken to orientate the bone.  
AIM® software (Zeiss) was used to configure the microscope to excite the sample using NIR laser and 
capture the emitted light using separate channels and band pass filters for DID dye and eGFP from 
fluorescently labelled myeloma cell and second harmonic generation (SHG) from bone. An initial pilot 
scan was done to determine the location of the bone and the ROI was set appropriately. Proximal 
metaphysis including the growth plate and epiphysis was chosen as the ROI. Entire ROI is covered as 
multiple grids (usually 5 X 6 tile scan) and scanned to a depth of 150 µm inside the bone. 
Principle of multiphoton microscopy imaging system is described in detail in figure 2.2-13. Long bones 
(R. Tibia) of 5TGM1-eGFP-DID labelled tumour-bearing mice were scanned using Zeiss LSM 510 META 
inverted microscope (Carl Zeiss), equipped with Chameleon™ Compact OPO-Vis (Coherent®) laser 
module for 820 nm multiphoton laser excitation. Bones from tumour-free untreated mice served as 
negative control. Prior imaging, bone samples were cleared off the residual OCT by wash dissolving it 
in 1 X PBS and the flat cut surface was placed onto a 35 mm glass bottom petridish (MatTek 
Corporation, USA). The petridish was covered with PBS to prevent the BM from drying out during the 
5 hr scanning process. Longitudinal cut surface was focused using a 20X dry piece Plan-Apochromat 
objective lens and a low resolution (128 X 128 pixel size) pilot image in a 5 X 6 grid fashion which 
included the upper 1/3 of the proximal tibia was taken. Each grid measured 450 X 450 µm2.  
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Figure 2.2-13: Principles of multiphoton microscopy and fluorescence imaging. 
Multiphoton microscopy is a modified laser scanning method in which there is localised, non-linear excitation of a 
fluorophore using a pulsed longer wavelength laser causing two-photon or multiphoton excitation. Here two 
photons of lesser energy are used to produce an excitation (normally excited by a single higher energy photon) by 
simultaneously interacting with a molecule in approximately less than 10-16s at a point focus. Here the excitation is 
due to intensity squared dependence (non-linear, quadratic dependence) of the photons which is greater at the 
point of focus which produces higher fluorescence and greater resolution (Zipfel et al., 2003). (A) The working 
principle of a Zeiss META 510 inverted confocal microscope equipped with a Chameleon ‗Coherent‘ multiphoton 
laser module. Here, longer wavelength 740-1140 nm (NIR, invisible) laser passes through a dichroic beam splitter, 
which deflects the laser light onto the specimen and allows the fluorescent emission to pass through. The emitted 
light is then projected onto a pinhole diaphragm by the objective and tube lens. The focus of the objective lens 
(excitation light into the specimen) and the tube lens (emission light onto the pinhole diaphragm) are set at 
―optically conjugate points‖ (confocal imaging principle). Appropriate emission band-pass filters are used to select 
the bandwidth and the signals are then sent to the photomultiplier tubes (PMT) for acquisition and image 
reconstruction. (B) The principle of fluorescence emission and SHG in BM when excited by multiphoton laser. The 
fluorophore present inside the tumour absorbs the photons from the multiphoton laser and gets excited to a higher 
energy state. Due to constant colliding of particles at the higher energy levels, the excited molecule slowly loses 
energy and decays back to the ground level. During this process it emits a photon of higher energy and lesser 
wavelength according to the fluorophore used. Collagen present in the bone is a non-centrosymmetric material 
which has the property of SHG when excited with a multiphoton laser. Here, the collagen combines the photons 
from the multiphoton laser and forms new photons with twice their energy and hence half their wavelengths. As 
the multiphoton laser used has a wavelength of 820 nm, the SHG generated has a wavelength of 410 nm which 
falls in the blue/violet range of the visible light (Deniset-Besseau et al., 2010).  
Scanning was done in multi-track mode. For the first track, 820 nm laser (20% AOTF) was used to 
excite the bone samples in order to visualise DID and eGFP signals using band pass filters 650-710 nm 
and 500-550 nm respectively, whereas bone was visualised in a second track as second harmonic 
generation (SHG) using band pass filter 390-465 nm. Other settings like detector gain (DG) and 
amplifier offset (AF) were adjusted in each scan to prevent photo-saturation of the photomultipliers 
(PMTs) and remove the background noise level. Each grid was scanned at 12 bit, frame by frame with a 
maximum scan speed of 1.92 µs to a depth of a 150 µm with 3 µm between each section at a resolution 
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of 256 X 256 pixel size) and the resultant image stacks were stitched to produce a three-dimensional 
image of the bone using the multi-time series protocol.  
2 . 2 . 2 3  S P E C T R A L  F IN GE R P R I N T IN G  
Spectral fingerprinting was done to confirm the emitted signals were correct for the measured 
fluorophore. A detailed explanation on the principle of spectral fingerprinting is given the figure 2.2-14 
below. Spectral analysis was done on some parts of the samples to verify the emission pattern of DID, 
eGFP and the SHG signals emitted from the bone.  
In order to authenticate the fluorescent signals emitted by 5TGM1-eGFP murine myeloma cells, both in 
in vitro cell aliquot and in the BM, tissue sections were imaged in lambda mode using Zeiss LSM510 
META microscope. Lambda scans were performed using 820 nm NIR laser at 20% AOTF in a 10.7 nm 
step size to collect emission signals ranging between 361.8 – 704.2 nm (eGFP emax 507-510 nm, DID emax 
675-710 nm and SHG emax 420 nm). Both 2D and 3D stack (40 µm depth for in vitro cell aliquot and 
150 µm depth for BM ) scans were performed using 20 X Plan-Apochromat objectives using a frame 
size 256 X 256 pixels on tissue sections with an interval of 3 µm between sections for the whole stack. 
 
Figure 2.2-14: Principles of spectral fingerprinting. 
Spectral or Lambda (λ) Imaging is a technique used to visually separate the emitted light into its component 
wavelengths by optical grating. (A) Emitted light from the specimen is separated into its component wavelength 
using a prism or a diffraction grating cassette. In the Zeiss LSM510 Meta system every 10.7 nm of wavelength from 
the emitted light is sent to a separate PMT and signals separated into their component wavelengths. This is then 
compared with the spectra of the individual dye. The spectral profile (spectral fingerprint) of the dye was defined 
using the eGFP labelled cells (in vitro) and control samples for the spectra and auto-fluorescence due to co-existing 
conditions inside the specimen. (B) A spectral image is a 3D dataset collection of the images from the same 
location in the specimen measured at different wavelength. (C) Spectral profile of SHG and eGFP plotted over the 
wavelength when excited with 820 nm NIR laser. SHG peaks with a maximum intensity (emax) 410 nm and eGFP 
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2 . 2 . 2 4  T H RE E - D I ME N S IO N AL  I M A G E  P R O C E S S IN G ,  V I S U AL I S AT I O N  &  
Q U A N T I T AT IV E  AN AL Y S I S  U S I N G  V O L O C IT Y  SO F T W AR E  
Volocity® 3D Image Analysis Software (PerkinElmer, USA) was used for image processing from raw 
multiphoton microscopy data for 3D visualization and quantitative analysis. Volumetric reconstruction 
and quantitative analysis was done by thresholding different signals such as eGFP, DID and SHG. 
Negative controls (tumour-free bone samples) were scanned to identify the maximum fluorescence free 
signal intensity for different channels and thresholded accordingly. Baseline background fluorescence 
signal intensity from all channels (DID, eGFP and SHG) was determined from quantitatively analysing 
tumour-free naïve bone samples. Baseline values were used to threshold the different fluorescent 
channels in order to identify DID, eGFP and bone (SHG) signals from the raw data for image 
visualization within the 3D volume of interest (VOI) (figure 2.2-15). VOI was selected by free hand 
drawing tool drawn to include the BM space in the proximal tibial metaphysis below the growth plate. 
For quantitative measurement, these thresholded signal intensities from different channels were further 
‗size thresholded‘. A ‗distance measurement‘ protocol was also used to automatically compute the 
minimum distance between the edges of DID
+
 cell to the edge of the nearest bone (SHG). Results were 
exported as Microsoft Excel® files for quantitative analysis. 
 
Figure 2.2-15: Volocity image processing for quantitation and analysis. 
(A) 3-D raw image acquired from Zeiss LSM 510 META microscope. Image shows signals from all three channels 
i.e., bone (white/gray) seen in SHG, DID (red) and eGFP (green) fluorescence as visualised from the MP. (B) Bone 
selection using volocity protocol in 3D. Bone selection protocol identifies SHG signals. (C) DID object signal 
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2 . 2 . 2 5  S T AT I ST IC A L  AN A L YS I S  
Statistical analysis was done using Microsoft Excel Professional 2010 and Prism GraphPad Ver 6.0 to 
plot graphs and the graphs were expressed as mean ± SEM unless stated otherwise. For simple 
comparison between two independent populations a ‗non-parametric‘ test with Mann Whitney-
Wilcoxon test was used where a P value less than 0.05 was statistically significant (Confidence interval 
> 95%). To determine the effect of ZA treatment on the event-free survival ‗Kaplan-Meir Survival 
Analysis‘ with Log-Rank test from GraphPad software was used. 
 






 CHAPTER 3 MODULATION OF 
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3 . 1  I N T RO D U C T IO N  
The role of BPs as inhibitors of osteoclastic bone resorption has been well established. Currently BPs, 
especially ZA, are the drugs of choice for the treatment of several osteolytic bone diseases including 
MBD and it has been identified as the most potent BP to-date. Recently, studies have shown that ZA, in 
addition to its anti-resorptive effects, also shows evidence of an anti-tumour effect in MM both in 
preclinical models and clinical trials (Croucher et al., 2003a, Avilés et al., 2007, Morgan et al., 2010a, 
Avilés et al., 2013). However, the preclinical evidence that supports the anti-tumour effect of ZA has 
focused on the late stages of the disease (Yaccoby et al., 2002, Croucher et al., 2003a). Although BPs 
like ZA and CLO showed evidence of delayed tumour incidence and prolonged survival, both in 
animal and human trials, no studies have so far focused on the effect of ZA induced inhibition of bone 
resorption on the homing and colonisation of myeloma cells in the BM.  
Over the last few years, a large body of work has been done to understand the interaction between 
the myeloma cell and the host BM mileu which might be responsible for the selective migration and 
development of myeloma cells in bone, at least during the early stages of disease development. 
Although myeloma cells were shown to interact positively with different cells of the BM mileu, the 
functional interplay between myeloma cell and osteoclast is alleged to result in a vicious cycle between 
bone destruction, release of bone derived growth factors, tumour angiogenesis and myeloma 
expansion (Hobbs 1969, Libouban et al., 2003, Oyajobi et al., 2007). Under these circumstances, it has 
been argued that the anti-myeloma effect exerted by BPs is a result of breaking the chain of 
propagation where inactive osteoclast and the subsequent inhibition of bone resorption will make the 
BM mileu a less conducive environment for the myeloma cell (Abe et al., 2004). 
In order to investigate the effect of ZA induced inhibition of bone resorption on the different 
developmental stages of MM in bone: from homing and colonisation of the tumour cell to the 
development of overt myeloma colonies, it was essential to achieve adequate suppression of the bone 
resorption using ZA prior to tumour cell injection and maintain this condition throughout the 
experimental time points in the in vivo myeloma models. In studies so far, the effect of BPs on 
myeloma development was studied where the treatment with ZA or any other BP was either initiated 
along with the tumour cell inoculation or after established disease and not prior to tumour cell 
inoculation (Dallas et al., 1999, Croucher et al., 2003a, Guenther et al., 2010). So far no study has 
optimised the dosage and duration of ZA treatment to effectively suppress osteoclastic bone resorption 
in murine models of myeloma. In this chapter, the dosage frequency effect of a subcutaneously 
administrated, clinically equivalent, dose of ZA was tested in C57BL/KaLwRij mice (5T series of 
transplantable syngeneic murine myeloma model) for a better understanding of the effect over time in 
order to determine the time taken for the onset of response and the suppression of bone resorption. 
The results from this experiment will be used in designing future experiments to achieve adequate ZA 
induced suppression of bone resorption prior to tumour cell inoculation and study the effect of these 
on myeloma development. 
J Gurubalan|Page|51  
 
3 . 2  A I M S  &  O B JE C T IV E S  
The aim of this chapter was to adequately and continuously suppress osteoclast induced bone 
resorption, over a period of time, using a clinically equivalent dose of ZA in C57BL/KaLwRij mice. 
Hypothesis: Short-term treatment of ZA (125 µg/kg X2) will be as effective as continuous treatment in 
maintaining suppression of osteoclastic bone resorption in C57BL/KaLwRij mice. 
To test this hypothesis, the effect of short-term treatment, ZA (125 µg/kg two doses in one week 
subcutaneously), was compared with a continuous treatment strategy (125 µg/kg twice a week, 
repeated every week). 
The objectives were:- 
1. To determine the time taken for the onset of ZA induced suppression of osteoclastic bone 
resorption. 
2. To determine whether short-term or continuous ZA treatment was required to maintain the 
inhibition of osteoclastic bone resorption over time. 
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3 . 3  M A T E R I A L S  &  ME T HO D S  
Detailed information on individual techniques performed are given in Chapter 2: General Materials 
and Methods. 
3 . 3 . 1  I N  V IV O  E X PE R I ME N T  
All animal work and experimental conditions were in accordance with the local guidelines and with the 
UK HOME OFFICE approval under the project licence number PPL No: 40/2901 held by Prof. Peter 
Croucher and PPL No:  40/3462 held by Dr. Colby L Eaton, University of Sheffield, UK.  
3 . 3 . 2   E X PE R I ME N T AL  D E S I G N  
For the short-term and continuous treatment regimen, age and sex matched 6-11 week old 
C57BL/KaLwRij mice were purchased from Harlan Animal Research Laboratory and housed in the 
University of Sheffield, Biological Services. For the short-term treatment regimen, mice (n=30) were 
injected with either ZA 125 µg/kg two doses three days apart or PBS subcutaneously. ZA treated (n=5) 
and PBS (control) (n=5) treated animal were sacrificed after 7, 14 and 21 days. A schematic description 
of the study design is given in figure 3.3-1 experiment I. All animals were starved 6 hr prior to the 
sacrifice in order to eliminate the circadian variation in the serum bone biomarkers. Mice were 
anaesthetized using 50-100 µl of pentobarbitone (intra-peritoneal injection) and blood samples were 
collected by cardiac puncture using 28G insulin syringe. All animals were culled by cervical dislocation 
and tissues harvested. Right tibiae from all mice were excised free of soft tissues and were stored in 
10% buffered formalin for microCT analysis and histology. Serum was collected from the blood by 
centrifugation and was stored in -80˚C for ELISA analysis. 
For the continuous treatment regimen, mice (n=32) were injected with either ZA 125 µg/kg two doses 
three days apart or PBS every week for 4 weeks. Animals (n=4, each group) were periodically 
sacrificed from both ZA treated and PBS treated control groups after 10, 17, 21 and 28 days. A 
schematic description of the study design is given in figure 3.3-1 experiment II. All animals were starved 
6 hr prior to the sacrifice in order to eliminate the circadian variation in the serum bone biomarkers. 
Animals were anaesthetized using 50-100 µl of pentobarbitone (intra-peritoneal injection) and blood 
samples were collected by cardiac puncture. Afterwards, the animals were culled by cervical dislocation 
and tissues harvested. Left tibiae from all animals were excised free of soft tissues and were stored in 
4% paraformaldehyde (PFA) for microCT analysis and histology. Serum was collected from the blood 
by centrifugation and was stored in -80˚C for ELISA analysis. 
A potential limitation in the present study is that the effect of short-term and continuous ZA treatment 
was not compared at the same time points. In the short-term treatment study comparison was done on 
day 7, 14 and 21 post ZA treatment, whereas in the continuous ZA treatment experiment comparison 
was done on day 10, 17 and 21 post ZA treatment. In the continuous treatment study, the time points 
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were chosen to fit the 5TGM1 tumour study in order to allow at least 7 days for the ZA treatment and 
3 days for the tumour burden assessment. 
 
Figure 3.3-1: Experimental design to study the effect of short-term and continuous ZA treatment. 
For the short-term treatment study (Expt I), mice were injected with 125 µg/kg ZA or PBS subcutaneously on ‗day 
0‘ and ‗day 3‘ and sacrificed after 7, 14 and 21 days following the first injection. For the continuous treatment 
study (Expt II), mice were injected with 125 µk/kg ZA or PBS on ‗day 0‘ and ‗day 3‘ and the treatment was 







































EXPERIMENT II: CONTINUOUS TREATMENT 
SACRIFICE 
EXPERIMENT I: SHORT-TERM TREATMENT  
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3 . 4  R E S ULT S  
3 . 4 . 1  C O N T I N UO U S  T RE A T ME N T  W I T H  ZA  I S  M O RE  E F F E C T IV E  A T  
I N H I B IT IN G  O ST E O C L AS T S  A N D  O S T E O BL A ST S  T H AN  S HO RT - T E R M 
T RE A T ME N T  
The number of osteoclasts (Oc) and osteoblasts (Ob) were counted in the proximal tibial metaphyseal 
region on sections stained with TRAP and H&E respectively. According to ASBMR, variables between 
subjects can be compared only when standardised to a common referent (Parfitt et al., 1987). As ZA is 
a potent bone anti-catabolic agent, a reduction in Oc number or activity following treatment is 
accompanied by an increase in bone volume. If the variables are expressed in terms of number per mm 
of bone in the trabecular region, it will result in an opposite interpretation as ZA treatment is 
accompanied by reduction in Oc number and increase in bone area and perimeter (dependent 
referent). In order to eliminate the measurement bias, for trabecular analysis, the results are expressed 
in terms of osteoclast and osteoblast index (i.e. the number of Oc or Ob per unit tissue area). For 
endocortical histomorphometric analysis, the results are expressed as Oc or Ob per mm of the 
endocortical bone, as endocortical bone perimeter is an independent referent.   
After 7 days post short-term ZA treatment, thickening of the growth-plate metaphyseal junction at the 
‗zone of provisional calcification‘ where transition from cartilage to bone occurs with distortion in the 
trabecular architecture was observed. Interestingly, after 14 and 21 days post-treatment, although there 
was a continual expansion of the zone of provisional calcification with minimal inter-trabecular spaces 
in the metaphyseal end and increased inter-trabecular space at the growth plate end, we also observed 
a progressive replacement of the upper region of this zone of calcified cartilage by normal BM 
separating it from the growth plate structures (figure 3.4-1). However, following a continuous ZA 
dosage regimen, only a moderate thickening of the zone of provisional calcification into the metaphysis 
of the tibia even after 28 days from the start of the treatment regimen was seen (figure 3.4-2).  
Following short-term ZA treatment strategy, quantitative static histomorphometry showed a significant 
reduction in Oc number in the trabecular region only after 7 days but an exponential increase after 14 
(~90%; P<0.01) and 21 days (~147%; P<0.01) post-treatment (figure 3.4-3 A). Comparison with PBS 
treated control mice showed that the high numbers of Oc in the ZA treated groups were seen on the 
surface of calcified cartilage that fills the tibial metaphysis. However, in the control mice, cartilage was 
promptly removed by osteoclastic resorption to form cancellous trabecular bone. Endocortical analysis, 
due to large variation, showed no clear evidence of changes in Oc number following short-term 
treatment strategy (figure 3.4-3 C).  
Quantitative analysis following continuous dosage with ZA showed significant increase in Oc number in 
the trabecular region at day 17 when compared with PBS treated control mice. However, no 
differences was observed at other time-points (figure 3.4-3 B). In the endocortical region, a significant 
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reduction in Oc number was seen after 28 days (figure 3.4-3 D). But, unlike the short-term regimen, 
there was no evidence of the thick band of calcified cartilage in the metaphysis following continuous 
treatment. However, a slight progressive thickening of the zone of the provisional calcification was 
observed in mice treated with ZA after all-time points. As the effect of ZA on cartilage resorption and 
growth plate modification was beyond the scope of this experiment, they were not investigated any 
further.  
In order to elucidate the effect of ZA treatment on bone formation, the numbers of Ob were 
quantitated. For trabecular analysis Ob index and for endocortical region the number of Ob per mm of 
endocortical bone was assessed. Short-term treatment regimen showed a temporary inhibition of Ob 
number in the trabecular region after 7 days when compared with PBS treated control groups; 
however, the Ob numbers resumed to control levels after 14 and 21 days post-treatment (figure 3.4-3 
E). In the continuous treatment study, there was a persistent reduction in Ob number in the trabecular 
region after all time-points when compared with PBS treated control groups (figure 3.4-3 F). In 
accordance, the endocortical analysis also showed significant reduction in number of Ob per mm of 
endocortical bone in both short-term and continuous dosage regimens when compared with PBS 
treated control groups at all-time points (figure 3.4-3 G and H).  
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CONTROL AFTER 7 DAYS AFTER 14 DAYS AFTER 21 DAYS 
    
    
Figure 3.4-1: The effect of short-term ZA treatment on bone in C57BL/KalwRij mice. 
The top panel shows representative images of TRAP stained sections of tibiae following short term ZA treatment 
after 7, 14 and 21 days post-treatment respectively. Bottom panel shows magnified proximal tibial metaphyseal 
region including the growth plate cartilage. In control PBS treated mice, the metaphyseal region showed normal 
trabecular architecture with widely interspersed trabecular bone. Following a short-term treatment strategy, 
progressive thickening of the zone of provisional calcification (ZC) extending into the metaphyseal region with 
distorted trabecular architecture was observed which was rich in osteoclasts with minimal inter-trabecular spaces 
between them. Interestingly, after 14 and 21 days, a separation between the trabecular bone and the growth plate 
cartilage was seen probably due to resumption of osteoclastic bone resorption.  
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CONTROL AFTER 10 DAYS AFTER 17 DAYS AFTER 21 DAYS AFTER 28 DAYS 
     
     
Figure 3.4-2: The effect of continuous ZA treatment on bone in C57BL/KalwRij mice. 
The top panel shows representative TRAP stained sections of tibiae from PBS treated mice (control) and following long term ZA treatment after 10, 
17, 21 and 28 days. Bottom panel shows magnified proximal tibial metaphysis including the growth plate cartilage after 10, 17, 21 and 28 days. 
Following continuous ZA treatment only a minimal thickening of the zone of provisional calcification was seen. At this point, it is interesting to note 
that, unlike the short-term treatment regimen, in this region reduced osteoclast numbers were seen. 
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Figure 3.4-3: The effect of short-term and continuous ZA treatment on the number of trabecular and cortical 
osteoclasts and osteoblasts. 
Changes in Oc index (A) and Oc number per mm of endocortical bone (C) following short-term ZA treatment. 
Changes in Oc index (B) and Oc number per mm of endocortical bone (D) following continuous ZA treatment. 
Changes in Ob index (E) and Ob number per mm of endocortical bone (G) following short-term ZA treatment 
Changes in Ob index (F) and Ob number per mm of endocortical bone (H) following continuous ZA treatment. 
Mann-Whitney‘s non-parametric two-tailed test was performed to determine significant differences between the 
control and ZA treated groups for each time point. For short-term ZA treatment n=5 for all time points and for 
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3 . 4 . 2  B O T H  S HO RT - T E R M  A N D  C O N T IN UO U S  Z A  T RE AT M E N T  R E D U C E D  
S E R U M  LE V E L S  O F  B O N E  R E S O R P T IO N  (T R A C P 5 b )  AN D  BO N E  
F O R M A T IO N  ( P 1N P )  M A R KE R S  
ELISA analysis was performed to determine the serum levels of TRACP5b and P1NP following short-
term and continuous ZA treatment. Both short-term and continuous ZA treatment regimens showed 
significant reduction in serum levels of TRACP5b and P1NP after all time points (figure 3.4-4 A, B, C 
and D). At this point, it is interesting to note that following the short term dosage regimen, 
quantitative static histomorphometry showed a gross increase in osteoclast numbers after 14 and 21 
days despite persistent reduction in serum TRACP5b levels following treatment. Interestingly, the 
elevated osteoclast numbers were also accompanied by grossly unresorbed trabecular bone in the tibial 
metaphysis which implies that following short-term ZA treatment, there is only a temporary cessation 
in the osteoclastic activity (both in terms of number and activity) which is followed by resumption of 
resorption recruiting new Oc which might be functionally less active explaining the reduced serum 
TRACP5b levels. 
 
SHORT-TERM ZA TREATMENT CONTINUOUS ZA TREATMENT 
  
  
Figure 3.4-4: Changes in serum levels of TRACP5b and P1NP following short-term and continuous ZA treatment. 
Changes in serum levels of TRACP5b (A) and P1NP (C) following short-term ZA treatment. Changes in serum levels 
of TRACP5b (B) and P1NP (D) following continuous ZA treatment assessed by ELISA analysis. For short-term ZA 
treatment n=5 for all time points and for the continuous ZA treatment n=4 for all time points Mann-Whitney‘s 
non-parametric two-tailed test was performed to determine significant differences between the control and ZA 
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3 . 4 . 3  C O N T I N UO U S  Z A  T R E AT M E N T  I S  M O RE  E F F E C T IV E  I N  P R E SE RV I N G  
B O N E  T H AN  SH O R T - T E R M  T R E AT ME N T  
As described in Chapter 2: General Materials & Methods, microCT was performed on the proximal 
tibial metaphysis to determine the structural changes following ZA treatment. Parameters such as 
trabecular bone volume (% BV/TV), cortical bone volume (Ct. V), trabecular number (Tb. N), 
trabecular thickness (Tb. Th), trabecular pattern factor (Tb. pf), structural modal index (SMI) were 
analysed. Analysis was done on a region 1 mm in length of the proximal tibial metaphysis region at a 
distance of 1.2 mm from the proximal epiphysis growth-plate junction (figure 2.2-5).  
Figure 3.4-5 shows longitudinal cross-sectional microCT images of tibiae treated with short-term ZA or 
PBS after 7, 14 and 21 days. Thickening of the growth plate was seen after 7 days post short-term ZA 
treatment; however after 14 and 21 days post ZA treatment, there was a thick band of calcified 
trabeculae with distorted architecture seen below the growth plate. At this point, it is interesting to 
note that there is widening of partially mineralised region between the calcified zone of the growth 
plate and the trabeculae below. 
Quantitative analysis showed a significant increase in both % BV/TV, Ct. V and Tb. N after 7, 14 and 
21 days whereas a reduction in Tb. Th, Tb. Pf and SMI were seen (figure 3.4-7 A, B, C D, E and F). 
Following short-term ZA administration a 2 fold, 3 fold and 5 fold increase in % BV/TV after 7, 14 and 
21 days respectively was seen with a concomitant increase in Tb. N in the metaphysis. Tb. Pf is 
quantitative parameter describing the trabecular inter-connectivity, while SMI describes the plate-rod 
characteristics of the trabeculae. Reduction in Tb. Pf and SMI following short-term ZA treatment 
showed that the highly interconnected trabecular architecture seen after 14 is a result of delayed 
osteoclastic resorption of the expanding growth-plate structures. At this point, it is interesting to note 
that the Tb. Pf and SMI values are negative after 14 and 21 days which describe the complexities of the 
calcified structure with multiple enclosed cavities within them. 
Following continuous ZA treatment, a significant increase in % BV/TV, Ct. V and Tb. N and a 
reduction in Tb. Pf and SMI was seen. No clear evidence of changes in Tb. Th was observed following 
continuous ZA treatment (figure 3.4-7 G, H, I J, K and L). Unlike the short-term treatment regimen, in 
continuous ZA treatment experiment there was no dramatic increase in the % BV/TV and Tb. N. 
Furthermore, there was no thick band of distorted trabeculae or calcified cartilage structures in the 
proximal tibial metaphysis as seen in the metaphysis of the short-term regimen. Morphologically, 
following continuous ZA regimen, the proximal tibial metaphysis showed architecturally similar 
trabecular structures when compared with control animals (figure 3.4-6).   
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Figure 3.4-5: The microCT changes in tibia following short-term ZA treatment. 
Representative longitudinal microCT cross-sections of tibiae showing the proximal tibial metaphysis of control and 
short term ZA treated animals after 7, 14 and 21 days respectively. Generalized thickening of cortical and 
trabecular bone was observed with the ZA treated mice when compared with PBS treated control animals. 
Following short term ZA treatment, we observed progressive thickening of the trabecular bone below the growth 
plate. Growth plate is the radiolucent (black) region which lies between the epiphysis and the trabecular bone 
below. After 14 and 21 days post-treatment, we also observed progressive widening between the trabecular bone 
and the calcified end of the growth plate structures. The trabecular bone which filled the metaphyseal region was 
distorted with highly interconnected trabecular bone in the short term ZA treated mice. In the control mice, this 
region was promptly resorbed by normal bone remodelling resulting in organized trabecular structures with 
normal trabecular architecture. Although the preservation of the trabecular bone in the short term ZA treatment 
indicated inhibition of bone resorption, the progressive widening of the space between the trabecular bone and 
the growth plate and the continued expansion of the trabecular bone into the metaphysis suggest only a 
temporary inhibition of osteoclastic bone resorption and osteoblastic bone formation.  
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Figure 3.4-6: The microCT changes in tibia following continuous ZA treatment. 
Representative longitudinal microCT cross-sections of tibiae showing the proximal tibial metaphysis of control and 
long term ZA treated animals after 10, 17, 21 and 28 days respectively. Like the short term ZA regimen, the long 
term ZA dosage also showed generalised thickening of both the cortical and trabecular bone when compared to 
PBS treated control mice. But unlike the short term dosage, here we observed only a minimal expansion of the 
calcified end of the growth plate structures. Although the metaphyseal region showed increased and thickened 
trabecular bone, the normal trabecular architecture was preserved and resembled the control animals. It is 
important to notice that, quantitative histomorphometry revealed continued osteoclastic and osteoblastic 
suppression following long term ZA regimen. This suggests that the continued suppression of osteoclastic bone 
resorption resulted in thickening of the cortical and trabecular bone which might have been removed or 
remodelled by normal bone remodelling whereas the continuous suppression of the osteoblastic bone formation 
resulted in the prevention of newly formed trabecular bone structures projecting and expanding into to the 
metaphyseal region.  
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Figure 3.4-7: Quantitative microCT analysis following short-term and continuous ZA treatment. 
Graphs show changes in the quantitative microCT parameters in tibia following short and continuous ZA treatment 
when compared with PBS treated age and sex matched control animals.  Quantitative parameter include %BV/TV. 
Ct. V, Tb. N and Tb. Th, and structural parameters include Tb. Pf and SMI. For short-term ZA treatment n=5 for 
all time points and for the continuous ZA treatment n=4 for all time points. Non-parametric Mann-Whitney 
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3 . 5  D I SC U SS I O N  
In this chapter, the effect of short-term and continuous treatment of ZA on bone remodelling was 
studied in the long bones of young C57BL/KaLwRij mice by histomorphometric evaluation of 
osteoclast and osteoblast numbers, serum levels of TRACP5b and H&E and microstructural changes in 
trabecular and cortical bone by microCT. As young naïve C57BL/KaLwRij mice were to be used to 
develop the 5TMM murine myeloma model (used in future experiments), which develops MM over a 
period of 3-6 weeks post tumour cell injection, it was essential to understand the quantitative and 
structural changes in the bone following ZA treatment. The main aim of this experiment was to 
determine the frequency of ZA treatment to effectively suppress osteoclastic bone resorption in young 
C57BL/KaLwRij mice. To the best of our knowledge, this is the first study that compared the effect of 
short-term and continuous doses of ZA over time in young naïve C57BL/KaLwRij mice.  
Bone remodelling is a tightly controlled process between osteoclastic bone resorption and osteoblastic 
bone formation by which bone is constantly renewed in order to maintain its structural and functional 
integrity (Raggatt and Partridge 2010). These processes also play an important role during the 
remodelling of the primary spongiosa which includes the resorption of the calcified cartilage, 
deposition of new bone and formation of trabecular bone during the longitudinal growth in young 
animals (Stroh et al., 2005). Response to inhibition of osteoclastic bone resorption will be more 
evident at parts of the bone that are actively remodelled at the time of treatment. In growing animals, 
the metaphyseal region of the bone is where there is on-going hyperactive modelling and remodelling 
directed toward resorption of the cartilage septa and bone deposition to form the organised trabecular 
bone. Therefore, static bone histomorphometry and microCT analysis was confined to analysing the 
proximal tibial metaphysis. 
The data reported in the present study shows both short-term and continuous ZA treatment inhibited 
osteoclastic bone resorption in young C57BL/KaLwRij mice which resulted in significantly greater bone 
mass. However, some clear differences have been demonstrated between the two dosage regimens. 
Short-term dosage of ZA was associated with a transient inhibition of calcified cartilage remodelling in 
the growth-plate metaphyseal junction. In contrast, following continuous ZA treatment, a continued 
inhibition of resorption in the zone of provisional calcification was seen. Interestingly, following short-
term ZA regimen there was continuous expansion of calcified cartilage structures extending from the 
zone of provisional calcification into the tibial metaphysis which contributed towards the dramatic 
increase in the trabecular bone volume when compared with continuous ZA treatment. In young 
animals, during the longitudinal growth phase, there is continuous remodelling of the calcified cartilage 
from the metaphyseal end of the growth plate which forms the cancellous trabecular bone (Schenk et 
al., 1973).  In the present study, after short-term treatment of ZA, although there was a transient 
reduction in the osteoclastic bone resorption after 7 days post-treatment, the presence of a widening 
band of complex calcified trabecular structure in the metaphysis after 14 and 21 days, rich in osteoclasts, 
suggest resumption of normal cartilage remodelling and/or resorption thus producing calcified cartilage 
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scaffolds, vascular invasions and recruitment of new osteoclasts. Contrastingly, following continuous ZA 
treatment, although there was greater cortical and trabecular bone mass, there was no significant 
variation in the osteoclast numbers when compared to PBS treated control bones. Furthermore, the 
absence of calcified cartilage structure in the tibial metaphysis suggests an inhibition of growth plate 
expansion in continuous ZA treatment regimen due to the presence of high levels of intercellular ZA. 
Similar findings were reported by Schenk et al., (1973) where treatment with BPs showed differential 
effects from inhibition of cartilage resorption to defective bone matrix mineralisation depending on the 
type of BP and the frequency of administration. 
To-date, ZA is a potent anti-resorptive agent with a high bone binding affinity (Green 2005). The 
inhibitory effect of ZA on osteoclastic bone resorption seems to be mediated by several different 
mechanisms: inhibition of osteoclast formation, interference with osteoclast function and induction of 
apoptosis (Coxon et al., 2000, Pan et al., 2004, Nyangoga et al., 2010). In addition to the inhibitory 
effect on osteoclasts, BPs were also shown to affect osteoblasts and their function. However, the effect 
of BPs on osteoblasts is quite controversial. BPs were shown to promote (Reinholz et al., 2000, Pan et 
al., 2004) and inhibit (Khokher and Dandona 1989, Klein et al., 1998) osteoblast formation, activation 
and mineralisation. Recently, Patntirapong et al., (2012) showed in addition to their inhibitory effect 
on osteoclasts, BPs also inhibited mineralisation and differentiation of MSCs and osteoblasts by direct 
cytotoxicity. At this point, it is interesting to note that in this experiment short-term ZA treatment was 
associated with a transient reduction (only after 7 days post-treatment) in osteoblast numbers in the 
trabecular region whereas normal control numbers were present after 14 and 21 days. However, in the 
case of continuous dosage regimen, there was a sustained reduction in osteoblast numbers in the 
metaphyseal region at all-time points. This suggests that the inhibitory effect of ZA on osteoblast is 
short-lived with the effect being prominent only for a short period following ZA injection and repeated 
dosage resulted in continuous suppression of osteoblast. Whether this reduction in osteoblast numbers 
in the metaphyseal region was a consequence of ZA induced direct cytotoxicity on osteoblasts or 
indirect effect due to inhibition of osteoclastic bone resorption was not clear from this experiments.  
Serum levels of bone resorption (TRACP5b) and bone formation (P1NP) markers were quantitated to 
assess the systemic changes in bone remodelling following ZA treatment. A significant reduction in both 
TRACP5b and P1NP levels suggested profound inhibition of both osteoclastic and osteoblastic activity 
after short-term ZA administration. However, it is particularly interesting that the serum TRACP5b 
levels remained low despite a substantial increase in osteoclast numbers in the trabecular region after 14 
and 21 days of short term ZA treatment. TRACP5b is produced by osteoclasts during active osteoclastic 
bone resorption and serves as an indicator for both osteoclast activity and osteoclast number (Halleen 
et al., 2006). Nordhal et al., (1998) showed osteoclasts that are involved in cartilage resorption (also 
referred as chondroclast) near the growth plate structurally differ in terms of high levels of intrinsic 
TRACP5b enzyme that is not released into the circulation. Furthermore, P1NP levels which are 
breakdown products released into circulation during osteoblastic bone formation were profoundly low 
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in the ZA treated groups. This further implies that the trabecular bone mass observed in the 
metaphyseal region was not the product of osteoblastic bone formation, but due to the preservation of 
calcified cartilage structure due to delayed osteoclastic bone resorption.  
It is now clear that, ZA treatment used to inhibit osteoclastic bone resorption is also accompanied by 
substantial inhibition in the osteoblastic bone formation. Importantly, the inhibitory effect of ZA on 
osteoblasts may be secondary to inhibition of osteoclastic resorption or due to direct cytotoxic effects 
(Patntirapong et al., 2012). However, the mechanisms responsible are not known. Furthermore, data 
from the present study also showed that ZA treatment is associated with considerable micro-structural 
alteration of the bone at least in growing animals, whether this will affect tumour progression in 
models of MM grown in these animals is not known. Most animal models of MM and bone metastases 
involve young animals; therefore interpretation of ZA effect on osteoclastic bone resorption has to be 
done with caution and must consider the effects on osteoblasts and bone formation.  
To conclude, short-term ZA treatment was associated only with a temporary inhibition of osteoclastic 
bone resorption and abnormal bone remodelling while a continuous ZA treatment was associated with 
continuous inhibition of osteoclastic bone resorption. Additionally, short-term ZA treatment was 
accompanied with a transient inhibition of bone formation and considerable micro-structural alteration 
of the trabecular bone, while continuous ZA treatment resulted in a continual suppression preserving 
the normal trabecular architecture in the metaphyseal region. Therefore, a continuous ZA treatment 
will be more suitable to achieve profound inhibition of osteoclastic bone resorption in experimental 
animals to study the effect of ZA on myeloma development. 






 CHAPTER 4 ESTABLISHING THE 
DEVELOPMENTAL STAGES OF 
MULTIPLE MYELOMA  
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4 . 1  I N T RO D U C T IO N  
Unlike other haematological cancer, MM is an antibody producing B lymphocyte malignancy 
characterised by infiltration of myeloma to the BM, profound increase in osteoclastic bone resorption, 
and development of severe osteolytic bone disease. This is attributed to the selective localisation of 
myeloma cells to the BM during the main course of the disease progression. Several studies have 
suggested that the interaction between the myeloma cell and the host BM microenvironment plays an 
important role in the selective migration and colonisation of myeloma cell to bone (Manier et al., 
2012). Furthermore, myeloma cell interactions with the BM microenvironment have also been 
implicated in the contribution of survival advantage and protection to myeloma cells against anti-
myeloma chemotherapy (Wei and Au 2005, Castells et al., 2012).  
Recent studies have focused on identifying the functional interactions between the myeloma cells and 
the cells of the BM microenvironment in an attempt to find newer therapeutic targets (Cheung and 
Van Ness 2001). The concept of ‗metastatic niche‘ in which the non-cancerous cells such as BMSC, 
BMEC and osteoclasts and the liquid mileu in the BM rich in bone-derived growth factors, chemokines 
and cytokines primes and augments the BM microenvironment for the homing and growth of 
myeloma cells has led to the possibility that targeting these non-cancerous compartments will offer 
therapeutic benefits (Manier et al., 2012). In  particular, the role of osteoclasts (Roodman 2001, Abe et 
al., 2004), which contributes to the ‗vicious cycle‘ between osteolytic bone destruction and myeloma 
expansion and the availability of specific inhibitors of osteoclastic bone resorption such as CLO and ZA 
have made these cells an attractive target for myeloma management (Galson et al., 2013). 
In order to study myeloma-osteoclast interactions, to identify key time points in myeloma progression 
and to study the effect of anti-osteoclast treatment, it is essential to characterise the developmental 
stages of myeloma and the associated BM alterations. Currently, in vivo murine models of myeloma 
such as SCID-hu model and 5T series are the extensively used to study these complex interactions and 
to determine the impact of drug treatment. In this study, flow cytometry, CD138 
immunohistochemistry and three-dimensional (3D) multiphoton microscopy techniques were used to 
detect and map the tumour cells in bone and to evaluate the progression of tumour burden from a 
‗single‘ cell that reached the BM to established ‗colonies‘ using the 5TGM1 murine model of myeloma. 
Furthermore, myeloma bone disease progression was also monitored by histomorphometry, microCT, 
measuring serum levels on bone turnover markers and computational image analysis methods to assess 
the changes in osteoclast and osteoblast numbers, microstructural alteration in bone, systemic changes 
in bone remodelling markers and myeloma induced osteolytic lesions respectively during myeloma 
progression. 
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4 . 2  A I M S  &  O B JE C T IV E S  
The aim of this chapter was to identify key time points and the temporo-spatial orientation of 
myeloma cells in bone during the developmental stages of the disease in bone: from a single cell to the 
development of overt myeloma colonies in bone using the 5TGM1 murine model of myeloma.  
Hypothesis: Individual myeloma cells extravasate from the peripheral circulation, home to specific 
locations in the BM and proliferate to establish overt myeloma colonies. 
In order to detect 5TGM1 cells in bone by flow cytometry and multiphoton microscopy, eGFP labelled 
5TGM1 cells were used. As eGFP was not adequately expressed until established colony formation the 
cells were further labelled with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine 4-
chlorobenzenesulfonate (DID), a far-red lipophilic fluorescent cell membrane dye, in order to visualise 
the cells during early stages of disease. 
The preliminary objectives were:- 
1. To optimise the DID labelling of 5TGM1-eGFP murine myeloma cells. 
2. To determine the effect of DID labelling on myeloma cell proliferation and of cell proliferation 
on DID labelling. 
The main objectives were:- 
1. To identify and quantify the number of 5TGM1 murine myeloma cells that arrive in the bone, 
the number of cells that proliferate to form colonies and the overall tumour burden in the 
bone at the end stages of disease. 
2. To study the local and systemic effects in bone during the development of myeloma.  
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4 . 3  M A T E R I A L S  &  ME T HO D S  
Detailed information on individual techniques performed is given in Chapter 2: General Materials and 
Methods. 
4 . 3 . 1  D E T E R M IN I N G  T HE  O P T I M AL  C O N C E N T R A T I O N  O F  V Y B R A N T  D ID  D YE  
T O  L A BE L  5 T M M - e GF P  M U R I N E  M YE LO M A  C E L L  
In order to determine the concentration of DID dye required to stably label eGFP expressing 5TMM 
murine myeloma cells, 2.5, 5, 10 and 15 µl/106 cell concentrations of the Vybrant DID dye (Catalogue 
No. V-22887; Life Technologies) was tested to identify the optimal concentration. 5TMM-eGFP murine 
myeloma cells were washed in PBS and suspended at concentration of 1 X 10
6
 cells per ml of serum free 
media (RPMI 1640). Vybrant® DiD Cell-Labelling solution was added at concentration 2.5, 5, 10 and 
15 µl/ml and mixed by gentle pipetting. Unlabelled 5TMM-eGFP cells were used as negative control. 
Cells were incubated in the dark at 37˚C in 5% CO2 incubator for 30 min. After incubation, cells were 
pelleted down by adding foetal calf serum (10% of the volume) and centrifuging at 1500 RPM for 5 
min. Cell pellets were then washed with normal complete media  and resuspended in 1 ml of PBS 
(Refer Materials & Methods Section 2.2.4). Flow cytometry analysis was done to determine the 
percentage of DID labelled cells. Propidium Iodide (PI) staining method was used to determine cell 
viability and the percentage of viable DID label and dead cells were computed. 
4 . 3 . 2  D E T E R M IN I N G  T HE  E F F E C T  O F  D I D  L AB E L L IN G  O N  5 T G M1  M U R I N E  
M Y E LO M A  C E L L  G RO WT H  
5TGM1-eGFP murine myeloma cells were labelled with 10 µl of DID (optimal concentration) or 
unlabelled. Cell proliferation was measured over time after 0, 1, 3, 5, 7, 9 and 11 days by cell counting 
and flow cytometry was used to measure DID labelled cell at each time point. Unlabelled 5TGM1-eGFP 
cells were used as negative controls. Refer Chapter 2: Materials and Methods for detailed explanations 
on Neubaeur cell counting method, flow cytometry and multiphoton microscopy detection of DID 
labelled 5TGM1-eGFP cells. 
5TGM1-eGFP-DID and unlabelled 5TGM1-eGFP cells were seeded at a concentration of 1 X 10
5
 cells in 
10 ml of complete media and incubated at 37˚C in a 5% CO2 incubator in T25 flask (Becton, 
Dickinson and Company). Four replicates were maintained in separate T25 flasks for both cell types for 
each day. At days 2, 4, 6, 8 and 10, 5 ml of fresh media was replaced in each flask by gently pipetting 
out 5 ml of used media. Detailed experimental design is given in figure 4.3-1. For in vitro  multiphoton 
microscopy a small aliquot of cells were placed on a glass slide with a 0.1 mm cover-slip on top and 
scanned using 820 nm laser for the detection of both DID and eGFP signals. Scanning was done on 
each of the four replicates to a depth of 40 µm and images were analysed using Volocity™ software.  
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Figure 4.3-1: Experimental design for determining the effect of DID labelling on cell proliferation. 
An in vitro longitudinal study was performed to investigate the effect of DID labelling on 5TGM1eGFP myeloma 
cell growth. DID labelled and unlabeled 5TGM1-eGFP cells were seeded at a concentration of 1 X 10
5
 cells in 10 ml 
normal complete media (RPMI 1640 + additives) in T25 flasks and maintained at 5% CO2 incubator at 37˚ C. 
Four T25 flasks were maintained for each cell type for every time point. 5 ml of fresh media was used to replace 
used media from every flask on days 2, 4, 6, 8 and 10.  
4 . 3 . 3  E X PE R I ME N T AL  D E S I G N  T O  C H A R AC T E R I S E  T H E  D E V E LO P M E N T AL  
S T A GE S  O F  M YE LO MA  I N  BO N E  
All animal work and experimental conditions were in done accordance with the local guidelines and 
the with the home office approval provided under the project licence number PPL No:  40/3462 held 
by Dr. Colby L Eaton University of Sheffield, UK.  
Age and sex matched 7-11 weeks old C57BL/KaLwRij mice were injected with 2 X 10
6
 5TGM1-eGFP-
DID cells (tumour-bearing) or PBS (tumour-free control) via the tail vein. Mice were randomised and 
sequentially grouped into four time points to study the early (day 3), intermediate (days 10 and 14) 
and end stage (day 21 +) of the disease. For the end stage, all animals were culled when the first animal 
show signs of morbidity such as development of hind limb paralysis or sickness. A schematic 
representation of the study design and the number of animals in each group at each time points is given 
figure 4.3-2. 
All animals were starved 6 hr prior to the sacrifice in order to eliminate the circadian variation in the 
serum bone biomarkers (Christgau 2000, Clowes et al., 2002). Mice were anaesthetised using 0.5 
ml/kg of pentobarbitone (intra-peritoneal injection) and blood samples were collected by cardiac 
puncture. Animals were culled by cervical dislocation while under deep non-recoverable anaesthesia 
and tissues harvested. The following tissues were harvested and stored appropriately. 
  
TIME LINE 
DAY 0 DAY 1 DAY 3 DAY 5 DAY 7 DAY 9 DAY 11 
5 ml of used media replaced with 5 ml of fresh conditioned media in each flask 
1. Cell counting (Neubaeur chamber method). 
2. Flow cytometry evaluation of percentage labeling. 
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Figure 4.3-2: Experimental Design for longitudinal assessment of myeloma development in the 5TGM1 murine 
model of myeloma. 
Naïve C57BL/KaLwRij mice were injected with either PBS or 2 X 10
6
 5TGM1-eGFP-DID cell via the tail vein and 
were sacrificed periodically after 3, 10, 14 and 21 days to investigate the different phases of myeloma development 
in bone over time. After 3, 10 and 14 days post injection time points naïve controls (n=4) and 5TGM1-eGFP-DID 
tumour (n=8) and after 21 days naïve controls (n=4) and 5TGM1-eGFP-DID tumour-bearing mice (n=7) were 
culled. 
4 . 3 . 4  S T AT I ST IC A L  AN A L YS I S  
Microsoft Office Excel 2010® was used to plot the graphs and values represented as Mean ± SEM 
unless stated otherwise. Prism GraphPad Ver 6.0 was used for comparison of parameters between 
naïve PBS and 5TGM1 tumour-bearing animals between two independent populations a two-tailed  
‗non-parametric‘ Mann Whitney-Wilcoxon test was used in unpaired tests to compare means with P 





DAY 0 DAY 3 DAY 10 DAY 14 DAY 21 
5TGM1-eGFP-DID 
labelled MM cell 
injection 
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4 . 4  R E S ULT S  
4 . 4 . 1  O P T I M IS IN G  D ID  L AB E L L IN G  O F  5 T M M - e G F P  M U R IN E  M Y E L O M A  C E L L S  
In order to detect and visualise the 5TMM myeloma cells in bone as they arrived and started to form 
colonies they were labelled with DID and eGFP. The preliminary objective was to identify the optimal 
Vybrant DID dye concentration required for labelling 5TGM1-eGFP cells. Flow cytometry evaluation 
was used to measure the percentage of cell death and viable DID labelled 5TMM-eGFP cell following 
the staining procedure. 
Results showed that DID labelling at a concentration of 10 µl/10
6
 cells for 30 min, incubated in 5% CO2 
incubator, achieved maximum labelling (>95 %) with minimal cell death (figure 4.4-1) while a lesser 
dosage resulted in reduced labelling and higher dosage resulted in increased cell death following 
labelling. This dose was used hereafter to label 5TGM1-eGFP myeloma cells. 
 
Figure 4.4-1: DID concentration versus 5TGM1-eGFP-DID cell viability. 
Concentration of vybrant DID labelling solution versus percentage viable and DID labelled cells and percentage cell 
death assessed by flow cytometry following 2.5, 5, 10 and 15 µl of vybrant labelling solution (n=3). 
4 . 4 . 2  5 T G M1  C E L L  P RO L I F E R A T I O N  E F F E C T S  O N  D ID  L A BE L L IN G  O V E R  T I ME  
In order to understand the effect of DID labelling on 5TGM1-eGFP cell proliferation and of cell 
proliferation on DID labelling a longitudinal study was performed to changes in percentage labelling 
over time by flow cytometry. Multiphoton microscopy was used to quantitate DID labelling and 











Optimising DID labelling concentration 
viable and labeled cells Dead cells
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Effect of DID labelling on 5TGM1-eGFP cell proliferation 
Results showed that there was no difference between DID labelled 5TGM1-eGFP cells and unlabelled 
5TGM1-eGFP cells in their rate of proliferation in vitro over a period of 11 days in complete media 
(figure 4.4-2). 
 
Figure 4.4-2: Effect of DID labelling on the proliferation of 5TGM1-eGFP cells in vitro. 
The number (in millions) of 5TGM1-eGFP-DID and unlabelled 5TGM1-eGFP cells after day 0, 1, 3, 5, 7, 9 and 11 
post DID dye labelling in vitro culture (n=4). 
The effect of 5TGM1-eGFP cell proliferation on DID labelling 
Flow cytometry quantitation of live and viable DID labelled 5TGM1-eGFP cells was done using the 
FACS Calibur flow cytometer (Becton Dickinson, Oxford UK). A Propidium Iodide (PI) staining method 
was used for the detection of dead cells. Figure 4.4-3 shows flow cytometry profile for live cell gating 
using PI staining method. The results showed that the DID labelling was stable and above 90% after 
day 0 and day 1 post labelling, however DID labelling dropped to 42.5% and 7.2% on day 3 and day 
5 respectively and continued to fall (figure 4.4-4 A). Interestingly, the mean fluorescence intensity 
(MFI) which is flow cytometric  measure of the fluorescence intensity of DID labelled cells also 
followed a similar pattern like the percentage labelling (figure 4.4-4 B) shows typical flow cytometry 
changes following labelling after 0, 1, 3, 5, 7, 9 and 11 days post DID labelling. A dramatic shift in the 
DID labelled 5TGM1-eGFP population over the FL-4 axis which suggested that there was not only a 
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Figure 4.4-3: Flow cytometric analysis of DID labelling of 5TGM1-eGFP cells over time. 
(A) Flow cytometry analysis was done to identify viable cell using Propidium iodide staining method with 
5TGM1-eGFP-DID cells without PI with side scatter (SSC) on X-axis and FL2 on Y-axis and the shift in the FL2-H 
channel following PI staining (n=4). A polygon gate was used to gate the PI negative viable cell population. (B) 
DID labelling of 5TGM1-eGFP cells was done and monitored for the percentage DID labelled cells longitudinally 
after day 0, 1, 3, 5, 7, 9 and 11 days using flow cytometry. Figures show serial flow cytometry profiles with FL1-H 
(eGFP
+
) on the x-axis and FL-4- H (DID
+
) on the Y-axis (n=4).  Percentage DID
+
 cells were analyzed only on the 
viable population. Figure shows a reduction in the percentage 5TGM1-DID
+
 cell and also a gradual shift (from 
right to left) in the DID
+
 population along the FL4-H axis suggesting a reduction in the mean fluorescence 
intensity (MFI) over time. 
 
  
Day 0 Day 1 Day 3 Day 5 
Day 7 Day 9 Day 11 
No PI With PI 
A. PI staining for detection of viable cell 
B. Percentage changes in DID labelling over time 





Figure 4.4-4: The effect of proliferation on DID labelled 5TGM1-eGFP cells as assessed by flow cytometry. 
(A) In vitro changes in the percentage 5TGM1-DID
+
 cells over time (n=4). (B) Changes in mean fluorescent 
intensity (MFI) of the 5TGM1-DID
+





























Days post labelling 


















Days post labelling 
Mean DID fluorescent intensity over time 
5TGM1-eGFP-DID
B 
J Gurubalan|Page|78  
 
Multiphoton spectral confirmation of 5TGM1-eGFP-DID murine myeloma cells in vitro 
Lambda imaging or spectral fingerprinting was done on in vitro 5TGM1-eGFP-DID cells in order to 
authenticate the emission fluorophore wavelengths. In vitro imaging of 5TGM1-eGFP-DID cells on glass 
slides showed emission signals that peaked at both 507 nm and 675 nm which corresponded to DID 
and eGFP signals respectively (figure 4.4-5). 
 
Figure 4.4-5: In vitro spectral imaging of 5TGM1-eGFP-DID cell. 





objects. Fig B shows spectral profile with emission peaks of the emitted signals form the 5TGM1-eGFP-
DID cells. (B) Wavelength against maximum fluorescence intensity of the emitted light showing emission peaks 
507-509 nm and 650-675 nm which corresponds to eGFP and DID spectral profiles suggesting emission of both 
eGFP and DID signals. 
The effect of 5TGM1-eGFP-DID cell proliferation on the distribution of the DID label on the cell 
membrane 
Multiphoton microscopy analysis was done to determine the number of 5TGM1-DID
+
 present in 
culture over time post-labelling. As the cells were labelled with both DID and eGFP results were 
expressed as the number of 5TGM1-DID
+
 per cent 5TGM1-eGFP
+
 cells. Results showed that the number 
of 5TGM1-DID
+
 labelled cells were 120% and 155% compared to the percentage of 5TGM1-eGFP
+
 
cells after 0 and 1 days post labelling respectively and drastically dropped down to 24.5% after day 3 
and continued to drop to 15.4% on day 11 post labelling (figure 4.4-6 A). This was unexpected, but 
may just reflect the increased intensity of DID labelling compared to eGFP and the ease of detection of 
these fluorophores. Figure 4.4-6 B shows multiphoton microscopy images of 5TGM1-eGFP-DID cell 
aliquot (in vitro) over time. 
  















Figure 4.4-6: Effect of 5TGM1-eGFP-DID cell proliferation on DID labelling by multiphoton microscopy. 
(A) Changes in the number of 5TGM1-DID
+
 cells expressed as a % of the 5TGM1-eGFP
+
 population (in vitro 
culture system) after 0, 1, 3, 5, 7 9 and 11 days post DID labelling as detected by multiphoton microscopy (n=4). 
(B) Representative multiphoton microscopy images of in vitro 5TGM1-eGFP-DID over time in DID-eGFP 
superimposed overlay, DID
+
 (red) and eGFP
+ 
channels (green). In vitro 5TGM1-eGFP-DID cells were scanned using 
820 nm laser using 20X objective in multiphoton microscopy. At day 1, cells were seen to be completely covered 
with DID label, however there was a gradual reduction in the amount of DID labels distributed on the surface of 
5TGM1-eGFP
+
 cells from day 1 to day 11. As DID label is a lipophilic cell membrane dye, cell proliferation resulted 
in random sharing of DID dye between the daughter cell causing gradual loss of the DID label from the cell 
membrane of rapidly diving cell over time. However, even after day 11 there is a small population of 5TGM1-DID
+
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B. In vitro multiphoton microscopy of 5TGM1-eGFP-DID cells over time   
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4 . 4 . 3  A S SE S S ME N T  O F  T UM O U R  P R O G RE S S IO N  I N  5 T GM 1  M U R I N E  M O D E L  
O F  M YE L O M A   
Flow cytometric evaluation of tumour burden over time 
Flow cytometric evaluation of the BM cells was done in order to quantify the number of 5TGM1-eGFP-
DID cells present in bone. The process of BM extraction and flow cytometry analysis are described in 









 cells. BM cells from naïve tumour-free mice served 
as negative control for gating unlabelled cells. Compensations were not required as there was no cross 
talk between eGFP (emax 507 nm) and DID (emax 675 nm). Quadrant gating was applied based on 









cells were measured (figure 4.4-7).  
 
Figure 4.4-7:  Flow cytometric profiles of 5TGM1-eGFP-DID tumour cells in the BM over time. 
Flow cytometry was done using Becton Dickinson FACS Calibur flow cytometer equipped with Cell quest software 




 & dual DID-GFP
+
 cells were measured 
from BM cells over time and expressed as ‗Pseudo colour plots‘. (A) Representative flow cytometry profile of 
naïve murine BM cell which served as a negative control. (B-F) Representative flow cytometry profiles of BM from 
5TGM1-eGFP-DID tumour-bearing mice after 3, 10, 14 and 21 days respectively. 
DAY 3 DAY 10 
DAY 14 DAY 21 
CONTROL A B C 
D E 
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Results showed the presence of 5TGM1-DID
+
 cells (1.64 ± 0.14 %) in BM after 3 days post tumour cell 
injection, whereas there was no evidence of eGFP
+





However, after 10 and 14 days, there was a gradual reduction in the percentage 5TGM1-DID
+
 
population (1.64% ± 0.14 to 0.66 ± 0.06%), while there was a gradual and increasing percentage of 
5TGM1-eGFP
+
 cell population evident in the BM (0.05 ± 0.01% to 0.86 ± 0.17%). At 21 days post 
injection, when the mice were sacrificed due to development of either sickness or hind limb paralysis, a 
1.35 ± 0.16 % of 5TGM1-DID
+
 cells and a dramatic increase in the 5TGM1-eGFP
+
 tumour population 




 cell population was 
noticeably very low at all-time points (figure 4.4-8). 
 
 
Figure 4.4-8: Quantitative flow cytometry analysis of 5TGM1-eGFP-DID tumour development in bone over time. 








 cells in BM after 3, 10, 14 and 21 
days post 5TGM1-eGFP-DID tumour cell injection (n=8 for day 3, 10 and 14; n=7 for day 21).  
Quantification of CD138
 
positive plasma cells in BM following 5TGM1 myeloma development 
Results showed that CD138
+
 population in naïve tumour-free animals appeared as single cells 
distributed throughout the BM at all-time points. There was no evidence of CD138
+
 cell colonies in 
tumour-free naïve control animals. However, in the 5TGM1 tumour-bearing animals, CD138
+
 colonies 
appeared in the BM as early as 10 days post tumour cell injection. Interestingly, quantitative analysis 
showed that there was no difference in the number of single CD138
+
 cells between naïve and tumour-
bearing animals after 3 and 10 days post tumour cell injection. However, after 10 days post tumour cell 
injection, in tumour-bearing animals 0.11 ± 0.03% of the BM space was occupied by CD138
+
 tumour 
colonies. After 14 days post tumour cell injection, there was an increase in both single cells and CD138
+
 
colonies in the tumour-bearing group with almost the entire BM being replaced with CD138
+
 
population at 21 days. At this point, the entire BM was densely packed with CD138
+
 cell which made 
3 10 14 21
% 5TGM1 DID+ eGFP+ 0.00 0.01 0.01 0.13
% 5TGM1 DID+ 1.64 0.58 0.66 1.35











Days post tumour cell injection 
Percenatge 5TGM1-eGFP-DID cells in BM over time 
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detection of single CD138
+
 cells highly impracticable and therefore the end point was described as 
percentage BM space filled with CD138
+
 tumour (figure 4.4-9 & figure 4.4-10). 
 
Figure 4.4-9: Changes in CD138
 
positive cells in the BM over time post injection of 5TGM1 cells. 
Double Y-axis graph showing changes in CD138
+
 cell number and percentage BM space occupied by CD138
+
 
colonies in naïve and 5TGM1 tumour-bearing animals after 3, 10, 14 and 21 days post tumour cell injection (n=8 
for day 3, 10 and 14; n=7 for day 21). Non-parametric Mann-Whitney Wilcoxon‘s test was used to compare the 
difference in single CD138
+
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Figure 4.4-10: CD138 immunohistochemistry staining showing the developmental stages of 5TGM1 murine 
myeloma in bone. 
Representative CD138 IHC stained tibial sections of naïve tumour-free (A) and 5TGM1 tumour-bearing mice after 3 
(B), 10 (C), 14 (D) and 21 (E) days post tumour cell injection showing CD138
+
 tumour colonies (black arrow). IHC 
was performed for all time points on naïve and 5TGM1-eGFP-DID tumour-bearing mice to detect the presence of 
single CD138
+
 plasma/myeloma cells (red arrow) and CD138
+
 tumour colonies (black arrow) in the BM. Magnified  
images of proximal tibial metaphysis of naïve (F) and 5TGM1 tumour-bearing mice after 3 (G), 10 (H), 14 (I) and 
21 (J) days post tumour cell injection shows the development of myeloma from single cell to overt myeloma 
colonies that fills the entire BM. Strong cell membrane CD138 immune reactivity is observed in both naïve and 
myeloma tumour-bearing animals. 
  
A B C D E 
F G H I J 
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Three-dimensional quantification of tumour burden in the 5TGM1 murine model of myeloma using 
multiphoton microscopy 
In order to understand the temporal and spatial relationship of 5TGM1-eGFP-DID myeloma 
development in bone over time, multiphoton microscopy was performed for the detection of 5TGM1-
eGFP-DID labelled tumour cell and bone using SHG (section 2.2.22). In order to confirm and 
authenticate DID, eGFP and SHG signals, spectral fingerprinting was done on bone samples with 
established tumour formation. In vivo spectral imaging from bone showed emission signals which 
peaked at 410 nm (blue), 507 nm (green) and 675 nm (red) which corresponded to bone, eGFP and 
DID wavelengths respectively (figure 4.4-11).  
 
Figure 4.4-11: In vivo spectral fingerprinting. 
(A) 2D spectral image (256 X 256 pixels) of 5TGM1-eGFP-DID tumour-bearing bone scanned using lambda mode 
using 820 nm NIR laser. (B) The spectral profiles and emission peaks (emax) of individual wavelengths (λ) emitted 
from bone, GFP and DID components. Bone emitted at 410 nm which is the second harmonic generation 
produced when 820 nm NIR laser is split into two individual photons with double the energy and half the 
wavelength (410 nm). eGFP present inside the cell cytoplasm emitted between 507-510 nm and DID that labels the 
cell membrane peaked between 675-710 nm. 
Results showed that 5TGM1-DID
+
 cells were seen in the BM at all-time points and 5TGM1-eGFP
+
 
colonies were seen only from 14 days post tumour cell injection (figure 4.4-12). Therefore quantitative 




 of BM and percentage of BM occupied by 
5TGM1-eGFP
+
 colonies (volume of 5TGM1-eGFP
+
 colonies/volume of BM). Quantitative analysis 
showed significant reduction difference in the number of 5TGM1-DID
+
 cells per mm
3
 of BM after day 
10 and day 21 post tumour cell injection when compared with day 3 post tumour cell injection 
(P<0.05;  figure 4.4-13 A). 5TGM1-eGFP
+
 tumour colonies appeared in the BM only at day 14 (1.8 ± 
0.76 %) with a dramatic increase at day 21 (47.34 ± 6.03 %; figure 4.4-13 B).  
In order to study the spatial distribution 5TGM1-DID
+
 cell in the BM over time, minimum distance of 
all 5TGM1-DID
+
 cell to the nearest bone was measured. This analysis was restricted to 5TGM1-DID
+
 cell 
and not to 5TGM1-eGFP
+
 tumour colonies, as they were surrounding the trabecular bone and revealed 













 cells from the nearest bone were constant and ranged between 42.29±1.58 µm (day 3), 
42.75±3.88 µm (day 10) and 42.21±2.55 µm (day 14) followed by a dramatic reduction to 
23.53±2.33 µm at day 21 post tumour cell injection (figure 4.4-13 C). 
 
Figure 4.4-12: Multiphoton microscopy images showing the development of 5TGM1-eGFP-DID murine myeloma 
cells in bone. 
Representative examples of 3D cut sections of multiphoton images of tibia following development of myeloma 
using 5TGM1-eGFP-DID cells after 3, 10, 14 and 21 days post tumour cell injection. Multiphoton microscopy was 
performed using 820 nm pulsed multiphoton laser in order to visualise bone using second harmonic generation, 
DID and eGFP signals from the 5TGM1-eGFP-DID cells. Images show the presence of DID labelled 5TGM1 cells 
(red objects) randomly distributed within the BM. eGFP expressing 5TGM1 myeloma colonies (green) were first 
observed at day 14 post tumour cell injection which progressively filled the BM at day 21. 
 
DAY 3 DAY 10 
DAY 14 DAY 21 





Figure 4.4-13: Quantitative assessment of tumour burden in 5TGM1 murine model of myeloma using multiphoton 
microscopy. 
(A) The number of DID
+
 cells per mm
3
 of BM, (B) percentage BM occupied DID
+
 cell, (C) percentage BM space 
occupied by 5TGM1-eGFP
+
 colonies after 3, 10, 14 and 21 days post tumour cell injection.  (D) Changes in the 
average minimum distance of 5TGM1-DID
+
 cell to the nearest bone after 3, 10, 14 and 21 days post tumour cell 
injection (n=8 for day 3, 10 and 14; n=7 for day 21). Values represent mean ± SEM. Mann-Whitney‘s non-
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4 . 4 . 4  T HE  E F F E C T  O F  M YE L O M A  D E V E L O PM E N T  O N  G RO S S  MO R P H O L O G Y  
No obvious morphological or clinical signs were observed in 5TGM1-eGFP-DID tumour-bearing mice 
until the latter stages of disease development when the animals developed unilateral or bilateral hind 
limb paralysis, generalized signs of morbidity such as hunched-back appearances, lethargy or weight 
loss. 4 out of 7 5TGM1 tumour-bearing animals developed bilateral hind limb paralysis after 21 days 
post tumour cell injection. 5TGM1-eGFP-DID myeloma bearing mice lost approximately 10% of body 
mass when compared with tumour-free control groups and a three-fold increase in the spleen weight 
and a one-fold increase in the liver weight was observed in the tumour-bearing group by the time they 
showed signs of morbidity when compared with tumour-free control group (figure 4.4-14). 
 
  
Figure 4.4-14: Effect of 5TGM1 tumour development on gross morphology 
Changes in body weight (A), Spleen weight (B) and liver weight (C) following 5TGM1 murine myeloma 
development when compared with disease-free control animals after 3, 10, 14 and 21 days post 5TGM1-eGFP-DID 
tumour cell injection (Controls n=4 for all time points; 5TGM1 tumour-bearing groups n=8 for day 3, 10 and 14; 
n=7 for day 21). Mann-Whitney‘s non-parametric two-tailed test was performed to determine significant 
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4 . 4 . 5  T HE  E F F E C T  O F  M YE L O M A  D E V E L O PM E N T  O N  BO N E  RE MO D E LL IN G  
Changes in osteoclast and osteoblast numbers during disease progression 
In order to understand the effect of myeloma development on the cellular compartments of bone 
remodelling, a comprehensive quantitative analysis of the osteoclast (Oc) and osteoblast (Ob) 
distribution in the left tibia by static histomorphometry was performed. Changes in Oc and Ob 
numbers were analysed both in the endocortical and trabecular regions of the proximal tibial 
metaphysis. Like the previous chapter, results are expressed as osteoclast and osteoblast index for 
trabecular region analysis and no. of osteoclast or osteoblast per mm of endocortical bone for the 
endocortical region. Results showed no significant change in the osteoclast index but a significant 
reduction in osteoblast index at day 10 (P<0.01) in the trabecular region between the naïve tumour-
free (control) group and 5TGM1 myeloma bearing group (figure 4.4-15). However, in the endocortical 
region, a significant increase in the number of Oc (2.38 ±0.26 vs. 4.41 ± 0.49, P<0.01) and a 
significant reduction in the number of Ob only after 14 (16.98 ± 1.9 vs. 11.95 ± 1.67, P<0.01) and 21 
days (13.5 ± 0.9 vs. 0.89 ± 0.39, P<0.001) in the 5TGM1 tumour-bearing animals when compared 
with control mice was observed (figure 4.4-16).  
  
Figure 4.4-15: Trabecular changes in osteoclast and osteoblast numbers following 5TGM1 myeloma development 
Changes in osteoclast index (A) and osteoblast index (B) following 5TGM1 tumour cell injection after 3, 10, 14 and 
21 days. Age and sex matched tumour-free naïve mice (n=4) were used as controls for each time point. The 
following numbers of mice were used for the 5TGM1 tumour-bearing group for each time point: day 3 n=8, day 
10 n=8, day 14 n=8 and day 21 n=7. Mann-Whitney‘s non-parametric two-tailed test was used to determine the 
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Figure 4.4-16: Endocortical changes in osteoclast and osteoblast number following 5TGM1 myeloma development. 
Changes in osteoclast numbers per mm of endocortical bone (A) and osteoblast numbers per mm of endocortical 
bone (B) following 5TGM1 tumour cell injection after 3, 10, 14 and 21 days. Age and sex matched tumour-free 
naïve mice (n=4) were used as controls for each time point. The following numbers of mice were used for the 
5TGM1 tumour-bearing group for each time point: day 3 n=8, day 10 n=8, day 14 n=8 and day 21 n=7. Mann-
Whitney‘s non-parametric two-tailed test was used to determine the statistical significance between controls and 
tumour-bearing groups. *P<0.05, **P<0.01, ***P<0.001. 
Tumour-induced changes in bone structure and morphology 
5TGM1 myeloma associated morphometric changes in long bones (tibia) were studied by micro-
computed tomographic analysis of proximal tibial metaphysis. Ct. Vol, % BV/TV, Tb. N and Tb. Th, 
Tb. Pf and SMI were assessed to study the micro-structural changes in bone following tumour 
development. Figure 4.4-17 shows representative examples of cross-sectional microCT images of tibia 
from naïve and 5TGM1 tumour-bearing mice after 3, 10, 14 and 21 days post tumour cell injection. 
Quantitative microCT analysis showed a significant reduction in Ct. Vol, %BV/TV and Tb. N (P<0.05) 
and significant increase in Tb. Pf and SMI (P<0.05) only at 10 day post tumour cell injection when 
compared with age-matched tumour-free naïve mice. Interestingly, no differences were observed at 
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Figure 4.4-17: Structural changes in tibia following 5TGM1 myeloma development over time. 
Representative micro-computed tomography cross-sectional images of the L. tibiae showing the proximal tibial 
metaphysis of both tumour-free control and tumour-bearing 5TGM1 mice after 3, 10, 14 and 21 days post tumour 
cell injection. No difference in the cortical or trabecular bone was seen between the tumour-free or tumour-
bearing mice after all time-points. 
  





Figure 4.4-18: Quantitative microCT analysis following 5TGM1 murine myeloma development. 
Changes in cortical bone volume (A), trabecular bone volume (B), trabecular number (C), trabecular thickness (D), 
trabecular pattern factor (E) and SMI (F) in the 5TGM1 tumour-bearing mice when compared to tumour-free age 
matched control animals. Age and sex matched tumour-free naïve mice (n=4) were used as controls for each time 
point. The following numbers of mice were used for the 5TGM1 tumour-bearing group for each time point: day 3 
n=8, day 10 n=8, day 14 n=8 and day 21 n=7. Non-parametric Mann-Whitney Wilcoxon‘s test was used to 
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Changes in systemic levels of bone turnover markers during disease progression 
In order to understand the effect of myeloma development in bone remodelling, systemic levels of 
bone turnover markers TRACP5b (osteoclastic resorption) and P1NP (osteoblastic formation) were 
determined by ELISA. Serum levels of TRACP5b showed no significant difference between naive and 
5TGM1 tumour-bearing animals until 14 days post tumour cell injection. However, there was a 
significant increase in the TRACP5b levels in the tumour-bearing animals at 21 days post tumour cell 
injection (figure 4.4-19 A). However, serum levels of P1NP showed reduced levels in the 5TGM1 
tumour-bearing mice after 3 days (P<0.05) and 21 days (P<0.05) when compared with naïve tumour-
free mice, whereas no difference was observed at 10 and 14 days (figure 4.4-19 B). 
 
 
Figure 4.4-19: Changes in systemic bone remodelling markers following 5TGM1 myeloma development. 
Changes in serum levels of TRACP5b (A) and P1NP (B) respectively between naïve and 5TGM1 tumour-bearing 
mice. Age and sex matched tumour-free naïve mice (n=4) were used as controls for each time point. The 
following numbers of mice were used for the 5TGM1 tumour-bearing group for each time point: day 3 n=8, day 
10 n=8, day 14 n=8 and day 21 n=7. Mann-Whitney‘s non-parametric one-tailed test was performed to 
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5TGM1 myeloma induces formation of osteolytic bone lesions in the skeleton 
Bone lesions were quantified on the posterior and lateral surfaces of the tibia in 2D in both naïve 
tumour-free and 5TGM1 tumour-bearing mice for all time points (Materials & Methods section 2.2.19). 
Figure 4.4-20 shows representative 3D microCT models of proximal tibial metaphysis (posterior 
surface) of 5TGM1 tumour-bearing mice. Results showed that mice injected with 5TGM1 myeloma cells 
developed osteolytic bone lesion as early as 10 days post tumour cell injection with a dramatic increase 
in the percentage bone surface occupied by osteolytic bone lesion observed after 21 days post tumour 
cell injection (P<0.05) (figure 4.4-21 A). A gradual increase in the average size (arbitrary unit) of the 
observed lesions (cortical holes) in the 5TGM1 tumour-bearing mice when compared with tumour-free 
control animals was also observed (figure 4.4-21 B; P<0.05). 
 
Figure 4.4-20: 5TGM1 myeloma induced development of osteolytic lesions. 
Representative 3D models of tibiae showing osteolytic lesion (arrow) in the 5TGM1 tumour-bearing mice after 3, 
10, 14 and 21 days post tumour cell injection respectively.  Development of osteolytic lesion was observed from 10 
days with a dramatic increase in both the percentage bone surface occupied by osteolytic lesions and lesion size at 
21 days post injection. 
AFTER 3 DAYS AFTER 10 DAYS 
AFTER 14 DAYS AFTER 21 DAYS 




Figure 4.4-21: Quantification of myeloma induced osteolytic bone lesions in the 5TGM1 model over time. 
Quantitative image analysis was performed using Image J to quantify the number of lesions (A) and average lesion 
size (B) on the posterior and medial cortical surfaces in 3D microCT models of L. tibia. Tumour-free naïve mice 
were also analysed to determine the base level cortical defects due to normal bone remodelling and vasculature. 
The following numbers of mice were used for the 5TGM1 tumour-bearing group for each time point: day 3 n=8, 
day 10 n=8, day 14 n=8 and day 21 n=7. Mann-Whitney‘s non-parametric two-tailed test was performed to 
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4 . 5  D I SC U SS I O N  
Currently, in vivo models of myeloma that precisely mimic human disease are needed not only to 
understand the cellular and molecular events related to the homing of myeloma cells to bone but also 
to test various anti-cancer treatment strategies. Although the currently available models such as the 
5TMM series and the SCID–hu model mimic the human disease (Asosingh et al., 2000, Tassone et al., 
2005), the lack of modalities to readily detect tumour cell development during the early stages of 
disease development in bone has been a limitation for testing newer anti-cancer therapies. In this study, 
a highly sensitive tumour detection system in bone using three-dimensional multiphoton microscopic 
imaging, CD138 immunohistochemical staining and flow cytometry in the in vivo 5TGM1 murine 
model of myeloma was developed. The main aim of this chapter was to identify key stages in the 
development of MM in bone from single cells arriving in the bone to the development of tumour 
colonies in BM and the accompanied cellular and micro-structural alterations that occur during the 
concurrent development of osteolytic lesions. 
In order to detect 5TGM1 murine myeloma cell in bone using multiphoton microscopy and flow 
cytometry, 5TGM1-eGFP labelled myeloma cells were used. As eGFP expression by the 5TGM1-eGFP 
cell could not be detected early on (personal communication with Dr Michelle Anne Lawson, 
University of Sheffield), the 5TGM1-eGFP cells were further labelled with DID, a far-red lipophilic 
fluorescent cell membrane dye. Preliminary objectives were focused on determining the effect of DID 
on 5TGM1-eGFP cell proliferation. From the results, it was clearly shown that DID labelling of 5TGM1-
eGFP cells did not affect their proliferation in vitro, but DID label was eventually lost during 
proliferation. At this point, it is important to understand that the 5TGM1 cells were transduced to 
produce eGFP continuously, whereas DID labels the cell membrane once, at the time labelling. 
Proliferation of 5TGM1-eGFP-DID cell resulted in non-homogenous distribution of the DID over the 
cell membrane due to arbitrary sharing of cell membrane between the daughter cells, resulting in 
progressive loss of DID in cells that are actively proliferating. This posed an important problem as this 
resulted in underestimation of the actual number 5TGM1-DID
+
 cell as eGFP is not detected in vivo 
during the early stages of tumour development in bone, and assessment of tumour burden during early 
stages was solely dependent on the number of 5TGM1-DID
+
 cell. Despite gradual loss of DID from the 
5TGM1 cell over time, a small number of 5TGM1-DID
+
 cells were seen even after 11 days post labelling 
suggesting that these cells may be cytokinetically quiescent. Hence this method can be also extended as 
a surrogate for the identification of non-dividing 5TGM1 cells in vivo in bone (Wallace et al., 2008). 
Data from the current study demonstrated the developmental course of 5TGM1 murine model of 
myeloma from homing of fluorescently labelled 5TGM1-eGFP-DID myeloma cells from circulation to 
the establishment of overt colonies in the skeleton. It is well accepted that the 5TGM1 murine model of 
myeloma mimics the human disease (Asosingh et al., 2000, Vanderkerken et al., 2003a) with homing 
of circulating myeloma cells to BM, paraproteinemia, development of osteolytic bone lesion at specific 
anatomical locations and resulting in typical MM clinical manifestations characterised by hind limb 
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paralysis. In my experiments, using 2 X 10
6
 5TGM1-eGFP-DID cells injected via the tail vein, myeloma 
was developed in young C57BL/KaLwRij mice which developed hind limb paralysis approximately 3 
weeks following tumour cell injection. Recently, bioluminescence imaging and confocal microscopy are 
being increasingly used to trace fluorescently tagged tumour cells for monitoring the development of 
cancer over time and treatment responses (Oyajobi et al., 2007, Rozemuller et al., 2008, Fryer et al., 
2013). However, reports from these studies have shown that although eGFP transduction of myeloma 
cell was successful in tracking the tumour cell, the relatively low expression of eGFP during the early 
stages of development in the BM has posed a problem for their detection during the early stages of 
myeloma development. In previous studies, myeloma detection was possible only after established 
tumour foci using eGFP myeloma cells (Oyajobi et al., 2007). Data from the present study confirmed 
the presence of tumour cells (5TGM1-DID
+
) in bone as early as 3 days post tumour cell injection by 
flow cytometry, and multiphoton microscopy. Contrastingly, no difference in the number of CD138
+
 
cells in BM of the 5TGM1 tumour-bearing mice when compared with tumour-free control groups after 
3 days post tumour cell injection, however CD138
+
 colonies appeared in BM from day 10 post tumour 
cell injections.  
Following initial engraftment at day 3, flow cytometry showed a dramatic increase in the percentage 
5TGM1-eGFP
+
 cells from day 14 to 21 (0.86±0.17% to 29.4±1.1%). This correlated well with the 
multiphoton microscopy finding which showed an increase in the percentage BM occupied by 5TGM1-
eGFP
+
 tumour colonies from day 14 to 21 (1.8±0.76% to 47.34±6.03%). CD138 IHC correlated well 
with the flow cytometry and multiphoton microscopic assessment of tumour burden which 
demonstrated the presence of CD138
+
 colonies in BM from 10 days but a dramatic increase between 14 
and 21 days post tumour cell injection (6.47±1.31% to 96.37±1.18%). The main advantage in this 
model is that flow cytometry and multiphoton microscopy revealed the presence of myeloma cell in 
BM at early stage (day 3) which was not possible by CD138 IHC. However, CD138 IHC demonstrated 
the colony formation begins day 10 which was not possible with the other techniques. Although flow 
cytometry revealed the presence of minimal number of 5TGM1-eGFP
+
 cells in BM from day 10, there 
was no evidence of single 5TGM1-eGFP
+
 cell or 5TGM1-eGFP
+
 colonies within the BM by multiphoton 
microscopy. 5TGM1-eGFP
+
 tumour colony formation using multiphoton microscopy could only be 
demonstrated after day 14 post tumour cell injection. This can be explained by the difference in the 
techniques involved in these detection systems. In flow cytometry, the BM cells are extracted and 
processed before subjecting them to analysis. Here single photon laser light are directed to 
hydrodynamically focussed streamlined liquid which contains the fluorophore labelled myeloma cells 
and this allows direct unimpeded detection benefits. However, in the multiphoton microscopy system, 
the multi-photon laser was directed through a thick band of biological BM tissue with heterogeneous 
refractive index which results in multiple scattering and reduced laser intensity before reaching the focal 
area (Theer and Denk 2006, Crosignani et al., 2012). Similar results were reported by Oyajobi et al., 
(2007), where eGFP
+
 tumour foci in bone were observed only after 10 days post tumour cell 
inoculation using bioluminescence imaging. Taken together, the study shows that 3 days post tumour 
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cell injection myeloma cells could be seen in BM and colony formation begins as early as 10 days post 
tumour cell injection. Contrary to reports from a previous study by Iriuchishima et al., (2012) which 
showed MM cells engraft adjacent to BM endosteum, no preferential localisation of MM cells was 
observed and the cells were randomly distributed throughout the BM in the present study.  
Although there was a progressive reduction in the 5TGM1-DID
+
 cell over time with a substantial 
replacement of the entire BM with myeloma colonies, a significant number of 5TGM1-DID
+
 cells 
(1.35±0.16% of the BM cells) were seen even at 21 days post tumour cell injection. From in vitro 
studies, it has already been shown that proliferation of DID labelled 5TGM1-eGFP cells resulted in loss 
of DID over time. Therefore, the presence of 5TGM1-DID
+
 cells in the BM even after 21 days post 
tumour cell injection suggests that these 5TGM1-DID
+
 cells may be in a quiescent state. This is 
particularly important as it shows that not all tumour cells that arrive in bone proliferate to form 
colonies (Matsui et al., 2004). Furthermore, when these quiescent cells are in the presence of other 
rapidly dividing cells, this suggests that they may represent a MM stem cell or a reserve population that 
could contribute to the pool of chemo-resistant cells when tumours are subjected to conventional 
chemotherapy which targets only the rapidly dividing cells (Allan et al., 2006). Interestingly, these 
5TGM1-DID
+
 cells were located closer to the bone suggesting that specific locations play a role in 
preserving these cells in quiescent state. Zhang et al., (2003) showed that long-term quiescent HSCs are 
found closer to the trabecular bone surfaces lined especially with spindle-shaped osteoblastic lining 
cells. This may also indicate that the location and the cellular association may regulate quiescence in 
these cells. 
The present study demonstrates the sequential alteration in the cellular and structural components of 
the host BM microenvironment during the concurrent course of myeloma development. From the 
present study, It is clear that the 5TGM1 myeloma induced alterations in the host BM were observed 
only at the later stages (day 21) of disease development including gross morphological changes such as 
loss of body weight, liver and splenic infiltration. Analysis of earlier time points (day 3, 10 and 14) 
revealed no alterations either in the osteoclast numbers or serum TRACP5b levels suggesting that 
smaller tumour foci do not significantly enhance osteoclastogenesis (Brown 2012). However, increase 
in osteoclast numbers and serum TRACP5b levels were observed only at later stages (day 21) when the 
BM was filled with gross tumour colonies. Several studies have shown that myeloma cells promote 
osteoclastogenesis both in vitro and in vivo (Roodman 2001). Certain myeloma cell lines have been 
shown to produce RANKL (Sezer et al., 2002, Buckle et al., 2012), MIP-1α (Uneda et al., 2003) and 
MIP-1β (Abe et al., 2002) which induces local activation and osteoclast maturation. Furthermore, 
myeloma cells via direct cell contact also inhibits stromal cell mediated production of osteoprotogerin 
(OPG) which in turn promotes osteoclastic bone resorption (Michigami et al., 2000). In the present 
study, significant suppression in serum P1NP levels after 3 and 21 days post 5TGM1 tumour cell 
injection and a significant reduction in osteoblast numbers after 21 day post tumour cell injection were 
observed. Several studies have established that MM cell inhibits osteoblastogenesis (Giuliani et al., 
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2006b, Roodman 2011). Guiliani and colleagues reported that several factors such as Wnt antagonist, 
Runx2, IL-3 and IL-7 are involved in MM induced suppression of osteoblastogenesis by inhibiting 
differentiation of MSCs (Giuliani et al., 2005, Giuliani et al., 2006b). Although the reduction in serum 
P1NP levels correlated with suppression of osteoblast numbers at 21 days post tumour cell injection, the 
reason for the transient reduction in serum P1NP levels 3 days post tumour cell injection was not clear 
(Similar observation was seen by Dr Lawson M A - personal communication). One possible explanation 
is that, DID dye used to label the 5TGM1 murine myeloma cells may be responsible for the observed 
effect. However, this is not clear and needs to be investigated further. Furthermore, in the present 
study, suppression of osteoblasts and activation of osteoclasts following tumour development (day 21) 
was seen only on the endocortical sites. This suggests a spatial involvement in the disruption of 
balanced or coupled bone remodelling associated with the tumour growth. Moreover, the relatively 
smaller tumour foci seen during the early and intermediate time points (day 3, 10 and 14) with no 
significant alterations in bone remodelling suggests not only a paracrine mechanism but also a spatial 
dependency associated with myeloma induced changes in bone turnover (Brown 2012, Iriuchishima et 
al., 2012).  
It is well known that clinically MM is associated with development of osteolytic bone lesions owing to 
myeloma-osteoclast interaction aggravating osteoclastogenesis and subsequent osteoclastic bone 
resorption. Interestingly, in the present study development of osteolytic lesions in the 5TGM1 tumour-
bearing mice was seen from day 10 post tumour cell injections despite no significant increase in 
osteoclast number or serum TRACP5b levels. Results were contrary to reports from breast cancer-
induced bone metastasis study where obvious bone remodelling changes were observed prior to the 
formation of osteolytic bone lesion (Brown 2012). Strikingly, in previous studies changes in reduction in 
bone volume by microCT were used for measuring osteolytic lesions which may not be sensitive 
enough to detect cortical defects at early stages: changes in bone volume following micro-structural 
bone defects might not significantly alter bone volume. Although myeloma development in the 5TGM1 
model showed evidence of disrupted bone remodelling only at late stages (day 21) of disease 
development, cortical defects were seen as early as 10 day post tumour cell injection. This suggests that 
of myeloma induced bone disease begins even before obvious changes in bone remodelling. 
In summary, this is the first study, to the best of our knowledge, to demonstrate the temporo-spatial 
relationship of the tumour development in bone in the 5TGM1 murine model of myeloma. Using 
multiple techniques (flow cytometry, CD138 IHC and multiphoton microscopy), myeloma cells were 
shown to home the BM as early as 3 days post intravenous injection and begin to form colonies 10 
days post tumour cell injection. Furthermore, the present study also reports the presence of dormant 
myeloma cells close to bone. Finally, tumour-induced osteolysis was shown to begin at early stages of 
tumour development without an increase in osteoclast numbers and serum TRACP5b levels or a 
decrease in osteoblast numbers and serum P1NP levels. This suggests that the effects of myeloma on the 
bone microenvironment are much localised, potentially only associated with developing colonies.  






 CHAPTER 5 THE EFFECT OF 
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5 . 1  I N T RO D U C T IO N  
ZA has been used in conjunction with standard chemotherapy to prevent bone damage and improve 
bone health in patients with MM for over 10 years. With emerging evidences from clinical trials and 
preclinical studies that support additional anti-tumour effects associated with ZA treatment (Croucher et 
al., 2003a, Morgan et al., 2010a, Avilés et al., 2013) there have been an increasing number of research 
studies conducted to investigate the mode of action of ZA in this context. Recently, studies have 
provided evidence that the addition of ZA to standard chemotherapy has improved OS and clinical 
outcome in early-diagnosed cases of MM (Berenson et al., 2006, Avilés et al., 2007, Morgan et al., 
2010b).  
Several studies have shown that BPs exert their anti-myeloma potential in various ways. In vitro studies 
have shown ZA have a direct cytotoxic effect on tumour cells inducing apoptosis and inhibiting cell 
proliferation in several myeloma cell lines (Ural et al., 2003, Baulch-Brown et al., 2007, Guenther et 
al., 2010). In addition, studies also showed in vitro synergistic cytoreductive effects on myeloma cell 
growth when ZA was combined with simvastatin, dexamethasone and thalidomide (Tassone et al., 
2000, Ural et al., 2003, Schmidmaier et al., 2006). Several preclinical studies have also shown that BP 
treatment was associated with inhibition of tumour burden, osteolytic bone disease and tumour-
induced angiogenesis (Croucher et al., 2003a, Guenther et al., 2010). Moreover studies by Sato et al., 
(2005) and Yuasa et al., (2009) have shown ZA treatment also activates Vɤ9Vδ2 subset T cells anti-
cancer response targeting tumour cells. However, the exact mechanisms that underlie the anti-myeloma 
effect in vivo are not clearly understood. The evolving concept of the myeloma niche and the factors 
involved in the entry or exit of the tumour cell from the niche are in far the focus of research interest. 
In particular, osteoclast activity in remodelling bone could disrupt niche structures, releasing tumour 
cells and initiating the release of tumour promoting factors from bone (Abe et al., 2004, Corso et al., 
2005, Massaia et al., 2009). 
So far, the anti-myeloma significance of ZA has been related to the end stage myeloma development. 
No study has focused on interrupting the early events of myeloma cell homing and colonisation in 
bone. With emerging evidences suggesting that myeloma-osteoclast interdependence ensures myeloma 
cell survival and growth within the BM, attempting to alter the BM microenvironment with ZA to 
inhibit osteoclastic resorption prior to myeloma cell arrival in the BM may inhibit the eventual 
development of growing lesions. In this study, the main aim was to investigate the effect of ZA induced 
suppression of osteoclastic bone resorption on the early events of homing and colonisation of 
myeloma cell using the 5TGM1 murine myeloma model. From the previous chapter, it was shown that 
myeloma-osteoclast interaction begins as early as 10 days post tumour injection, as evidenced by the 
development of tumour-induced osteolytic bone disease. Therefore, it was hypothesised that blocking 
bone resorption using ZA will inhibit early tumour cell colonisation and growth in the 5TGM1 murine 
model of myeloma. 
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5 . 2  A I M S  &  O B JE C T IV E S  
The aims of this chapter were to test whether treatment with ZA initiated prior or after the tumour cell 
injection will affect the early stages of tumour cell homing and colonisation. 
Hypothesis: ZA treatment initiated prior to tumour cell injection will inhibit the colonisation of 
myeloma cell in bone in the 5TGM1 murine model of myeloma. 
The objectives were:- 
1. To determine whether treatment of mice with ZA pre or post tumour cell injection significantly 
inhibits osteoclastic bone resorption. 
2. To determine whether ZA treatment initiated pre or post tumour cell injection will prevent the 
development of MBD. 
3. To determine whether ZA treatment initiated pre or post tumour cell injection will inhibit the 
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5 . 3  M A T E R I A L S  &  ME T HO D S  
Detailed information on individual techniques performed is given in Chapter 2: Materials and 
Methods. 
5 . 3 . 1  E X PE R I ME N T AL  D E S IG N  T O  ST U D Y  T HE  E F F E C T  O F  Z A  T RE A T M E N T  
I N I T I AT E D  P R I O R  T O  T U M O U R  C E L L  I N J E C T I O N  O N  T H E  E A R L Y  
S T A GE S  O F  M YE LO MA  D E V E LO P ME N T  ( PR E - T R E AT ME N T  E X PE R I ME N T )  
All animal work and experimental conditions were done in accordance with the local guidelines and 
with the home office approval under the project licence number PPL No:  40/3462 held by Dr. Colby L 
Eaton University of Sheffield, UK.  
9-12 week old C57BL/KaLwRij mice were randomised, age matched and grouped as shown in figure 
5.3-1. All mice were treated with either PBS (n=12) or ZA (n=12) (125 µg/kg subcutaneously twice-
weekly) throughout the experiment. 7 days after the initiation of ZA or PBS treatment, animals in 
groups 3 and 4 were injected with 2 X 10
6
 5TGM1-eGFP-DID labelled cells via the tail vein. All the 
animals were regularly monitored for signs of illness or the development of hind limb paralysis. In 
order to study the effect of ZA treatment on the early stages of disease, the mice were sacrificed after 
10 days post tumour cell injection. Naïve C57BL/KaLwRij mice treated with PBS (n=4) or ZA (n=4) 
were used as tumour-free controls. A schematic representation of the study design is given below 
All animals were starved 6 hr prior to the sacrifice in order to eliminate the circadian variation in the 
serum bone biomarkers (Christgau 2000, Clowes et al., 2002). Mice were anaesthetised using 0.5 
ml/kg of pentobarbitone (intra-peritoneal injection) and blood samples were collected using cardiac 
puncture.  
 
Figure 5.3-1:  Experimental design to study the effect of ZA treatment initiated prior to tumour cell injection on the 
early stages of myeloma. 
Mice were age matched, randomised and grouped into those receiving ZA or PBS treatment. ZA treatment was 
initiated 7 days prior to tumour cell injection. Mice were injected with 125 µg/kg ZA (n=8) or sterile PBS (n=8) 
subcutaneously twice a week (three days apart) and repeated till the day of sacrifice. Mice were injected with 2 X 
SACRIFICE 
C57BLKalwRij/TIME LINE 
DAY 0 DAY 10 DAY -7 
Inj ZA 125 µg/kg s.c twice-
weekly 
Group 1: Naïve + PBS (n=4) 
Group 2: Naïve + ZA (n=4) 
Group 3: 5TGM1 + PBS (n=8) 
Group 4: 5TGM1 + ZA (n=8) 
5TGM1-eGFP-DID 
labelled MM cell 
injection 




 5TGM1-eGFP-DID cells via the tail vein on Day 0 and sacrificed after 10 days post tumour cell injection. Naïve 
tumour-free mice injected with PBS (n=4) or ZA (n=4) served as tumour-free controls for each group.  
5 . 3 . 2  E X PE R I ME N T AL  D E S I G N  T O  S T UD Y  T HE  E F F E C T  O F  Z A  I N I T I AT E D  
A F T E R  T U MO U R  C E L L  I N JE C T IO N  O N  T HE  E A R L Y  ST A G E S  O F  
M Y E LO M A  D E V E L O PM E N T  ( PO ST - T R E AT M E N T  E X P E R IM E N T )  
6-9 week old female C57BL/KaLwRij mice were randomised, age matched and grouped as shown in 
figure 5.3-2. Mice were randomised, age matched and sequentially grouped to receive either PBS 
(n=12) or ZA (n=13). 3 days prior to ZA or PBS treatment, group 3 and 4 were injected with 2 X 10
6
 
5TGM1-eGFP-DID labelled cells via the tail vein. Animals were injected with either ZA 125 µg/kg two 
doses three days apart or PBS every week. Mice were sacrificed after 10 days post tumour cell injection. 
Naïve C57BL/KaLwRij mice treated with PBS (n=4) or ZA (n=5) were used as tumour-free controls. 
On the day of the sacrifice, all animals were starved 6 hr prior to the sacrifice in order to eliminate the 
circadian variation in the serum bone biomarkers.  
Mice were anaesthetised using 0.5 ml/kg of pentobarbitone (intra-peritoneal injection) and blood 
samples were collected using cardiac puncture. Animals were culled by cervical dislocation while under 
deep non-recoverable anaesthesia and tissues harvested. 
 
Figure 5.3-2: Experimental design to study the effect of ZA treatment initiated after the tumour cell injection on 
the early stages of myeloma. 
Mice were age matched, randomised and grouped into those receiving ZA or PBS treatment. ZA treatment was 
initiated 3 days after tumour cell injection. Mice were injected with 125 µg/kg ZA (n=7) or sterile PBS (n=7) 
subcutaneously twice a week (three days apart) and repeated till the day of sacrifice. Mice were injected with 2 X 
10
6
 5TGM1-eGFP-DID cells via the tail vein on Day 0 and sacrificed after 10 days post tumour cell injection. Naïve 




DAY 0 DAY 3 DAY 10 
Inj ZA 125 µg/kg s.c twice-
weekly 
5TGM1-eGFP-DID 
labelled MM cell 
injection 
Group 1: Naïve + PBS (n=4) 
Group 2: Naïve + ZA (n=5) 
Group 3: 5TGM1 + PBS (n=7) 
Group 4: 5TGM1 + ZA (n=7) 
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5 . 3 . 3  S T AT I ST IC A L  AN A L YS I S  
Microsoft Office Excel 2010® was used to plot the graphs and values represented as Mean ± SEM. 
Prism GraphPad Ver 6.0 was used for comparison of parameters between untreated and ZA treated 
5TGM1 tumour-bearing animals. The graphs show 4 groups: naïve, naïve + ZA, 5TGM1 and 5TGM1 + 
ZA. Although a ‗Kruskal-Wallis‘ test is appropriate with graph that has more the 3 groups, comparison 
was done between the untreated with ZA treated naïve groups and the  untreated with ZA treated 
5TGM1 tumour bearing groups. Therefore, a two-tailed ‗non-parametric‘ Mann Whitney-Wilcoxon test 
was used in to compare the difference with P <0.05 as being statistically significant (Confidence 
interval > 95%). 
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5 . 4  R E S ULT S  
5 . 4 . 1  Z A  T R E AT ME N T  E IT H E R  P R E  O R  P O ST  I N JE C T IO N  O F  5T GM 1  M U R I N E  
M Y E LO M A  C E L L S  S I G N IF I C AN T L Y  S U P P R E S SE D  B O T H  O ST E O C L A ST S  
A N D  O ST E O B L AS T S  I N  T HE  5 T G M 1  M U R I N E  M O D E L  O F  M Y E LO M A  
D U R I N G  T H E  E A RL Y  S T A GE S  O F  M YE LO MA  D E V E L O P ME N T  
The effect of ZA treatment on osteoclast numbers assessed 10 days after injection of 5TGM1 murine 
myeloma cell 
Static histomorphometry was performed to assess the changes in Oc numbers following ZA treatment. 
Following the ZA pre-treatment strategy, no significant difference in Oc index (1/mm
2
) between PBS 
and ZA treated 5TGM1 tumour-bearing mice was observed. However, a significant increase in the Oc 
number was seen in the tumour-free group treated with ZA when compared to tumour-free PBS 
treated controls (P<0.05) (figure 5.4-1 A). Moreover, a significant increase (P<0.05) in the no. of Oc 
per mm of endocortical bone surface (1/mm) following ZA treatment in the 5TGM1 tumour-bearing 
group when compared with PBS treated 5TGM1 tumour-bearing group was seen. However, no 
difference in the number of Oc per mm of endocortical bone surface was observed between tumour-
free naïve mice treated with PBS or ZA (figure 5.4-1 C). 
Following the ZA post-treatment experiment, a significant reduction was seen in Oc index in the ZA 
treated 5TGM1 tumour-bearing group when compared with PBS treated 5TGM1 tumour-bearing mice 
(P<0.05). However, no difference was seen between ZA or PBS treated tumour-free naïve group 
(figure 5.4-1 B). No difference in the number of Oc per mm of endocortical bone between ZA and PBS 
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PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 5.4-1: The effect of ZA treatment on Oc numbers in the 5TGM1 murine model of myeloma 10 days post 
tumour cell injection. 
Changes in Oc index (A) and number of Oc per mm of endocortical bone (C) in 5TGM1 tumour-bearing mice pre-
treated for 7 days with ZA (n=8) or PBS (n=8) assessed 10 days post tumour cell injection. Tumour-free mice 
injected with either PBS (n=4) or ZA (n=4) served as controls. Changes in Oc index (B) and number of Oc per 
mm of endocortical bone (D) in 5TGM1 tumour-bearing mice post-treated with ZA (n=7) or PBS (n=7) 3 days 
after tumour injection, assessed 10 days post tumour cell injection. Tumour-free mice injected with either PBS 
(n=4) or ZA (n=5) served as controls. Comparison was done between PBS or ZA treated groups in both naïve 
tumour-free and 5TGM1 tumour-bearing groups using a one-tailed ‗non-parametric‘ Mann Whitney-Wilcoxon test 
with P<0.05 as statistically significant. *P<0.05, **P<0.01, ***P<0.001. 




) was determined for trabecular region analysis and the number of Ob per mm of 
endocortical bone surface (1/mm) for endocortical region analysis. Results showed that following pre-
treatment with ZA, there was a significant reduction in both Ob index (P<0.01) and number of Ob per 
mm of endocortical bone (P<0.001) in mice when compared with PBS treated groups in both 5TGM1 
tumour-bearing group 10 day post tumour cell injection. A significant reduction in both Ob index 
(P<0.001) and number of Ob per mm of endocortical bone (P<0.01) in tumour-free mice pre-treated 
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Following ZA post-treatment, a significant reduction was observed in both Ob index (P<0.01) and 
number of Ob per mm of endocortical bone (P<0.01) in 5TGM1 tumour-bearing mice treated with ZA 
when compared with PBS treated 5TGM1 tumour-bearing mice 10 day post tumour cell injection.  
However, when comparing the effect of ZA post-treatment in the tumour-free mice, a significant 
reduction only in the number of Ob per mm of endocortical bone (P<0.01) in the ZA treated group 
when compared with PBS treated groups was observed. No significant difference was observed in the 
Ob index between ZA or PBS treated naive tumour-free mice (figure 5.4-2 B & C). 
PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 5.4-2: The effect of ZA treatment on Ob numbers in 5TGM1 murine model of myeloma 10 days post 
tumour cell injection. 
Changes in Ob index (A) and number of Ob per mm of endocortical bone (C) in 5TGM1 tumour-bearing mice pre-
treated for 7 days with ZA (n=8) or PBS (n=8) assessed 10 days post tumour cell injection. Tumour-free mice 
injected with either PBS (n=4) or ZA (n=4) served as controls. Changes in Ob index (B) and number of Ob per 
mm of endocortical bone (D) in 5TGM1 tumour-bearing mice post-treated with ZA (n=7) or PBS (n=7) 3 days 
after tumour injection, assessed 10 days post tumour cell injection. Tumour-free mice injected with either PBS 
(n=4) or ZA (n=5) served as controls. Comparison was done between PBS or ZA treated groups in both naïve 
tumour-free and 5TGM1 tumour-bearing groups using a one-tailed ‗non-parametric‘ Mann Whitney-Wilcoxon test 
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Treatment with ZA either pre or post injection of 5TGM1 murine myeloma cells preserved both 
trabecular and cortical bone volume in 5TGM1 model assessed 10 days post tumour cell injection 
Representative microCT images of tibia of 5TGM1 tumour-bearing mice after pre-treatment with PBS or 
ZA are shown in figure 5.4-3 A & B. Results showed that ZA treatment was initiated prior to 5TGM1 
tumour cell injection cells (pre-treatment experiment) there was a significant increase in Ct. V in both 
5TGM1 tumour-bearing group (P<0.001) and tumour-free naïve control (P<0.01) group when 
compared with PBS treated 5TGM1 tumour-bearing and PBS treated-free control groups. A significant 
increase in % BV/TV (P<0.001) following ZA treatment in the 5TGM1 tumour-bearing animals when 
compared with PBS treated 5TGM1 mice was also observed (figure 5.4-3 E & G).  
Similarly, in mice where ZA treatment was initiated after the 5TGM1 tumour cell injection (post-
treatment experiment), a significant increase in Ct. V (P<0.01) and % BV/TV (P<0.01) was observed 
when compared with PBS treated 5TGM1 tumour-bearing mice (figure 5.4-3 F and H). Representative 
micro CT images of tibia of 5TGM1 tumour-bearing mice after post-treatment with ZA or PBS are 
shown in figure 5.4-3 C and D. 
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PRE-TREATMENT  EXPERIMENT POST-TREATMENT EXPERIMENT 




Figure 5.4-3: MicroCT changes following ZA (pre or post) treatment in the 5TGM1 murine model of myeloma 
assessed 10 days post tumour cell injection. 
Representative micro CT longitudinal cross-section images of tibia from 5TGM1 tumour-bearing mice 10 day post 
tumour cell injection following pre (A, B) and post-treatment (C, D) with ZA or PBS respectively. Changes in Ct. V 
(E) and % BV/TV (G) in 5TGM1 tumour-bearing mice treatment initiated 7 days prior to tumour cell injection with 
ZA (n=8) or PBS (n=8) assessed 10 days post tumour cell injection. Tumour-free mice injected with either PBS 
(n=4) or ZA (n=4) served as controls. Changes in Ct. V (F) and % BV/TV (H) following post ZA treatment where 
treatment was initiated 3 days after tumour cell injection with ZA (n=7) or PBS (n=7). Tumour-free mice injected 
with either PBS (n=4) or ZA (n=5) served as controls. Comparison was done between PBS or ZA treated groups in 
both naïve tumour-free and 5TGM1 tumour-bearing groups using a one-tailed ‗non-parametric‘ Mann Whitney-
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The effect of ZA treatment on serum bone turnover markers assessed 10 days post injection of 5TGM1 
murine myeloma cells. 
In this study, the serum levels of TRACP5b and P1NP in both ZA and PBS treated 5TGM1 tumour-
bearing mice (after 10 days post tumour cell injection) were measured in order to understand the early 
effects of ZA treatment in the 5TGM1 model. Results showed that ZA treatment (pre or post-treatment 
experiments) was associated with a significant reduction (P<0.001) in serum levels of TRACP5b in both 
the 5TGM1 tumour-bearing and tumour-free age-matched control mice (figure 5.4-4 A and B). 
Regarding the serum levels of P1NP in the pre-treatment experiment, no significant reduction in the ZA 
treated 5TGM1 tumour-bearing mice was seen when compared with PBS treated 5TGM1 tumour-
bearing control groups. Interestingly, a significant reduction (P<0.001) in P1NP levels were observed in 
the ZA treated groups when compared to PBS treated age-matched tumour-free control mice (figure 
5.4-4 C). However, a significant reduction in serum P1NP levels were observed following ZA treatment 
(post-treatment experiment) in both 5TGM1 tumour-bearing and age-matched tumour-free control 
groups when compared with their respective controls (P<0.001) (figure 5.4-4  D). 
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PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 5.4-4: The effect of ZA treatment on serum TRACP5b and P1NP levels in the 5TGM1 murine model of 
myeloma 10 days post tumour cell injection. 
Changes in serum levels of TRACP5b (A) and P1NP (C) respectively in 5TGM1 tumour-bearing mice pre-treated 
with ZA (n=8) or PBS (n=8) assessed 10 days post tumour cell injection. Age matched naïve tumour-free 
C57BLKalwRij mice injected with either PBS (n=4) or ZA (n=4). Changes in serum levels of TRACP5b (B) and 
P1NP (D) respectively in 5TGM1 tumour-bearing mice post-treated with ZA (n=7) or PBS (n=7) assessed 10 days 
post tumour cell injection. Age matched naïve tumour-free C57BL/KaLwRij mice injected with either PBS (n=4) or 
ZA (n=5). Comparison was done between PBS or ZA treated groups in both naïve tumour-free and 5TGM1 
tumour-bearing groups using a one-tailed ‗non-parametric‘ Mann Whitney-Wilcoxon test with P<0.05 as 
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ZA prevents formation of early osteolytic bone lesions induced by myeloma cell growth, assessed 10 
days post tumour cell injection 
In order to investigate whether ZA treatment would inhibit the development of osteolytic lesions 
induced by 5TGM1 myeloma cells in the BM at early time points, the percentage cortical bone surface 
area (posterior and medial) with cortical defects and number of osteolytic lesions were quantified in 
both the pre and post-treatment experiments. In the pre-treatment experiment, a significant increase in 
the percentage of bone surface occupied by lesion (P<0.01) and average number of lesions (P<0.05) 
was observed in the 5TGM1 tumour-bearing mice when compared to tumour-free naïve control mice 
(figure 5.4-5 E and G). With ZA pre-treatment, a significant 74.41% (P<0.001,) reduction in both 
percentage lesion area in bone and 53.93% reduction (P<0.01) in the average number of lesions was 
observed when compared to PBS treated 5TGM1 tumour-bearing mice. Interestingly, there was also a 
significant reduction in the percentage lesion area (P<0.05) and average lesion numbers (P<0.05) in 
the ZA treated tumour-free mice when compared with PBS treated tumour-free group. In contrast, in 
the ZA post-treatment experiment, no significant difference in the percentage lesion area or average 
lesion numbers was seen in the 5TGM1 tumour-bearing group when compared to tumour-free control 
group. However, a 69.5% significant reduction (P<0.001) was observed in the percentage lesion area 
and 72.2% reduction in average lesion numbers (P<0.001) in the ZA treated 5TGM1 tumour-bearing 
animals when compared with PBS treated 5TGM1 group (figure 5.4-5 G and H). Representative images 
showing the posterior surface of the tibia with cortical defects from 5TGM1 tumour-bearing mice with 
or without ZA pre or post-treatment are shown in figure 5.4-5 A, B, C and D respectively. 
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Figure 5.4-5: The effect of ZA treatment on the onset of tumour-induced osteolysis in the 5TGM1 murine model of 
myeloma. 
Representative 3D models of proximal tibial metaphysis of 5TGM1 tumour-bearing mice following PBS or ZA 
treatment assessed 10 days post tumour cell injection showing osteolytic bone lesion (A), (B), (C) and (D). 
Osteolytic lesions (cortical defects) are shown in red arrows in the PBS treated 5TGM1 tumour-bearing mice. 
Changes in percentage osteolytic lesion (E) and average number of lesions (G) in the 5TGM1 tumour-bearing mice 
pre-treated with ZA (n=8) or PBS (n=8) assessed 10 days post tumour cell injection. Age matched naïve tumour-
free C57BL/KaLwRij mice injected with either PBS (n=4) or ZA (n=4). Changes in percentage osteolytic lesion (F) 
and average number of lesions (H) in the 5TGM1 tumour-bearing mice post-treated with ZA (n=7) or PBS (n=7) 
assessed 10 days post tumour cell injection. Age matched naïve tumour-free C57BL/KaLwRij mice injected with 
either PBS (n=4) or ZA (n=5) served as control. Mann-Whitney non-parametric test was used to compare the 
statistical difference between the mean in the PBS and the ZA treated groups with P value <0.05 as statistically 
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5 . 4 . 2  T HE  E F F E C T  O F  Z A  T R E AT ME N T  O N  T U M O U R  B U RD E N  I N  B O N E  
D U R I N G  T H E  E A RL Y  S T A GE S  O F  M YE LO MA  D E V E LO P ME N T  
Flow cytometric analysis revealed no changes in 5TGM1-eGFP-DID cell burden in BM following ZA 
treatment assessed 10 day post tumour cell injection 
From chapter 4, it was shown that 5TGM1-eGFP-DID cells could be identified in the BM as early as 3 
days post tumour cell injection using flow cytometry. Therefore, flow cytometry was used to assess the 






 cells in the 
BM of mice injected. Figure 5.4-6 shows typical flow cytometry profiles of BM cell with 5TGM1-eGFP-
DID cells with DID labelling on Y-axis and eGFP labelling on X-axis. BM cells from naïve tumour-free 




 fluorophore channel. Analysis revealed 




 and dual labelled DID-eGFP
+
 population in the BM of tumour-
bearing mice injected with 5TGM1 cells 10 day post tumour cell injection treated with VEH or ZA. 
Quantitative flow cytometry analysis showed no significant difference between VEH treated and ZA 




 and dual labelled DID-eGFP
+
 population in the BM (figure 5.4-7 































   
Figure 5.4-6: Flow cytometry profiles of BM cells from naïve C57BL/KaLwRij mice and 5TGM1 tumour-bearing 
mice treated with VEH or ZA. 
Typical flow cytometric profiles of BM cells from mice injected with 5TGM1-eGFP-DID cells after 10 days post 
injection. BM profile from naïve tumour-free (A) and (D) mice was used to gate normal cells (negative controls). 
Profiles from 5TGM1 tumour-bearing mice after pre-treatment with VEH (B) or ZA (C) with FL1 (eGFP
+
) channel 
on Y axis and FL4 (DID
+
) channel on X-axis. BM profiles from 5TGM1 tumour-bearing mice after post-treatment 
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Figure 5.4-7: The effect of ZA treatment on tumour burden in the 5TGM1 model of myeloma assessed 10 days 
post tumour cell injection. 






 dual labelled 5TGM1 in 
tumour-bearing mice pre-treated (A) with ZA (n=8) or VEH (n=8) assessed 10 days post tumour cell injection. 






 dual labelled 5TGM1 in 
tumour-bearing mice post-treated (B) with ZA (n=6) or VEH (n=7) assessed 10 days post tumour cell injection. 
Comparison was done between VEH or ZA treated groups in 5TGM1 tumour-bearing groups using a ‗non-
parametric‘ Mann Whitney-Wilcoxon test with P<0.05 as statistically significant. *P<0.05, **P<0.01, 
***P<0.001. 
ZA treatment showed no significant difference in the CD138
 
positive population in BM in the 5TGM1 
tumour-bearing mice assessed 10 day post tumour cell injection. 
Results showed that following pre-treatment with ZA no significant difference was observed in the 
number of CD138
+
 cells in BM of 5TGM1 tumour cell bearing mice when compared with VEH treated 
5TGM1 tumour-bearing mice. Similarly there was no significant difference in the number of CD138
+
 
cells in the tumour-free C57BL/KaLwRij mice following VEH or ZA treatment (figure 5.4-8 A). CD138
+
 
colonies were expressed as percentage BM area occupied by CD138
+
 colonies. Results showed no 
significant difference in the percentage BM space occupied by CD138
+
 colonies between VEH and ZA 
pre-treatment assessed 10 days post tumour cell injection. There was no evidence of CD138
+
 colony 
formation in naive tumour-free C57BL/KaLwRij mice following VEH or ZA treatment (figure 5.4-8 B). 
Representative examples of CD138 stained BM from 5TGM1 tumour-bearing mice following VEH or 
ZA pre-treatment are shown in figure 5.4-9 A and B. 
With ZA treatment post tumour cell injection, there was a significant reduction in the number of 
CD138
+
 tumour cells in the ZA treated tumour-free naïve C57BL/KaLwRij when compared with 
untreated tumour-free control group. However, no difference in the number of CD138
+
 cells were 
observed in the 5TGM1 tumour cell group treated with ZA when compared with VEH treated 
respective control groups (figure 5.4-8 B). Like the pre-treatment experiment, there was no evidence of 
CD138
+
 colony formation in the tumour-free mice and no significant difference was seen in the 
percentage BM space occupied by CD138
+
 colonies in the 5TGM1 tumour-bearing mice treated with ZA 
when compared to VEH treated group (figure 5.4-8 D). Representative examples of CD138 stained BM 
 %DID
eGFP+
 %DID+  %eGFP+
5TGM1 + VEH 0.00625 0.58375 0.04625
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from 5TGM1 tumour-bearing mice (10 days post tumour cell injection) following VEH or ZA post-
treatment are shown in Figure 5.4-10 A and B. 
PRE-TREATMENT POST TREATMENT 
  
  




 population between 5TGM1 + VEH and 5TGM1 + ZA treated group were expressed as 
changes in individual number of CD138
+
 population and percentage BM space occupied by CD138
+
 colonies 
assessed 10 days post tumour cell injection. Changes in the number of CD138
+
 cells (A) and percentage CD138
+
 
tumour colonies (C) in the 5TGM1 tumour-bearing mice pre-treated with ZA (n=8) or VEH (n=8) assessed 10 days 
post tumour cell injection. Tumour-free mice injected with either VEH (n=4) or ZA (n=4) served a controls. 
Changes in the number of CD138
+
 cells (B) and percentage CD138
+
 tumour colonies (D) in the 5TGM1 tumour-
bearing mice post treated with ZA (n=7) or VEH (n=7) assessed 10 days post tumour cell injection. Tumour-free 
mice injected with either VEH (n=4) or ZA (n=5) served as controls. Mann-Whitney non-parametric test was used 
to compare the statistical difference between the VEH and the ZA treated groups with P value <0.05 as statistically 
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PRE-TREATMENT ZA STRATEGY 
  
Figure 5.4-9: The effect of ZA pre-treatment on the CD138 positive tumour cell population 10 days post tumour 
cell injection. 
Representative CD138 IHC stained sections of tibiae from mice bearing 5TGM1-eGFP-DID tumour cells (10 day 
post tumour cell injection) pre-treated with VEH (A) or ZA (B). Images are 2X magnified showing the proximal 
one third of the tibia (scale bar 1000 µm) with magnification of CD138+ tumour colonies (inner box, 40X). 
 
  
5TGM1 + VEH 5TGM1 + ZA 
A B 
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POST TREATMENT ZA STRATEGY 
  
Figure 5.4-10: The effect of ZA post-treatment on the CD138 positive tumour cell population, 10 days post tumour 
cell injection. 
Representative CD138 IHC stained sections of tibiae from mice bearing 5TGM1-eGFP-DID tumour cells (10 day 
post tumour cell injection) post-treated with VEH (A) or ZA (B). Images are 2X magnified showing the proximal 
one third of the tibia (scale bar 1000 µm) with magnification of CD138+ tumour colonies (inner box, 40X). 
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Treatment with ZA initiated pre or post tumour cell injection showed no significant reduction in 
5TGM1-DID
+
 tumour cells, 10 days post tumour cell injection 
Multiphoton microscopy was used to quantify the tumour burden in the BM. Bone sections from 
tumour-free-control (both naïve and naïve + ZA; negative controls) were scanned using multiphoton 
microscope in order to determine the baseline fluorescence signals from the BM and was used to 
threshold the baseline bone and DID signals.  
From chapter 4, it was clearly shown that only 5TGM1-DID
+
 were visualised in the BM 10 days post 
tumour cell injection, so, in this experiment the number of 5TGM1-DID
+
 cells was quantified. As 
expected 5TGM1-DID
+
 cells were clearly seen inside the BM and no evidence of eGFP
+
 signals were 
observed in both pre or post ZA treatment experiments. Figure 5.4-11 shows representative 
multiphoton microscopy images of naïve, naïve + ZA, 5TGM1 + VEH and 5TGM1 + ZA. 
Representative examples of multiphoton images following pre or post ZA treatment showing the 
presence of 5TGM1-DID
+
 cells are shown in figure 5.4-12. Results were expressed as mean number of 
5TGM1-DID
+
 cells present in mm
3
 of BM. Results showed that following ZA treatment, there was no 
significant difference in the number of 5TGM1-DID
+
 cells seen in the BM between VEH and ZA treated 
5TGM1 tumour-bearing animals both after pre or post-treatment (figure 5.4-13 A and B).  
A. NAÏVE + VEH B. NAÏVE + ZA C. 5TGM1 + VEH D. 5TGM1 + ZA 
    
Figure 5.4-11: Representative examples of multiphoton images showing bone and 5TGM1-DID cells assessed 10 
days post tumour cell injection. 
Representative 2D multiphoton microscopic sections of tibiae (450 X 450 µm2) of naive, naïve + ZA, 5TGM1 + 
VEH and 5TGM1 + ZA showing bone (SHG) and DID
+
 signals, 10 days after 5TGM1-eGFP-DID tumour cell 
injection. Naïve (tumour-free) (A) and Naïve treated with ZA (B) were used as negative controls to determine 
baseline fluorescence of bone in order to threshold the images. (C) BM of mice injected with 5TGM1-eGFP-DID 
tumour cells treated with VEH and (D) mice injected with 5TGM1-eGFP-DID treated with ZA shows the presence 
of DID
+
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PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 5.4-12: The effect of ZA pre or post-treatment on 5TGM1 tumour cell colonisation 10 days post tumour cell 
injection assessed by multiphoton microscopy. 
Representative cross-sectional images of proximal metaphysis of tibia captured by multiphoton microscopy 
showing bone architecture and 5TGM1-DID
+
 cells (red) inside the BM following pre or post-treatment with ZA. 
Comparison of the effect of ZA (A) or VEH (C) treatment initiated prior to tumour cell injection on tumour load 
assessed by multiphoton microscopy assessed 10 days post tumour cell injection. Comparison of the effect of ZA 
(B) or VEH (D) treatment initiated after tumour cell injection assessed after 10 days post tumour cell injection. 
 
5TGM1 + VEH 5TGM1 + VEH 
5TGM1 + ZA 5TGM1 + ZA 
A B 
C D 
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PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPEIRMENT 
  
Figure 5.4-13: The effect of ZA on the early stages of myeloma development using multiphoton microscopy. 




 of BM (A) in the tumour-bearing mice pre-treated with ZA (n=8) or 




 of BM (B) in 
the tumour-bearing mice post-treated with ZA (n=7) or VEH (n=7) assessed 10 days post tumour cell injection. A 
Mann-Whitney non-parametric test was used to compare the statistical difference between the mean in the VEH 
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5 . 5   D I SC U S S I O N  
Studies on anti-myeloma therapeutics often neglect to focus the effect of chemotherapy on the early 
stage of disease development due to lack of sensitive methods to detect subtle changes following 
treatment. There is increasing evidence supporting the concept of the myeloma niche in the BM 
microenvironment playing a vital role in the development of myeloma. Targeting homing of tumour 
cells to bone by modification of the BM microenvironment during the early stages of disease diagnosis 
might offer alternative therapeutic strategies to those currently available which focus only on 
established disease.  
To the best of my knowledge, this is the first study to show the effect of ZA treatment on the early 
events of tumour cell homing and colonisation in MM. In this chapter, the effect of ZA treatment on 
bone remodelling during myeloma development, development of osteolytic bone disease and tumour 
colonisation in the 5TGM1 murine myeloma model was tested 10 days after the tumour cell injection. 
In this study, ZA was administered in two different treatment strategies. In the first experiment, ZA 
treatment was initiated before tumour cell injection with a view that prior suppression of osteoclastic 
bone resorption would interfere with the homing and colonisation of the tumour cells to bone. In the 
second experiment a post-treatment strategy was used where ZA treatment was started after the 
tumour cells have homed to the BM.  
Data from the present study shows that ZA treatment effectively suppresses osteoclastic bone 
resorption and osteoblastic bone formation irrespective of whether treatment was initiated prior to or 
after tumour cells had homed to bone. The study also provides strong evidence that both treatment 
strategies resulted in suppression of bone remodelling in a manner similar to tumour-free animals 
suggesting that the presence of tumour cells in bone did not alter the effects of ZA on bone 
remodelling. However, certain differences were observed between the two experiments. For example, 
following the pre-treatment of animals with ZA showed a significant increase in osteoclast number on 
the endocortical surface while in the ZA post-treatment experiment a significant decrease in osteoclast 
numbers was seen on the trabecular region. This difference may be due to the different age groups of 
mice used in the two studies. Furthermore, data on osteoclast numbers were quite varied even when 
compared with the tumour-free control mice. Secondly, in the pre-treatment experiment, no difference 
was seen in the P1NP levels of the 5TGM1 tumour-bearing mice following ZA treatment, whereas in the 
post-treatment experiment, prompt reduction was observed. This is particularly interesting because the 
P1NP levels in the 5TGM1 tumour-bearing mice following pre-treatment with ZA remained normal 
despite reduction in osteoblast numbers. The cause for this effect seen only in the pre-treatment and 
not in the post-treatment experiment is not known. In chapter 4, it is clearly shown that the presence 
of tumour cells in bone 10 days after tumour induction did not alter the indices of bone remodelling, 
which suggests smaller tumour foci during the early stages of myeloma development do not 
profoundly alter bone remodelling. Therefore, it is not surprising to see that ZA treatment initiated 
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before or after tumour cell injection showed similar suppression of bone remodelling because at the 
time of evaluation the presence of tumour cells in the BM did not affect the bone remodelling.    
The effect of ZA treatment was tested on the development of myeloma-induced osteolytic lesion. 
According to the American Society Of Clinical Oncology (ASCO), induction of BP treatment in MM 
should commence only with the detection of lytic bone lesion on plain radiograph or evidence of 
spinal cord compression using imaging modalities (Kyle et al., 2007). Moreover, several preclinical 
studies have also shown that cancer-induced osteolytic lesions were observed only during the late 
stages of disease development using x-ray radiography techniques. Data from chapter 4 showed that 
the development of osteolytic bone lesions commences as early as 10 days post tumour cell injection 
albeit with no significant changes in bone remodelling markers such as serum levels of bone turnover 
markers or changes in osteoclast or osteoblast numbers. Results from the present study showed that ZA 
significantly prevented the development of myeloma-induced osteolytic lesions and was independent 
of whether the treatment was initiated before or after tumour cell injection. Similar results were 
reported by Croucher et al., (2003a) in the 5T2MM model where ZA treatment initiated at the time of 
tumour cell injection resulted in a complete protection against MBD, however when the  treatment 
was initiated at the time of serum paraprotein detection it resulted only in partial protection. In their 
study the effect was tested on the late stages of disease where they showed increase in osteoclast 
number and suggested that this was responsible for lesion formation. In a recent clinical trial, Musto et 
al., (2008) reported that ZA treatment in patients with asymptomatic myeloma resulted in significant 
reduction in skeletal related events at the time of progression. Interestingly, in the present study ZA 
treatment showed a significant reduction in the normal cortical pores in tumour-free naïve 
C57BL/KaLwRij mice. Compston et al., (2011) showed that cortical bone morphology in humans with 
advancing age is associated with an increase in cortical porosity. This suggests that ZA treatment was 
not only associated with inhibition of osteoclastic bone resorption but was an extreme suppressor of 
bone remodelling preventing normal age-related bone loss. Taken together, the data from the present 
study suggests that clinically, MM induced osteolytic lesion are diagnosed well beyond the time of 
initiation of lesions in bone and due to the poor sensitivity in the methods used for diagnosis, 
treatments are only initiated with established bone disease. The study provides strong clinical rationale 
for the prophylactic commencement of ZA treatment in order to adequately prevent the development 
of MBD and preserve bone health.  
Finally, the effect of ZA treatment was tested on the early stages of tumour homing and colonisation in 
bone in the 5TGM1 murine myeloma model using multiple methods (flow cytometry, CD138 IHC and 
multiphoton microscopy). Striking differences in the tumour load was observed in the CD138 IHC and 
multiphoton microscopy assessment between the two experiments. This may be a result of using 
different age group of mice between the pre-treatment and post-treatment experiments. In addition, in 
the post-treatment experiment, multiphoton microscopy scanning was done at 512 X 512 pixel size 
which resulted in higher resolution images but longer time-frame (approx. 10 hr) for image acquisition. 
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Therefore there were high chances for photo bleaching due to prolonged exposure of the laser to the 
specimen. In order to reduce photo bleaching, in the pre-treatment experiment bone were scanned 
using low resolution 256 X 256 pixel images which shortened the scan time to approximately 3 hr 
compromising image quality and an improved detection of DID
+
 in the BM. This might also explain the 
observed difference in the tumour load between the two experiments when assessed by multiphoton 
microscopy. 
Currently, there is little available published data where the effect of treatment was tested on the early 
stages of tumour cell colonisation in MM. Data from the present study demonstrates that ZA treatment, 
either initiated prior or after tumour cell homing to bone, did not significantly affect the tumour load 
in BM during the early stages (day 10 post tumour cell injection) of myeloma development. In contrast 
to the present study, reports by Daubiné et al., (2007) showed weekly and daily ZA treatment initiated 
prior to tumour cell injection significantly inhibited homing of B02/GFP.2/luc
+
 breast cancer cell in 
BALB/c (nu/nu) athymic mice. In another study, van der Pluijm et al., (2005) reported reduction in 
bone metastases in MDA-321-luc
+
/BALBc mice following olpadronate treatment. In both these studies 
ZA or olpadronate treatment was initiated one day before tumour cell injection and the doses of ZA 
used by Daubiné et al., (2007) in their studies (100 µg/kg) were similar to what was used in the current 
study. Studies using in vivo breast cancer models have shown that ZA treatment prevented the 
development of early bone metastasis (Sasaki et al., 1995, Brown 2012). Studies on breast cancer bone 
metastases show that cancer cells in the primary tumour site produce growth factors and chemokines 
such as VEGF, placental growth factor, SDF-1 resulting in a ‗pre-metastatic bone niche‘ formation that 
attracts the tumour cells to bone. Moreover, tumour cells within the BM were also shown to enhance 
osteoclast activation, which in turn releases bone-derived growth factors such as TGF-β, IGF from the 
bone matrix promotes the survival of tumour cells. However, in the present study suppression of 
osteoclastic bone resorption by ZA showed no effect on the early stages of tumour load in the 5TGM1 
model. Myeloma cells are derivatives of normal plasma cells which develop from HSCs which normally 
exist in the BM. This suggests that the early phase of tumour development in MM in 5TGM1 murine 
model is independent of the local changes in bone remodelling. BM is a complex environment capable 
of supporting a wide variety of cells including cancer cells. The functional interplay between the cellular 
compartments and liquid mileu comprised of bone derived growth factors, cytokines and chemokines 
within the BM offers a supportive environment not only for HSC but variety of tumour cells such as 
breast, prostate, MM, lung and kidney cancer cells (Manier et al., 2012). In vitro studies have also 
shown that ZA treatment to inhibit tumour cell migration by inhibiting SDF-1/CXCR-4 chemotaxis 
mechanism (Denoyelle et al., 2003). 
To conclude, the current study shows that the presence of 5TGM1 tumour cells (10 day post tumour 
cell injection) in the BM did not significantly alter the bone remodelling indices except for preventing 
the onset of osteolytic bone disease. ZA treatment (pre or post-treatment strategies) in the 5TGM1 
murine model of myeloma resulted only in suppression of bone remodelling similar that was observed 
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in tumour-free naïve mice. Contrary to the current perception where osteoclastic bone resorption plays 
an important role in the early homing and colonisation of myeloma cells to bone, results show that 
early treatment with ZA whether initiated prior to the introduction of myeloma cells or after 
established colony formation in bone in 5TGM1 murine myeloma model resulted only in prevention of 
the development of osteolytic bone disease but not the tumour load. This suggests that the on-going 
normal bone remodelling especially osteoclastic bone resorption may not play a role in the homing of 
myeloma cell to the bone. Although, the presence of 5TGM1 cells in bone triggers the onset of lytic 
lesion formation this is not sufficient to increase colony formation in this model. Treatment with ZA did 
suppress osteolytic lesion formation but did not affect colony formation, suggesting that the process of 
expansion from single cell to colonies was not reliant on a so called ‗vicious cycle‘ in the 5TGM1 
model. 






 CHAPTER 6 THE EFFECT OF 
ZOLEDRONIC ACID TREATMENT 
ON THE LATE STAGES OF 
MYELOMA DEVELOPMENT IN 
BONE 
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6 . 1  I N T RO D U C T IO N  
Over the last few years, the BPs such as CLO, PAM and ZA have been shown to be an effective anti-
osteolytic agent and are frequently used for the symptomatic management of hypercalcaemia of 
malignancy and cancer-induced bone disease. In a recently published phase III randomized clinical trial 
(MRC Myeloma IX study), ZA inclusion along with standard chemotherapy showed reduction of 
skeletal related events and improvement in OS by 5.5 months (50 vs 44.5 months, P=0.0118) and PFS 
by 2 months (19.5 vs 17.5 months, P=0.0179) when compared to CLO and this effect was independent 
of prevention of skeletal related events. However, there was a higher incidence of osteonecrosis of the 
jaw associated with the ZA treatment (Morgan et al., 2010b). In a more recent phase III clinical trial, 
ZA inclusion with HDT followed by ASCT showed improvement in 10 years OS (61%) and PFS (66%) 
when compared to no ZA control (Avilés et al., 2013). Although a survival benefit was seen with ZA 
inclusion to standard chemotherapy suggesting anti-tumour effect, the mechanisms underlying is not 
known. Currently, in UK and Europe, ZA is included in the management of symptomatic myeloma 
with or without bone disease. However, in patients with asymptomatic myeloma, although addition of 
ZA had a bone protective effect did not affect the tumour progression (Musto et al., 2008). However, 
in a recently published study ZA added with thalidomide treatment showed prolongation in time to 
progression to symptomatic myeloma. However there is only little evidence to support the early 
inclusion of ZA and therefore not included for the treatment of asymptomatic myeloma.  
Emerging evidence from preclinical studies suggests ZA may have potential anti-tumour effects 
(Croucher et al., 2003b). Several preclinical studies have demonstrated that ZA exerts anti-tumour 
effects in MM in vitro and in vivo directly or indirectly by altering bone remodelling, resulting in an 
overall reduction in tumour burden in several preclinical  models of MM (Croucher et al., 2003a, 
Clezardin et al., 2005). Although results from in vivo preclinical studies are encouraging, supporting 
anti-tumour response with early ZA treatment associated with reduction in tumour burden and 
improvement in disease-free survival (Croucher et al., 2003a, Dairaghi et al., 2012), no clear evidence 
has been offered to explain the mechanism behind the anti-myeloma effect with ZA. Several studies 
have shown that myeloma cells promote osteoclastogenesis which enhances osteoclastic bone 
resorption, thereby forming osteolytic bone disease which in turn releases bone derived factors which 
promote tumour progression (Michigami et al., 2000). Furthermore, Abe et al., (2004) also showed 
that osteoclasts not only support the growth and survival of myeloma cells but also renders them drug 
resistant to standard anti-cancer therapy such as doxorubicin. Therefore, it is expected that inhibiting 
osteoclastic bone resorption with ZA will inhibit tumour development by breaking the vicious cycle 
between osteoclastic bone resorption and tumour expansion. Although several studies have already 
shown the effect of ZA treatment on tumour burden in MM and other cancers, in this study ZA 
treatment was initiated before the tumour cells arrived in bone and to see whether this had additional 
benefits than when treatment was initiated at the time of clinical diagnosis. Furthermore, the effect of 
ZA treatment was also studied after the tumour cell colonised the BM in order to test whether ZA 
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treatment affects the resident myeloma cells in bone. Finally the effect of ZA treatment was also studied 
on the development of signs of clinical morbidity in the 5TGM1 murine model of myeloma.  
 
6 . 2  A I M S  &  O B JE C T IV E S  
The aims of this chapter were to test whether treatment with ZA initiated prior or after tumour cell 
injection will affect the late stages of tumour burden and development of the signs of clinical illness. 
Hypothesis: ZA treatment initiated prior to tumour cell injection will inhibit the end-stage tumour 
burden and will delay the onset of development of signs of clinical illness. 
The objectives were:- 
1. To determine whether treatment with ZA pre or post-treatment injection of myeloma cells will 
significantly inhibit osteoclastic bone resorption and prevent the development of MBD. 
2. To determine whether pre or post-treatment with ZA will reduce end-stage tumour burden in 
bone. 
3. To determine whether ZA treatment will prolong the disease-free survival in the 5TGM1 
murine model of myeloma. 
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6 . 3  M A T E R I A L S  &  ME T HO D S  
Detailed information on individual techniques performed is given in Chapter 2: Materials and 
Methods. 
6 . 3 . 1  E X PE R I ME N T AL  D E S IG N  T O  ST U D Y  T HE  E F F E C T  O F  Z A  T RE A T M E N T  
I N I T I AT E D  P R I O R  T O  T U MO U R  C E L L  I N J E C T I O N  O N  T H E  L AT E  
S T A GE S  O F  M Y E LO M A  D E V E LO P ME N T  I N  B O N E  ( P R E - T RE A T M E N T  
E X PE R I ME N T )  
9-12 week old male C57BL/KaLwRij mice were randomised, age matched and grouped as shown in 
figure 6.3-1. All mice were treated with either PBS (n=11) or ZA (n=11) (125 µg/kg subcutaneously 
twice-weekly) throughout the experiment. 7 days after the initiation of ZA or PBS treatment, animals in 
groups 3 and 4 were injected with 2 X 10
6
 5TGM1-eGFP-DID labelled cells via the tail vein. All the 
animals were regularly monitored for signs of illness or the development of hind limb paralysis. In 
order to study the effect of ZA treatment on the late stages of disease, the study was continued until 
the first signs of clinical sickness (approximately 21 days post tumour cell injection). Naïve 
C57BL/KaLwRij mice treated with PBS (n=4) or ZA (n=4) were used as tumour-free controls. A 
schematic representation of the study design is given below. 
 
Figure 6.3-1: Experimental design to study the effect of ZA treatment initiated prior to tumour cell injection on the 
late stages of myeloma in bone. 
ZA or PBS treatment was initiated in C57BL/KaLwRij mice (male, 9-12 weeks old) 7 days prior to tumour cell 
injection and continued throughout the experiment.  5TGM1 myeloma was induced by injecting mice with 2 X 10
6
 
5TGM1-eGFP-DID labelled cells on day 0. Mice were sacrificed on day 21 when the first mouse showed signs of 
clinical illness. Naïve C57BL/KalwRij mice treated with ZA or PBS served as tumour-free controls. 
  
SACRIFICE 
DAY 0 DAY 21 
5TGM1-eGFP-DID 
labelled MM cell 
injection 
DAY -7 
Inj ZA 125 µg/kg s.c or PBS twice- weekly 
C57BL/KaLwRij/TIME LINE 
Group 1: Naïve + PBS (n=4) 
Group 2: Naïve + ZA (n=4) 
Group 3: 5TGM1 + PBS (n=7) 
Group 4: 5TGM1 + ZA (n=7) 
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6 . 3 . 2  E X PE R I ME N T AL  D E S IG N  T O  S T UD Y  T HE  E F F E C T  O F  Z A  T RE A T M E N T  
I N I T I AT E D  A F T E R  T U M O U R  C E L L  I N J E C T I O N  O N  T H E  L A T E  ST A GE S  
O F  M Y E LO M A  D E V E L O P ME N T  I N  B O N E  ( P O ST - T R E AT M E N T  
E X PE R I ME N T )  
6-9 week old female C57BL/KaLwRij mice were randomised, age matched and grouped as shown in 
figure 6.3-2. Mice were randomised, age matched and sequentially grouped to receive either PBS 
(n=11) or ZA (n=10). 3 days prior to ZA or PBS treatment, group 3 and 4 were injected with 2 X 10
6
 
5TGM1-eGFP-DID labelled cells via the tail vein. Animals were injected with either ZA 125 µg/kg two 
doses three days apart or PBS every week. Mice were sacrificed after 21 days post tumour cell injection. 
Naïve C57BL/KaLwRij mice treated with PBS (n=5) or ZA (n=5) were used as tumour-free controls. A 
schematic representation of the study design is given below. 
On the day of the sacrifice, all animals were starved 6 hr prior to the sacrifice in order to eliminate the 
circadian variation in the serum bone biomarkers (Christgau 2000, Clowes et al., 2002). Mice were 
anaesthetised using 50-100 µl of pentobarbitone (intra-peritoneal injection) and blood samples were 
collected using cardiac puncture. Animals were culled by cervical dislocation while under deep non-
recoverable anaesthesia and tissues were harvested.  
 
Figure 6.3-2: Experimental design to study the effect of ZA treatment initiated after the tumour cell injection on 
the late stages of myeloma development. 
5TGM1 myeloma was induced by injecting C57BL/KaLwRij mice (female, 6-9 weeks old) with 2 X 10
6
 5TGM1-
eGFP-DID labelled cells on day 0. ZA or PBS treatment was initiated on day 3 post tumour cell injection and 
continued. Mice were sacrificed on day 21 when the first mouse showed signs of clinical illness. Naïve 




DAY 0 DAY 3 DAY 21 
5TGM1-eGFP-DID 
labelled MM cell 
injection 
Inj ZA 125 µg/kg s.c twice-weekly 
Group 1: Naïve + PBS (n=5) 
Group 2: Naïve + ZA (n=5) 
Group 3: 5TGM1 + PBS (n=6) 
Group 4: 5TGM1 + ZA (n=5) 
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6 . 3 . 3  E X PE R I ME N T AL  D E S IG N  T O  S T UD Y  T HE  E F F E C T  O F  Z A  T RE A T M E N T  
O N  D I S E AS E - F RE E  S UR V IV A L  
Mice were randomised into three experimental groups. Group A (n=11) mice were treated with PBS 
(100 µl subcutaneously twice-weekly) 7 days prior and injected with 2 X 10
6
 5TGM1-eGFP-DID labelled 
cell via the tail vein. PBS treatment was continued every week throughout the experiment until the 
development of signs of morbidity. Group B (n=11) mice received ZA treatment (125 µg/kg s.c. twice-
weekly) beginning with 2 X 10
6
 5TGM1-eGFP-DID labelled cell injection and continued until the 
development of signs of morbidity. Group C (n=11) mice received ZA treatment (125 µg/kg s.c. twice-
weekly) 7 days  prior to 2 X 10
6
 5TGM1-eGFP-DID labelled cell injection and continued until the 
development of signs of morbidity. All animals were monitored regularly. A schematic representation 
of the study design is given in figure 6.3-3. 
 
Figure 6.3-3: Schematic representation to study the effect of ZA treatment on the onset of illness. 
C57BL/KaLwRij mice (female, 8-9 weeks old) were injected with 2 X 10
6
 5TGM1-eGFP-DID labeled cells on day 0. 
ZA treatment was initiated on day -7 (ZOL LONG, Group C, n=12) and day 0 (ZOL SHORT, Group B, n=12). PBS 
treated 5TGM1 tumour-bearing mice (Group A, 5TGM1 + VEH, n=11) served as controls. 
  
C57BLKalwRij/TIME LINE 
Injection of 2 X 10
6
 5TGM1-
eGFP-DID cell  
(All groups) 
Inj ZA 125 µg/kg 
s.c twice-weekly 
Group A: 5TGM1 + VEH  
Group B: 5TGM1 + ZOL SHORT 
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6 . 3 . 4  S T AT I ST IC A L  AN A L YS I S  
Microsoft Office Excel 2010® was used to plot the graphs and values represented as Mean ± SEM. 
Prism GraphPad Ver 6.0 was used for comparison of parameters between untreated and ZA treated 
5TGM1 tumour-bearing animals. The graphs show 4 groups:  naïve, naïve + ZA, 5TGM1 and 5TGM1 + 
ZA. Although a ‗Kruskal-Wallis‘ test is appropriate with graph that has more the 3 groups, comparison 
was done between the untreated with ZA treated naïve groups and the untreated with ZA treated 
5TGM1 tumour bearing groups. Therefore, a two-tailed ‗non-parametric‘ Mann Whitney-Wilcoxon test 
was used in to compare means with P <0.05 as being statistically significant (Confidence interval > 
95%). 
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6 . 4  R E S ULT S  
6 . 4 . 1  Z A  T R E AT ME N T  E IT H E R  P R E  O R  P O ST  IN JE C T IO N  O F  5T GM 1  M U R I N E  
M Y E LO M A  C E L L S  S I G N IF I C AN T L Y  S U P P R E S SE D  B O T H  O ST E O C L A ST S  
A N D  O ST E O BL AS T S  I N  T H E  5 T G M 1  M U R I N E  M Y E L O M A  M O D E L  
D U R I N G  T H E  L A T E  ST A GE  O F  M YE LO M A  D E V E LO P ME N T  
The effect of ZA treatment on osteoclast numbers assessed 21 day post tumour cell injection of 5TGM1 
murine myeloma cells 
Changes in Oc numbers following pre or post ZA treatment in the trabecular and endocortical region 
of the proximal tibial metaphysis in the 5TGM1 tumour-bearing mice (21 days post tumour cell 
injection) was assessed using static histomorphometry. In the pre-treatment experiment (ZA treatment 
initiated 7 days prior to 5TGM1 tumour cell injection), a significant reduction in the Oc number in both 
the trabecular and endocortical region was observed in the ZA treated 5TGM1 tumour-bearing mice 
when compared with PBS treated 5TGM1 tumour-bearing controls. However, no difference was 
observed in the number of Oc in the trabecular region between the PBS or ZA treated tumour-free 
naïve, age and sex matched C57BL/KaLwRij mice that were used as controls (figure 6.4-1 A and C). 
Interestingly, a significant increase in the number of Oc lining the endocortical surface in the 5TGM1 
tumour-bearing mice when compared to tumour-free, naïve C57BL/KaLwRij control mice was 
observed (figure 6.4-1 C). 
Following post-treatment (ZA treatment initiated 3 days after 5TGM1 tumour cell injection), a 
significant reduction in Oc number both in the trabecular and endocortical region was observed both in 
5TGM1 tumour-bearing and tumour-free naïve controls when compared with age and sex matched PBS 
treated respective controls (figure 6.4-1 B and D). A significant increase in the number of Oc lining the 
endocortical surface in the 5TGM1 tumour-bearing mice when compared to tumour-free naïve controls 
was also seen at 21 days post tumour cell injection (figure 6.4-1 D). 
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PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 6.4-1: The effect of ZA treatment on Oc numbers in the 5TGM1 murine model of myeloma, 21 days post 
tumour cell injection. 
Histological analysis of Oc index (A) and number of Oc per mm of endocortical bone (C) in 5TGM1 tumour-
bearing mice pre-treated for 7 days with ZA (n=7) or PBS (n=7) assessed 21 days post tumour cell injection. 
Tumour-free mice injected with either PBS (n=4) or ZA (n=4) served as controls. Changes in Oc index (B) and 
number of Oc per mm of endocortical bone (D) in 5TGM1 tumour-bearing mice treated with ZA (n=5) or PBS 
(n=6) 3 days after tumour injection, assessed 21 days post tumour cell injection. Tumour-free mice injected with 
either PBS (n=5) or ZA (n=5) served as controls. Comparison was done between PBS or ZA treated groups in 
both naïve tumour-free and 5TGM1 tumour-bearing groups using a one-tailed ‗non-parametric‘ Mann Whitney-
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The effect of ZA treatment on osteoblast numbers in the 5TGM1 murine model of myeloma assessed at 
21 day post tumour cell injection 
In 5TGM1 tumour-bearing mice pre-treatment with ZA significantly reduced the numbers of Ob both in 
the trabecular and endocortical region when compared to PBS 5TGM1 tumour-bearing mice. There was 
no statistically significant difference in Ob number in the naïve tumour-free mice treated with ZA or 
PBS assessed at 21 days post tumour cell injection (P=0.05; figure 6.4-2 A and C). However, there was 
a significant reduction in the number of Ob lining the endocortical region in the 5TGM1 tumour-
bearing mice when compared with tumour-free control mice.  
In the post-treatment experiment, a significant reduction in the number of Ob in the trabecular and 
endocortical region was observed in the 5TGM1 tumour-bearing mice 21 days post tumour cell 
injection when compared with tumour-free controls. Following ZA post-treatment, a significant 
reduction in trabecular Ob number was observed in the tumour-free PBS treated mice when compared 
with PBS treated groups. However, in the 5TGM1 tumour-bearing group following ZA treatment, a 
reduction in Ob number was observed but not statistically significant when compared to PBS treated 
tumour-bearing control groups (figure 6.4-2 B and D). 
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PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 6.4-2: The effect of ZA treatment on Ob numbers in the 5TGM1 murine model of myeloma, 21 days post 
tumour cell injection. 
Histological analysis of Ob index (A) and number of Ob per mm of endocortical bone (C) in 5TGM1 tumour-
bearing mice pre-treated for 7 days with ZA (n=7) or PBS (n=7) assessed 21 days post tumour cell injection. 
Tumour-free mice injected with either PBS (n=4) or ZA (n=4) served as controls. Changes in Ob index (B) and 
number of Ob per mm of endocortical bone (D) in 5TGM1 tumour-bearing mice treated with ZA (n=5) or PBS 
(n=6) 3 days after tumour injection, assessed 21 days post tumour cell injection. Tumour-free mice injected with 
either PBS (n=5) or ZA (n=5) served as controls. Comparison was done between PBS or ZA treated groups in 
both naïve tumour-free and 5TGM1 tumour-bearing groups using a one-tailed ‗non-parametric‘ Mann Whitney-
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Treatment with ZA either pre or post injection of 5TGM1 murine myeloma cells preserved both 
trabecular and cortical bone volume in 5TGM1 model assessed 21 days post tumour cell injection 
Representative microCT images of tibia following pre-treatment with PBS or ZA are shown in figure 
6.4-3 A and B respectively. MicroCT analysis showed that there was a significant increase in cortical 
bone volume in both tumour-free and 5TGM1 tumour-bearing mice treated with ZA when compared 
to PBS treated respective control mice (figure 6.4-3 E). Similarly, greater trabecular bone volume (% 
BV/TV) was seen in the ZA treated tumour-free and 5TGM1 tumour-bearing animals when compared 
with respective PBS treated control groups (figure 6.4-3 G).  
In the experiment where ZA treatment was initiated post tumour cell injection, there was a significant 
increase in cortical bone volume in both tumour-free and 5TGM1 tumour-bearing mice 21 days post 
tumour cell injection (figure 6.4-3 F). Similarly, increase in trabecular bone volume was seen in the ZA 
treated 5TGM1 tumour-bearing mice when compared with PBS treated tumour-bearing groups. 
Interestingly, a reduction in trabecular bone volume was observed in the 5TGM1 tumour-bearing mice 
when compared to tumour-free mice (figure 6.4-3 H). Representative microCT images of tibia 
following post-treatment with PBS or ZA are shown in figure 6.4-3 C and D respectively. 
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Figure 6.4-3: MicroCT analysis following pre and post ZA treatment in the 5TGM1 murine model of myeloma, 21 
days post tumour cell injection 
Representative micro CT longitudinal cross-section images of tibia from 5TGM1 tumour-bearing mice 21 day post 
tumour cell injection following pre (A, B) and post-treatment (C, D) with ZA or PBS respectively. Changes in Ct. V 
(E) and % BV/TV (G) in 5TGM1 tumour-bearing mice treatment initiated 7 days prior to tumour cell injection with 
ZA (n=7) or PBS (n=7) assessed 21 days post tumour cell injection. Tumour-free mice injected with either PBS 
(n=4) or ZA (n=4) served as controls.  Changes in Ct. V (F) and % BV/TV (H) following post ZA treatment where 
treatment was initiated 3 days after tumour cell injection with ZA (n=5) or PBS (n=6). Tumour-free mice injected 
with either PBS (n=5) or ZA (n=5) served as controls. Comparison was done between PBS or ZA treated groups in 
both naïve tumour-free and 5TGM1 tumour-bearing groups using a one-tailed ‗non-parametric‘ Mann Whitney-
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Treatment of animals with ZA either pre or post injection of 5TGM1 murine myeloma cells reduced 
both serum levels of TRACP5b and P1NP assessed 21 days post tumour cell injection 
Following ZA treatment prior to 5TGM1 tumour cell injection, a significant reduction in serum levels of 
TRACP5b in both 5TGM1 tumour-bearing mice and tumour-free naïve C57BL/KaLwRij mice was seen 
when compared to PBS treated respective control groups (figure 6.4-4 A). However, a significant 
reduction in serum levels of P1NP was observed only in the tumour-free naïve mice and not in the 
5TGM1 tumour-bearing group 21 days post tumour cell injection when compared with respective PBS 
treated control group (figure 6.4-4 C). In the post-treatment experiment, a significant reduction in 
serum levels of TRACP5b and P1NP was observed in both 5TGM1 tumour-bearing mice and tumour-
free naïve C57BL/KaLwRij mice with ZA treatment when compared to PBS treated control groups 
(figure 6.4-4 B and D). Interestingly, a significant increase in serum TRACP5b levels was observed in 
5TGM1 tumour-bearing mice 21 days post tumour cell injection when compared with tumour-free 
control group (P<0.001). 
PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 6.4-4: The effect of ZA treatment on serum bone turn over markers in the 5TGM1 murine model of 
myeloma 21 days post tumour cell injection. 
Changes in serum levels of TRACP5b (A) and P1NP (C) respectively in 5TGM1 tumour-bearing mice pre-treated 
with ZA (n=7) or PBS (n=7) assessed 21 days post tumour cell injection. Age matched naïve tumour-free 
C57BL/KaLwRij mice injected with either PBS (n=4) or ZA (n=4) served as controls. Changes in serum levels of 
TRACP5b (B) and P1NP (D) respectively in 5TGM1 tumour-bearing mice post-treated with ZA (n=5) or PBS (n=6) 
assessed 21 days post tumour cell injection. Age matched naïve tumour-free C57BL/KaLwRij mice injected with 
either PBS (n=5) or ZA (n=5) served as controls. A one-tailed ‗non-parametric‘ Mann Whitney-Wilcoxon test was 
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ZA prevents development of osteolytic lesions induced by myeloma cell growth, assessed 21 days post 
tumour cell injection 
In the previous chapter (Chapter 5), it was shown that ZA treatment (both pre and post-treatment 
strategy) was effective in preventing the development of osteolytic bone lesion as early as 10 days post 
5TGM1 tumour cell injection. Here the effect of ZA treatment was tested on the development of 
osteolytic lesions 21 days post 5TGM1 tumour cell injection when the animals showed signs of clinical 
illness. In the ZA pre-treatment experiment, there was a 540% increase (0.25 ± 0.03 1.6 ± 0.39; 
P<0.01) in the percentage lesion area in the 5TGM1 tumour-bearing mice (21 days) when compared 
with tumour-free naïve control mice. However, following ZA treatment initiated prior to 5TGM1 
tumour cell injection, a dramatic 92.5% reduction (1.6 ± 0.39  0.12 ± 0.03; P<0.001) in the 
percentage lesion area was seen when compared with PBS treated 5TGM1 tumour-bearing mice (figure 
6.4-5 E). Similar pattern was also observed in the average number of lesions with a 154% increase 
(83.09 ± 5.16  211.7 ± 27.2; P<0.01) in the average number of osteolytic lesions in the 5TGM1 
tumour-bearing mice when compared with tumour-free control group. Following ZA pre-treatment, 
87.3% reduction (211.7 ± 27.2  27.3 ± 4.2; P<0.001) in average lesion numbers was seen when 
compared with PBS treated 5TGM1 tumour-bearing mice (figure 6.4-5 G). 
In the post ZA treatment experiment, there was a 250% increase (0.32 ± 0.06  1.12 ± 0.29; 
P<0.01) in the percentage lesion area in the 5TGM1 tumour-bearing mice (21 days) when compared 
with tumour-free naïve control mice. However, following ZA treatment, a dramatic 91% reduction 
(1.12 ± 0.29  0.10 ± 0.01; P<0.001) in the percentage lesion area in the percentage lesion area was 
seen when compared with PBS treated 5TGM1 tumour-bearing mice levels (figure 6.4-5 F). Similar 
pattern was also observed in the average number of lesions with a 123% increase (108.3 ± 6.41  
230.6 ± 12.6; P<0.01) in the average number of osteolytic lesions in the 5TGM1 tumour-bearing mice 
when compared with tumour-free control group. Following ZA pre-treatment, 90.9% reduction 
(230.6 ± 12.6  20.9 ± 4.07; P<0.001) in average lesion numbers was seen when compared with 
PBS treated 5TGM1 tumour-bearing mice (figure 6.4-5 H). 
Representative images showing the posterior surface of the tibia with cortical defects from 5TGM1 
tumour-bearing mice pre or post treated with PBS or ZA are shown in figure 6.4-5 A, B, C and D 
respectively. 
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Figure 6.4-5: Effect of ZA treatment on the onset of tumour-induced osteolysis assessed 21 days post tumour cell 
injection. 
Representative 3D models of proximal tibial metaphysis of 5TGM1 tumour-bearing mice following PBS or ZA 
treatment assessed 21 days post tumour cell injection showing osteolytic bone lesion (A), (B), (C) and (D). 
Osteolytic lesions (cortical defects) are shown in red arrows in the PBS treated 5TGM1 tumour-bearing mice. 
Changes in percentage osteolytic lesion (E) and average number of lesions (G) in the 5TGM1 tumour-bearing mice 
pre-treated with ZA (n=7) or PBS (n=7) assessed 21 days post tumour cell injection. Age matched naïve tumour-
free C57BL/KaLwRij mice injected with either PBS (n=4) or ZA (n=4). Changes in percentage osteolytic lesion (F) 
and average number of lesions (H) in the 5TGM1 tumour-bearing mice post-treated with ZA (n=5) or PBS (n=3) 
assessed 21 days post tumour cell injection. Age matched naïve tumour-free C57BL/KaLwRij mice injected with 
either PBS (n=5) or ZA (n=5) served as control. Mann-Whitney non-parametric test was used to compare the 
statistical difference between the mean in the PBS and the ZA treated groups with P value <0.05 as statistically 
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6 . 4 . 2  T HE  E F F E C T  O F  Z A  T R E AT ME N T  O N  T U M O U R  B U R D E N  I N  B O N E  
D U R I N G  T H E  L A T E  ST A G E S  O F  M Y E L O M A D I S E A S E  D E V E LO P ME N T  
Flow cytometric analysis revealed no changes in 5TGM1-eGFP-DID cell burden in BM following ZA 
treatment assessed after 21 days post tumour cell injection 




 and dual labelled 5TGM1-
eGFP-DID
+
 tumour cell in the BM following pre and post ZA treatment. Figure 6.4-6 shows typical 
flow cytometry profiles of BM cell with 5TGM1-eGFP-DID cells with DID labelling on Y-axis and eGFP 





 fluorophore channels. Results showed no significant difference between VEH treated and ZA 






 population in the BM 21 days post 































   
Figure 6.4-6: Flow cytometric profiles of BM cells positive for DID, eGFP and dual labelled 5TGM1-eGFP-DID cells 
Typical flow cytometric profiles of BM cells from mice injected with 5TGM1-eGFP-DID after 21 days post injection. 
BM profile from naïve tumour-free (A) and (D) mice was used to gate normal cells. Profiles from 5TGM1 tumour-
bearing mice after pre-treatment with VEH (B) or ZA (C) with FL1 (eGFP
+
) channel on Y axis and FL4 (DID
+
) 
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Figure 6.4-7: The effect of ZA treatment on 5TGM1 tumour burden 21 days post tumour cell injection. 






 dual labelled 5TGM1 in 
tumour-bearing mice pre-treated (A) with ZA (n=7) or VEH (n=7) assessed 21 days post tumour cell injection. 






 dual labelled 5TGM1 in 
tumour-bearing mice post-treated (B) with ZA (n=5) or VEH (n=6) assessed 21 days post tumour cell injection. 
Comparison was done between VEH or ZA treated groups in the 5TGM1 tumour-bearing groups using a ‗non-
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ZA treatment showed no significant difference in the CD138 positive cell population in BM of the 
5TGM1 tumour-bearing mice 
In chapter 5, it was shown that ZA treatment (pre or post-treatment) did not affect the CD138
+
 
population in the BM following 10 days post 5TGM1 tumour cell injection. In this section, the effect of 
ZA treatment was tested on CD138
+
 population 21 days post 5TGM1 tumour cell injection. Results 
were expressed as number of CD138
+
 cell per mm
2
 of BM in order to quantitate the individual cells and 
percentage BM space occupied by CD138
+
 colonies in order to quantitate the CD138
+
 colonies. In both 
experiments (pre or post-treatment), only individual CD138
+
 cells were seen mice and no there was no 
evidence of CD138
+
 colonies in tumour-free control (both VEH or ZA treated). In the pre-treatment 
experiment, a significant reduction in the number of CD138
+
 cells per mm
2
 of BM was seen in ZA 
treated tumour-free control mice when compared with VEH treated tumour-free control (figure 6.4-8 
A). However, no difference was observed between ZA and VEH treated tumour-free groups in the 
post-treatment experiment (figure 6.4-8 B). No evidence of individual CD138
+
 cells were seen in the 
5TGM1 tumour-bearing mice (day 21) in both the experimental strategies. However, individual CD138
+
 
cells were seen in ZA treated 5TGM1 tumour-bearing mice only in the pre-treatment experiment. 
CD138
+
 tumour colonies were seen in 5TGM1 tumour-bearing mice (ZA or VEH treated) in both the 
experimental strategies. Following pre ZA treatment, although a 33.08 % (VEH vs. ZA, 96.37 ±1.18 vs. 
64.49 ± 14.64; P=0.057) reduction in the percentage BM space occupied by CD138
+
 colonies was 
observed when compared with VEH treated 5TGM1 tumour-bearing mice, it did not reach statistical 
significance (figure 6.4-8 C). Following post-treatment experiment, no significant difference was 
observed in the percentage BM space occupied by CD138
+
 colonies in the ZA treated 5TGM1 tumour-
bearing group when compared with VEH treated control (figure 6.4-8 D). 
Representative examples of CD138 stained BM sections from 5TGM1 tumour-bearing mice (21 days 
post tumour cell injection) following VEH or ZA treatment (pre and post) are shown in figure 6.4-9 
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Figure 6.4-8: Effect of ZA on CD138 positive population on the late stages (21 day) of myeloma development in 
5TGM1 murine model of myeloma. 
Changes in CD138
+
 population between 5TGM1 + VEH and 5TGM1 + ZA treated group was expressed as changes 
in individual number of CD138
+
 population and percentage BM space occupied by CD138
+
 colonies assessed 21 
days post tumour cell injection. Changes in the number of CD138
+
 cells (A) and percentage CD138
+
 tumour 
colonies (C) in the 5TGM1 tumour-bearing mice pre-treated with ZA (n=7) or VEH (n=7) assessed 21 days post 
tumour cell injection. Tumour-free mice injected with either VEH (n=4) or ZA (n=4) served as controls. Changes 
in the number of CD138
+
 cells (B) and percentage CD138
+
 tumour colonies (D) in the 5TGM1 tumour-bearing mice 
post treated with ZA (n=5) or VEH (n=6) assessed 21 days post tumour cell injection. Tumour-free mice injected 
with either VEH (n=5) or ZA (n=5) served as controls. Mann-Whitney non-parametric test was used to compare 
the statistical difference between the VEH and the ZA treated groups with P value <0.05 as statistically significant 
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PRE-TREATMENT ZA STRATEGY 
  
Figure 6.4-9: The effect of ZA pre-treatment on CD138 positive tumour cells 21 days post tumour cell injection. 
Representative CD138 IHC stained images of tibia from mice bearing 5TGM1-eGFP-DID tumour cells (21 day post 
tumour cell injection) pre-treated with VEH (A) or ZA (B). Images are 2X magnified showing the proximal one 
third of the tibia (scale bar 1000 µm) with magnification of CD138+ tumour colonies (inner box, 40X). 
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5TGM1 + ZA 
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B 
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POST-TREATMENT ZA STRATEGY 
  
Figure 6.4-10: The effect of ZA post-treatment on CD138 positive cells 21 days post tumour cell injection. 
Representative CD138 IHC stained of tibia from mice bearing 5TGM1-eGFP-DID tumour cells (21 day post tumour 
cell injection) post-treated with VEH (A) or ZA (B). Images are 2X magnified showing the proximal one third of 
the tibia (scale bar 1000 µm) with magnification of CD138+ tumour colonies (inner box, 40X). 
  
5TGM1 + VEH 5TGM1 + ZA 
A B 
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Treatment of animals with ZA prior to 5TGM1-eGFP-DID murine myeloma cells showed significant 
reduction in 5TGM1-eGFP
+
 tumour colonies, 21 days post tumour cell injection 
From chapter 5, it was clearly shown that using multiphoton microscopy 5TGM1-DID
+
 cell could be 
seen in the BM of mice injected with 5TGM1-eGFP-DID cells and ZA treatment (pre or post-treatment 
strategies) did not affect the number of 5TGM1-DID
+
 cells in the BM 10 days post tumour cell injection. 
In this section, the effect of ZA treatment (pre and post treatment strategies) on 5TGM1 murine model 
21 days post tumour cell injection will be discussed. Multiphoton microscopy showed the presence of 
5TGM1-DID
+
 tumour cells and 5TGM1-eGFP
+
 tumour colonies in the BM of mice injected with 5TGM1-
eGFP-DID cells, 21 days post tumour cell injection. Figure 6.4-11 shows the representative multiphoton 
microscopy images of naïve, naïve + ZA, 5TGM1 + VEH and 5TGM1 + ZA showing the baseline 
fluorescent signals. 
Results showed no significant difference in the number of 5TGM1-DID
+
 cells per mm
3
 of BM following 
pre and post-treatment with ZA when compared with VEH treated control 5TGM1 tumour-bearing 
mice, 21 days post tumour cell injection (figure 6.4-12 A and B). Interestingly, following pre-treatment 
with ZA, a significant 48.54 % reduction (VEH vs. ZA; 47.34 ± 6.03 vs. 24.36 ± 0.01; P<0.01) in the 
percentage 5TGM1-eGFP
+
 tumour colonies occupying the BM space (figure 6.4-12 C). However, no 
significant difference was observed with ZA post-treatment (figure 6.4-12 D). Representative 
multiphoton microscopy images of the proximal tibia metaphysis following pre or post ZA treatment 
are shown in figure 6.4-13 A, B, C and D. 
In order to determine the effect of ZA treatment on the localisation of 5TGM1-DID
+
 cells in the BM, 
minimum distance of 5TGM1-DID
+
 cells to the nearest BM was quantitated. Following pre-treatment 
with ZA, a significant increase in the average minimum distance of 5TGM1-DID
+
 cells when compared 
to VEH treated 5TGM1 tumour-bearing mice 21 days post tumour cell injection (P<0.001) (figure 
6.4-13 E). Strikingly, contradictory results were observed in the post ZA treatment experiment which 
showed a significant reduction in the average minimum distance of 5TGM1-DID
+
 cells to the nearest 
bone structure following ZA treatment when compared to VEH treated tumour-bearing mice (P<0.05) 
(figure 6.4-13 F). 
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A. NAÏVE + VEH B. NAÏVE + ZA C. 5TGM1 + VEH D. 5TGM1 + ZA 
    
Figure 6.4-11: Multiphoton images of bones showing bone structures DID and eGFP labelling 21 days post tumour 
cell injection. 
Representative 2D multiphoton microscopic images of tibiae (450 X 450 µm2) of naive, naïve + ZA, 5TGM1 + 




 signals 21 days after 5TGM1-eGFP-DID tumour cell 
injection. Naïve (tumour-free) (A) and Naïve treated with ZA (B) were used as negative controls to determine 
baseline fluorescence of bone in order to threshold the images.  (C) BM of mice injected with 5TGM1-eGFP-DID 
tumour cells treated with VEH and (D) mice injected with 5TGM1-eGFP-DID cells treated with ZA shows the 
presence of DID
+
  5TGM1 tumour cells (red objects), 5TGM1-eGFP
+
 (green objects) myeloma colonies in the BM. 
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Figure 6.4-12: The effect of ZA on the late stages of myeloma development using multiphoton microscopy. 




 of BM (A), percentage BM occupied by 5TGM1-eGFP
+
 colonies (C) 
and the minimum distance (E) of 5TGM1-DID
+
 cells to the nearest bone in the 5TGM1 tumour-bearing mice pre-
treated with ZA (n=7) or VEH (n=7) assessed 21 days post tumour cell injection. Tumour-free mice injected with 




 of BM (B), 
percentage BM occupied by 5TGM1-eGFP
+
 colonies (D) and the minimum distance (F) of 5TGM1-DID
+
 cells to the 
nearest bone in the 5TGM1 tumour-bearing mice post-treated with ZA (n=5) or VEH (n=4) assessed 21 days post 
tumour cell injection. Tumour-free mice injected with either VEH (n=5) or ZA (n=5) served as controls. A Mann-
Whitney non-parametric test was used to compare the statistical difference between the mean in the VEH and the 
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PRE-TREATMENT EXPERIMENT POST-TREATMENT EXPERIMENT 
  
  
Figure 6.4-13: The effect of ZA pre or post-treatment on 5TGM1 tumour cell colonisation assessed 21 days post 
tumour cell injection. 
Representative multiphoton cross-sectional images of proximal metaphysis of tibia captured by multiphoton 
microscopy showing bone architecture and 5TGM1-DID
+
 cells (red), 5TGM1-eGFP
+
 (green) myeloma colonies 
inside the BM following pre or post-treatment with ZA. Comparison of the effect of VEH (A) or ZA (B) initiated 
prior to tumour cell injection assessed 21 days post tumour cell injection. Comparison of the effect of VEH (B) or 
ZA (D) treatment initiated after tumour cell injection assessed after 21 days post tumour cell injection. 
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J Gurubalan|Page|152  
 
6 . 4 . 3  T HE  E F F E C T  O F  Z A  T RE A T M E N T  O N  D I S E AS E - F RE E  S U RV I V AL  I N  
5 T G M1  T U MO U R - BE A R I N G  M IC E  
Result showed that continuous subcutaneous injection of ZA (125 µg/kg) significantly prolonged 
disease-free survival and delayed the onset of development of hind limb paralysis when compared with 
VEH treated 5TGM1 tumour-bearing control mice (figure 6.4-14 ). Interestingly there was no significant 
change in prolongation of disease-free survival when the ZA treatment was initiated prior or along 
with the tumour cell injection. Although the degree of delayed onset of morbidity was only 3 days 
when compared to the VEH treated 5TGM1 tumour-bearing animals, considering the severity and 
aggressiveness of the disease progression and symptoms development in the 5TGM1 murine model of 
myeloma and the treatment with ZA at dosages merely at the levels of bone disease management 
suggests that ZA treatment is responsible for delaying the onset of clinical signs of morbidity.  
As all animals were sacrificed at the time of onset of morbidity, survival analysis was not performed 
due the limitation in the UK Home Office Project Licence Regulation (40/3096) demanding to sacrifice 
animals at the first sign of illness. 
 
Figure 6.4-14: The effect of ZA treatment on the onset of morbidity. 
A Kaplan Meir curve shows the effect of ZA treatment initiated prior to tumour cell injection (ZA LONG; n=11) 
and treatment initiated along with tumour cell injection (ZOL SHORT; n=11) on the onset of morbidity in the 
5TGM1 murine model of myeloma when compared to VEH treated control group (n=11). Log-Rank (Mantel Cox) 
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6 . 5  D I SC U SS I O N  
In this study, an in vivo model for myeloma growth in bone was developed by injecting the 5TGM1 
murine myeloma cell line via the tail vein of C57BL/KaLwRij mice. This resulted in growth of myeloma 
cells in the BM, which gradually replaced the normal BM over a period of 21 days post tumour cell 
injection. Data from the present study showed that the development of 5TGM1 myeloma in the bone 
was associated with a significant increase in osteoclast numbers, increase in serum TRACP5b levels, 
reduction in osteoblast numbers, reduction in serum P1NP levels and formation of osteolytic bone 
lesion. Treatment with ZA either initiated prior to tumour cell homing (pre-treatment) or after tumour 
cell homing (post-treatment) resulted in significant reduction in both osteoclastic as well as osteoblastic 
activity with complete prevention of osteolytic bone disease. Results were in agreement with the 
previous studies where ZA or IBN administration resulted in the prevention of myeloma-induced 
osteolytic bone disease in the 5T2 and the 5TGM1 murine models of myeloma respectively (Dallas et 
al., 1999, Croucher et al., 2003a). Croucher et al., (2003a) showed using 5T2MM murine model of 
myeloma that ZA treatment initiated after serum paraprotein detection only resulted in partial 
prevention of bone loss whereas ZA treatment initiated along with tumour cell injection resulted in 
complete prevention of myeloma-induced bone loss. This suggests that myeloma-induced osteoclastic 
activity begins early and ZA treatment initiated after established disease was not able to fully abrogate 
the myeloma-induced bone loss (Croucher et al., 2003a). From chapter 4, it was clearly shown that 
until 3 days post tumour cell injection; there were no alterations in the indices of bone remodelling 
between the 5TGM1 tumour-bearing mice and the tumour-free control groups (figure 4.4-15 and figure 
4.4-16). Therefore, in the present study, when ZA treatment was initiated either 7 days prior or 3 days 
after tumour cell injection, the bone remodelling in the 5TGM1 tumour-bearing mice was similar to the 
tumour-free control groups. This suggests that, if ZA treatment is initiated before onset of myeloma 
induced osteoclastic activity, it will completely prevent the development of tumour-induced bone loss.  
Data from the current study showed that ZA treatment resulted in the reduction of tumour burden 
after 21 days post tumour cell injection in the 5TGM1 murine model of myeloma, only if initiated prior 
to tumour cell injection. The effect of ZA treatment on 5TGM1 tumour burden was assessed using flow 
cytometry, CD138 IHC and multiphoton microscopy. The data reported here shows that ZA treatment 
initiated prior to the 5TGM1 tumour cell injection reduced the number of 5TGM1-eGFP
+
 cells (30% 
reduction by flow cytometry; P=0.07) and CD138
+
 colonies in BM (33.13% reduction in tumour 
burden; P=0.057) although these were not statistically significant. However, using the 3D multiphoton 
microscopic technique, a significant 48.54% (P<0.01) reduction in 5TGM1-eGFP
+
 tumour colonies in 
BM was observed with ZA pre-treatment. The data presented here are in agreement with previous 
studies reported by Yacoby et al., (2002) and Croucher et al., (2003a) using ZA in the SCID/hu and 
5T2MM murine myeloma models respectively. Interestingly, in the present study, no evidence of 
reduction of tumour burden was seen when ZA treatment was started after tumour cell homing to 
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bone. This was contrary to the reports of Croucher et al., (2003a) where ZA (120 µg/kg) treatment 
initiated at the time of tumour cell injection or after detection of serum paraprotein (approx. 8 weeks 
after tumour cell injection) both resulted in significant reduction in tumour burden. The major 
difference between present study and the reports of Croucher et al., (2003a) is that they used the 
5T2MM murine model of myeloma whereas in this study 5TGM1 murine model of myeloma was used.  
Data from the present study contradicts the reports of Dallas et al., (1999)  and Cruz et al., (2001) who 
demonstrated that IBN, another potent BP effectively inhibited the development of osteolytic bone 
disease but not the tumour burden in the 5TGM1 and ARH77/SCID murine models of myeloma 
respectively. The differences in the BPs or the murine models used could also be responsible for the 
observed discrepancies. In both these studies, although IBN treatment was associated with inhibition of 
osteoclastic activity; there was no evidence of reduction in tumour burden. In both these studies IBN 
treatment was initiated along with tumour cell injection, unlike in the present study in which ZA 
treatment was initiated prior to tumour cell injection. This strongly implies that initiation of ZA 
treatment prior to tumour cell arrival in bone has definitive advantages in reducing the tumour burden 
during the late stages of disease development. Whether this was due to a direct inhibitory effect on the 
tumour cells when they home to the BM or an indirect effect mediated by inhibition of osteoclastic 
bone resorption is not clear from this experiment and warrants further investigation. 
It has already been shown in Chapter 4 that a pool of dormant 5TGM1-DID
+
 cells existed in the BM 
even when the BM was completely replaced with proliferating tumour colonies. Myeloma cells arriving 
in the BM proliferate to form colonies and replace the entire BM over time. The presence of these 
subpopulations of dormant cell in BM proximal to the bone suggests that their preferential localisation 
near bone may play an important role in suppressing their ability to proliferate. Studies have shown 
that the endosteal niche which is seen adjacent to the trabecular bone plays an important role in 
maintaining the HSCs in a quiescent state. Whether these dormant 5TGM1-DID
+
 cells have hijacked the 
HSC niche and whether this mechanism is responsible for the quiescent nature of these cells are not 
known. Studies on HSCs suggest that osteoblasts are important components of the endosteal niche 
which maintains the HSCs in a quiescent state (Zhang et al., 2003). Furthermore, Iriuchishima et al., 
(2012) also showed that myeloma cells forms complexes with osteoblasts and osteoclasts near the 
endosteal regions. If the dormant tumour cells seen in this study were hijacking the endosteal niche, 
then ZA induced ablation of osteoblasts would result in the disruption of the niche, then it would be 
expected to result in mobilisation of these dormant cells. Contrastingly, Soki et al., (2013) showed that 
ZA treatment was associated with an increase in the endosteal niche with concomitant increase in HSCs 
in the BM. In this study, ZA treatment was shown to increase the trabecular bone volume which in turn 
increases the endosteal niche sites in the bone. However, data from the present study showed that ZA 
treatment initiated pre or post tumour cell injection did not affect the number of these low cycling, 
persistently DID
+
 labelled 5TGM1 cells seen in the BM. Moreover, when ZA was initiated prior to 
5TGM1-eGFP-DID tumour cell injection these cells were seen significantly further away from the bone, 
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whereas when ZA treatment was initiated after tumour cell injection these cells were seen closer to 
bone when compared to VEH treated controls (figure 6.4-12 E & F). This suggest that time of initiation 
of ZA treatment may play a crucial role on the distribution of these dormant myeloma cells inside the 
BM. The hypoxic nature of the endosteal niche is another factor shown to be responsible for the 
quiescent nature of the HSC in the endosteal niche (Noll et al., 2012). Several studies have shown that 
ZA is able to inhibit angiogenesis by inhibiting endothelial cell proliferation or by blocking VEGF or 
FGF (Wood et al., 2002). If this was the case, treatment with ZA should have reduced vascularity of 
the BM and induced more hypoxia, arresting more myeloma cells in a quiescent phase. However, ZA 
treatment (pre or post treatment experiments) did not modify the number of 5TGM1-DID
+
 cells seen in 
the BM when compared with VEH treated tumour–bearing controls. Techniques in the identification of 
dormant tumour cells and their proximity to bone using multiphoton microscopy are at their initial 
stages and require more studies using three-dimensional perfusion models to better understand the 
interactions between the myeloma cells and their putative endosteal niche sites. 
It is interesting to speculate how pre-treatment with ZA inhibit colony formation but not the number of 
5TGM1-DID
+
 cells arriving in the BM. Assuming that the myeloma colonies seen arises from the 
5TGM1-DID
+
 cells observed at early time points after injection, ZA pre-treatment would appear to be 
suppressing the number of specific DID
+
 cells that are activated to form colonies or the survival of these 
cells. The number of 5TGM1-DID
+
 cells present in BM reduces over 21 days in animals that were 
studied (figure 4.4-13 A). This could be because some of the 5TGM1-DID
+
 cells were activated to form 
colonies, but equally this reduction could also represent the loss of cells via apoptosis or movement of 
these tumour cells out of the BM. The putative myeloma niche could have several roles: it could retain 
tumour cells in a dormant state in the same way HSCs are held, it could aid in the survival of single 
MM cells which then adapt to the new environment or it could act as a trap holding cells in the BM. If 
ZA pre-treatment reduces niche frequency, potential colony forming cells could die or lost and this 
might provide an explanation for the observed effects on colony formation at later time points. 
In the present study, ZA treatment was also shown to prolong disease-free survival in the 5TGM1 
murine model of myeloma. In untreated 5TGM1 tumour-bearing mice, the median time for the 
development of signs of morbidity was 21 days. With ZA treatment initiated 7 days prior to or at the 
time of tumour cell injection, the median time for the development of hind limb paralysis or sickness 
was 24 days (P<0.05). Similar results were shown by Croucher et al., (2003a) in the 5T2MM model 
using single dose ZA where the median survival was 37 days compared to 35 days in untreated tumour 
controls. Development of hind limb paralysis is a sign of clinical disease and may reflect the onset of 
either extramedullary tumour development through vascular channels or collapse compression fracture 
of the vertebral column leading to spinal cord injury and paralysis. As ZA treatment showed clear 
evidence of prevention of development of osteolytic bone lesion in the tibia even after 21 days post 
tumour cell injection, it is less likely that collapse compression of vertebrae may happen at this stage. 
Therefore, haematogenous spread of the tumour cells to the spinal canal is more likely to be 
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responsible for the development of hind limb paralysis. This suggests that, the delay in the onset of 
hind limb paralysis or sickness associated with ZA treatment observed in the present study may be due 
to ZA induced inhibition of tumour development or spread. The results of the current study contradicts 
with reports of Dallas et al., (1999) and Cruz et al., (2001) who showed following IBN administration 
(160µg/kg) continuously in the 5TGM1 and ARH77/SCID model, although there was inhibition in 
development of bone disease there was no evidence of delay in the onset of paraplegia or 
prolongation of survival. This suggests that ZA exert anti-myeloma benefits in the 5TGM1 murine 
myeloma models in ways other than inhibiting osteoclastic bone resorption. However, the mechanisms 
are not known yet. 
To conclude, the present study evaluated the effects of ZA on late stages of 5TGM1 murine model of 
myeloma in the absence of other anti-cancer therapeutics in an attempt to evaluate the anti-cancer 
potentials of the drug. ZA treatment (pre or post) was effective in inhibiting osteoclastic activity and 
preventing the development of osteolytic bone lesions in the 5TGM1 model, 21 days post tumour cell 
injection. ZA in a prophylactic strategy was effective in inhibiting myeloma tumour burden within the 
BM and prolonged disease-free survival.  
  






 CHAPTER 7 DISCUSSION 
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Despite modern advancements in the field of myeloma research, MM still remains incurable with 
majority of patients relapsing into a more drug-resistant type. With the introduction of high-dose 
chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) and the development 
of newer chemotheraphy agents such as thalidomide, lenalidomide and bortezomib, extraordinary 
increase in survival outcomes have been made when compared to conventional chemotherapies (Durie 
2010). Currently, the introduction of newer chemotherapeutic agents such as thalidomide, 
lenalidomide and bortezomib has resulted in dramatic improvements in the expected OS especially in 
newly diagnosed young myeloma patients (aged less than 45 years) (Brenner et al., 2009). Although 
currently available treatments are successful in treating the condition in the short-term, they fail to cure 
the disease, resulting in relapse or refractory myeloma in almost all myeloma patients. Recently, it has 
been identified that the BM microenvironment plays an important role in the evolution of the disease 
contributing to proliferation, differentiation, migration, adhesion and chemoresistance of the myeloma 
tumour cell in the host BM (Manier et al., 2012). The BM microenvironment is composed of stromal 
cells, endothelial cells, immune cells, osteoclasts and osteoblasts which interact with myeloma cells by 
close cell to cell contact. These interactions between the myeloma cells and the host BM 
microenvironment are discussed in detail in Chapter 1: Introduction. MM corresponds to the late stage 
continuum of MGUS, an asymptomatic premalignant phase during which malignant myeloma cells 
gradually home, proliferate and replace the BM with myeloma colonies, interacts with the BM cells and 
results in signs and symptoms of overt myeloma. It has been shown that myeloma cells reside in BM 
niches which not only promotes survival and colonisation but also protect these cancer cells against 
anti-myeloma chemotherapies (Meads et al., 2008, Castells et al., 2012, Manier et al., 2012). There are 
two important considerations for clinical intervention in MM. Firstly, the presence of a premalignant 
phase offers a therapeutic window in which altering the BM may hinder early disease progression. 
Secondly, as myeloma cells were shown to evade treatment by hiding in specific BM niches, making the 
BM less conducive may result in increasing the susceptibility to the currently available treatments. 
Currently, research is already focussing on developing novel agents that target not only the cancer cells 
but also the BM microenvironment in order to completely eradicate tumour cells from the bone. 
Work presented in this thesis has used a number of methods. Firstly, the effects of myeloma on bone 
remodelling during the different stages of disease development in order to determine the sequential 
development of tumour in bone from a single cell to established colonies over time has been studied.  
The effect of ZA treatment on the early and late stages of tumour development and the effect of ZA 
treatment on the onset of morbidity using the 5TGM1 murine model of myeloma has also been 
studied. As the main aim of thesis was to study the anti-tumour effects of ZA at different stages of 
myeloma development, initial studies were performed to understand the effects of short-term (125 
µg/kg X 2) and continuous (125 µg/kg X 2 weekly, repeated every week) ZA treatment on normal 
bone remodelling in C57BL/KaLwRij mice (Chapter 3). The study provided strong evidence that ZA 
treatment, irrespective of whether it was short-term or continuous treatment, inhibited osteoclastic 
bone resorption and in addition inhibited osteoblastic bone formation. This was in agreement with 
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previous studies where BPs and an anti-RANKL antibody (Denosumab), in addition to suppressing bone 
resorption, markedly reduced bone formation (Pozzi et al., 2009, Baron et al., 2011). It is well 
established that bone remodelling is a tightly coupled process between bone resorption and formation 
with cross talk mechanisms between osteoclasts and osteoblasts in order to ensure balanced bone 
remodelling. Furthermore, it is also well established that osteoclasts regulates several osteoblast 
stimulating cytokines and the process of bone resorption releases bone matrix derived growth factors 
such as TGF-β, IGF and BMPs which promote osteoblast differentiation (Baron et al., 2011). Therefore, 
disruption of one arm of the bone remodelling process is expected to alter the other. Moreover, 
Patntirapong et al., (2012) also showed that ZA can directly inhibit osteoblast differentiation and 
suppress bone mineralisation. Taken together, this suggests that the inhibition of bone formation seen 
with ZA treatment might be a combined effect of direct ZA mediated cytotoxicity and indirect 
suppression of osteoclast. Data from the present study also showed that short-term ZA treatment 
resulted only in temporal and incomplete suppression of bone remodelling, whereas continuous 
treatment was required to profoundly suppress and maintain inhibition of bone remodelling over time. 
Chen et al., (2002) showed that the anti-resorptive effects of ZA remain active in bone over a period 
of 28 days, even after a single dose. In contrast, the data presented here shows short-term ZA 
treatment was associated only with a temporal inhibition followed by a dramatic increase in osteoclast 
numbers and a thick band of primary spongiosa in the trabecular region parallel to the growth plate 
after 14 and 21 days post-treatment. Although uninterrupted reduction was seen in serum levels of 
TRACP5b after 14 and 21 days following the short-term ZA treatment, it only suggested that the 
osteoclasts were functionally less active and the existence of these elevated numbers of osteoclasts in 
the trabecular region after 14 and 21 days was the outcome of the short-term treatment. Similar 
observations were reported by Muderis et al., (2007), where cyclical pamidronate treatment in 
children resulted in abnormal bands of opacities parallel to the growth plate in radiographs suggesting 
temporary cessation of osteoclastic activity with failure of primary spongiosa resorption following ZA 
treatment. This might primarily be a consequence of using young animals without skeletal maturity 
which are in their active phase of bone growth. As the majority of murine models of myeloma use 
young mice, short-term treatment with BPs will be ineffective in suppressing bone resorption over long-
term and therefore a continuous dosage regimen will be required. 
Chapter 4 reports the first longitudinal in vivo study describing the temporal and spatial development 
of myeloma in bone over time using the 5TGM1 murine model of myeloma. Work presented here 
shows the first comprehensive analysis of changes in bone remodelling, development of osteolytic 
lesions and tumour progression from the time of tumour cell injection to the development of overt 
myeloma colonies. The study provided strong evidence that tumour-induced changes in bone 
remodelling begins even before they can be clinically detected. For example, in this study, 
development of osteolytic bone disease following tumour cell injection was seen as early as 10 days 
post tumour cell injection. In the previous studies, the development of osteolysis following tumour 
development were seen only after established clinical disease such as the development of paraplegia or 
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serum paraproteinemia (Alsina et al., 1996, Vanderkerken et al., 1997, Dallas et al., 1999, Croucher et 
al., 2003a). This might be due to the use of less sensitive techniques such as x-rays for the detection of 
bone lesions in these studies. Recently, Berenson et al., (2009) also showed evidence of bone loss and 
skeletal deformity in patients with MGUS and these patients might benefit from prophylactic 
bisphosphonate treatment. In the present study, an increase in osteoclast numbers and serum levels of 
TRACP5b and a reduction in osteoblast numbers and serum levels of P1NP were evident only during 
the later stages (day 21) of tumour development. Interestingly, changes in osteoclast and osteoblast 
numbers following myeloma development were noted only in the cortico-endosteal regions suggesting 
that bone cells may have heterogeneous responses depending on their location (trabecular or cortical) 
(Henriksen et al., 2011). Bataille et al., (1991) showed in myeloma patients, that an increase in both 
osteoclastic and osteoblastic activity was observed during the early stages of disease and increased 
osteoclastic but decreased osteoblastic activity was seen during late stages. The data from the present 
study agrees with the later stages as described by Bataille et al., (1991) with increased osteoclastic 
activity but decreased osteoblastic activity in the 5TGM1 model (day 21). However, during the early 
stages (day 10) of myeloma development, indices of bone remodelling were similar to tumour-free 
control mice. This discrepancy might be due to the inherent differences between the myeloma patients 
and the murine models, especially the time taken for the development of overt myeloma. However, 
considering the time taken to evolve from MGUS to myeloma in humans, in the 5TGM1 murine model 
of myeloma which develops in 3 weeks this early asymptomatic stage may represent the MGUS stage 
in mice.  
The thesis also provided evidence that myeloma progression is associated with a strong inhibition of 
osteoblastic bone formation activity and this may additionally contribute to the development of 
myeloma bone disease. In particular, the moderate increase in osteoclasts and serum levels of TRACP5b 
and an almost complete absence of osteoblasts and a reduction in the serum levels of P1NP observed 
during the later phase of the disease suggests uncoupling of bone remodelling. This was in agreement 
with the report of Hjorth-Hansen et al., (1999) where partial inhibition of osteoclasts and complete 
absence of osteoblasts were seen in a SCID hu model using the JJN-3 cell line when the mice were 
sacrificed after the onset of hind-limb paralysis. Tian et al., (2003) showed that in patients, myeloma 
cells produce DKK-1, an inhibitor of osteoblast function by paracrine mechanism. Besides, studies have 
also shown that myeloma cells inhibit osteoblast formation by supressing Runx2 (an osteoblast 
transcription factor) activity in pre-osteoblasts as well as induce osteoblast apoptosis by inducing 
overexpression of Fas (cell surface death receptor) by the osteoblast (Heider et al., 2005). 
The present study is also the first comprehensive work to show the longitudinal development of 
myeloma in bone using the 5TGM1 murine model of myeloma. Previously, assessment of tumour 
burden in MM was made using indirect measures such as changes in tumour markers (e.g. serum 
paraprotein), development of spinal injury (morbidity), organ involvement and MRI which were 
evident only after established or late stage disease (Dallas et al., 1999, Croucher et al., 2003a, Dairaghi 
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et al., 2012). To detect changes in tumour burden following treatment, changes in serum levels of 
immunoglobulins (paraprotein) are routinely used which has relatively long plasma half-life (approx. 3 
weeks). Although, few studies in the past used histomorphometric quantitation of tumour, CD138 IHC 
or flow cytometry in bone which represented direct measure of tumour burden also had their 
limitations (Croucher et al., 2003a, Fryer et al., 2013). For example, using histology although it was 
possible to identify tumour colonies based on morphology in bone at late stages, identification of 
single tumour cells during the early stages of myeloma development were impracticable. Likewise, the 
presence of CD138
+
 normal plasma cells and CD138
—
 myeloma cells in BM complicated the 
quantitation of tumour burden especially during the early stages of myeloma development using IHC 
or flow cytometry. Although Oyajobi et al., (2007) successfully introduced the technique of direct 
tumour burden assessment by whole body fluorescence imaging using 5TGM1-eGFP cells, the technique 
allowed the detection of tumour burden only after established tumour colonies (approximately 2 
weeks post tumour cell injection). In the present study, a syngeneic murine myeloma model was 
developed using 2 X 10
6 
5TGM1-eGFP-DID labelled myeloma cells injected into the tail vein of 
immunocompetent C57BL/KaLwRij mice. This model is superior to the previously existing models for a 
number of reasons. Firstly, in this model, tumour cells were injected via the tail vein and they homed 
and colonised the BM similar to the human disease. Secondly, the course of the disease development 
mimicked human disease in which there was a brief asymptomatic phase followed by development of 
osteolytic bone disease and hind limb paralysis. Thirdly, the model allowed the detection of tumour 
burden even at a single cell stage by using combinations of methods such as flow cytometry, three-
dimensional multiphoton microscopy and CD138 IHC. The ability to visualise the tumour cells in 3D 
may be useful to understand the complex interactions with the neighbouring BM cells. Finally, the 
model had a shorter time lag (3 weeks) for tumour development and allowed detection of minor 
changes in tumour burden which may be beneficial for testing anti-cancer therapy in the future.   
Data presented here demonstrated the presence of MM cells in the proximal tibial metaphysis after 3 
days post tumour cell injection. Similar observation were seen by Iriuchishima et al., (2012) using 
U266-GFP labelled human myeloma cells in NOG-hMM (NOD/SCID/ɤcnull) mice, However, they 
showed that the myeloma cells were preferentially localised on the endosteal region of the bone 
whereas in this model the MM cells were randomly distributed throughout the metaphysis. Although 
flow cytometry and multiphoton microscopy confirmed the presence of MM cells in the BM as early as 
3 days post tumour cell injection, CD138 IHC analysis revealed no difference in the number of CD138
+
 
cells between 5TGM1 myeloma bearing mice and tumour-free control groups during early time-point 
(day 3 post tumour cell injection). This suggests that the 5TGM1-eGFP-DID cells present in the BM 3 
days post tumour cell injection predominantly could have been CD138
—
 cells. This may be due to 
either a selective homing of the CD138
—
 cells to the BM or the 5TGM1-eGFP-DID cells injected into the 
mice could have predominantly been a CD138
—
 population. Zlei et al., (2007) showed that during 
long-term in vitro culture of the human myeloma cell lines U266 and L363 resulted in the down 
regulation of CD138 expression. However, Matsui and colleagues (2004) showed that in vitro 
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passaging of human myeloma cell lines such as RPMI 8226 and NCI-H929 contributed a less than 5% 
CD138
—
 population. This suggests that, in the present study, it is less likely that the 5TGM1-eGFP-DID 
cells injected to the mice to be predominantly CD138
—
 population. Moreover, the same group also 
showed that, CD138
—
 myeloma cells were able to form colonies in vitro and engrafted murine long 
bones whereas CD138
+
 cells were not clonogenic in vitro and were incapable of forming tumours in 
mice. Furthermore, CD138
—
 myeloma cells both in vitro or in vivo produced CD138
+
 colonies (Matsui 
et al., 2004). This correlated well with the present study, as the 5TGM1-eGFP-DID cells seen in the BM 
3 days post tumour cell injection were CD138
—
, but there was an increase in number of single CD138
+
 
cells and appearance of CD138
+
 tumour colonies (approx. 0.1% of the BM) in BM 10 days post tumour 
cell injection. This implicates that during the early stages of myeloma tumourigenesis, there is a selective 
homing of CD138
—
 tumour cells into the BM, but eventually leads to the development of CD138
+
 
tumour colonies formed from these clonogenic CD138
—
 cells in BM in this murine model of myeloma. 
In agreement, Linlin Xu and colleagues (2013) using NCI-H929 human myeloma cell line reported that 
although the percentage of CD138
—
 cells (in vitro) were less than 4% in culture, there was significantly 
higher percentage (>50%) of CD138
—
 cells that homed to the BM when injected to NSG mice. Taken 
together, the data from the present study provides evidence for the preferentially homing of CD138
—
 
cells to the BM, although the mechanisms are not known yet.  
This study also provided strong evidence supporting the presence of inactive or cytokinetically 
quiescent tumour cells in BM (persistently DID labelled 5TGM1 cells) even after entire BM was replaced 
with myeloma colonies. The concept of tumour cell dormancy has been previously shown in a variety 
of solid tumours such as breast, thyroid and prostate which possibly explains late relapse in some 
patients declared disease-free (Uhr and Pantel 2011). Several mechanisms were indicated to be 
responsible for the development of tumour dormancies such as epigenetic alterations in tumour cell, 
interaction of the tumour cells with the host BM microenvironment, angiogenic switching and anti-
tumour immune surveillance (Gelao et al., 2013). Evolving evidences suggests that these dormant 
populations may represent the MM-cancer stem cells (MM-CSC) which are limited in number, quiescent 
and capable of reinitiating tumour growth (Allan et al., 2006). In addition, Matsui et al., (2004) also 
demonstrated the presence of phenotypically heterogeneous populations in both patient myeloma cells 
and myeloma cell lines. They also showed that the MM-CSCs are a rare population (2 to 5%) of 
CD138
—
 cells which are highly clonogenic, immature and resemble mature B cells but not plasma cells. 
On the other hand, the CD138
+
 tumour cells which contributed to the tumour bulk were shown to be 
unable to form colonies both in vitro and in vivo. It has already been well established that tumour-host 
BM interactions play an important role in the propagation of myeloma in the BM. Tumour cells 
arriving at BM proliferate into overt colonies due to the stimulatory signals released upon close cell-cell 
contact and production of stimulatory cytokines and chemokines promoting tumour cell growth and 
tumour associated neovasculogenesis. However, those cells arriving at specific BM niches remains 
quiescent, especially in the case of the MM-CSCs with their unlimited self-renewal and their stem cell 
nature which renders them resistant to DNA damaging chemotherapy, making them potential targets 
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responsible for relapse. Moreover, these quiescent MM-CSCs may not be a part of the tumour bulk and 
therefore could be independent of the tumour associated vascular supply and chemotherapy. 
Therefore, targeting tumour angiogenesis might not affect these cells thereby making them resistant to 
chemotherapy treatments such as doxorubicin, lenalidomide or bortezomib (Naumov et al., 2003). 
Furthermore, in the present study these dormant cells were found closer to the bone surface (endosteal 
and trabecular) when compared with 5TGM1-DID
+
 cells from earlier time points. It has already been 
suggested that the cross-talk between tumour cells and the host BM microenvironment may contribute 
to the quiescent nature of these cells (Gelao et al., 2013). Recently studies have shown that MM cells 
and HSCs express similar cell surface molecules and share common signalling pathways within the BM 
microenvironment (Noll et al., 2012). Quiescence in HSCs are attributed to the relative lower oxygen 
tension in specific sites within the BM referred to as  ‗HSC niches‘ which are identified to be closer to 
bone surface and far away from endothelial vasculature (Kubota et al., 2008). Pre-osteoblasts also 
plays a very important role by β-catenin-N-cadherin complex formation between the osteoblasts and 
HSCs (Zhang et al., 2003). This may suggest that MM-CSCs may hijack the HSC niche owing to the 
preservation of their stem cell characteristics and might contribute to the tumour re-initiating 
population. Further studies are required to understand the complex interactions between these 
quiescent cells and their niche environment especially using three‐dimensional perfusion model may 
give further insights and newer potential targets.  
Chapter 5 and 6 are the first novel and comprehensive studies to demonstrate the effects of early ZA 
treatment initiated 7 days prior (pre-treatment) or 3 days after (post-treatment) tumour cell injection 
on the early and late stages of tumour development (10 and 21 days post tumour cell injection 
respectively) in the 5TGM1 murine model of myeloma. Although several in vivo studies have 
previously established the anti-tumour effect of BPs in MM, in these studies treatment was only 
initiated after established disease similar to clinical scenarios (Dallas et al., 1999, Choi et al., 2001, 
Croucher et al., 2003a). Even in human clinical trials, the treatment was initiated after the disease had 
clinical symptoms and the results were often compounded with the simultaneous use of other 
chemotherapeutic agents. Data from the present study indicates that initiation of ZA treatment prior to 
the tumour cell injection significantly prevented the early onset of tumour-induced osteolytic bone 
lesions and significantly inhibited tumour burden at the late stages (day 21) of disease. However, no 
effect was seen on the early stages (day 10) in this murine model of myeloma. In the other experiment 
where ZA treatment was initiated 3 days after the tumour cells were injected, although this prevented 
the early onset of tumour-induced bone disease, it had no effect on tumour burden at either the early 
or late stages of disease. In contrast to the data reported here, a study on breast cancer bone metastasis 
showed that ZA treatment either alone or in combination with doxorubicin effectively inhibited early 
and late tumour formation in bone (Brown 2012). Evolving evidence suggests that in breast cancer 
bone metastasis there is the development of pre-metastatic niche sites in bone owing to the release of 
signalling mechanisms from the primary tumour site promoting the homing and colonisation of tumour 
cells to bone (Kaplan et al., 2005). However, in the case of MM, the myeloma cells are derived from 
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malignant transformation of normal plasma cells which normally reside in bone. Therefore, it is 
probable that myeloma cells home to bone using similar mechanism to their non-malignant 
counterparts and thus may be independent of the local changes in bone remodelling. In addition, in 
chapter 4 it has been clearly shown that the presence of tumour cells in BM at 10 days post tumour cell 
injection did not alter the bone remodelling which further suggests that tumour development during 
the early stages is independent of the local changes in bone remodelling. Interestingly, Croucher et al., 
(2003a) reported that ZA treatment initiated at the time of tumour cell injection or after the detection 
of serum paraprotein (approximately 8 weeks after tumour cell injection) showed substantial reduction 
in tumour burden in bone in the 5T2MM murine model of myeloma. The reason for discrepancy 
between these studies may be due to the two different murine models used. Although, the 5T2 and 
5TGM1 models evolved in C57BL/KaLwRij mice, the 5T2MM model takes about 3 months to develop 
compared to 3 weeks for the 5TGM1 model.  
The concept of vicious cycle between the myeloma cells and the host BM cells has been of interest in 
the recent years. Several studies have shown that the myeloma cells interact with the BMSCs and 
osteoclasts thereby establishing a vicious cycle between myeloma expansion and bone disease (Abe et 
al., 2004, Matsumoto and Abe 2006, Tanaka et al., 2007). Data presented in the current study shows 
that the effect of ZA on myeloma tumour burden in bone is highly dependent on the time of initiation 
of treatment. ZA treatment initiated prior to tumour cell injection resulted in a reduction of bone 
tumour burden whereas treatment initiated after tumour cell injection did not. There could be several 
reasons to explain this phenomenon. In the pre-treatment experiment, mice received more doses of ZA 
compared with the post-treatment experiment suggesting that this could be a dosage dependent direct 
anti-tumour effect. Furthermore, in both these experiments ZA treatment resulted in a similar 
suppression of both osteoclastic bone resorption and osteoblastic bone formation which raises the 
possibility that the 5TGM1 model does not depend on the BM microenvironment for development. In 
agreement, Dallas et al., (1999) showed that IBN treatment did not affect the tumour burden in the 
5TGM1 model. However, recent reports from Dairaghi et al., (2012) showed contrasting evidence that 
ZA treatment either initiated prior to tumour cell injection or after established disease significantly 
reduced tumour burden in the 5TGM1 model. However, in these experiments serum immunoglobulin 
levels were used as tumour burden indices which may not be accurate. Several in vitro studies have 
shown that ZA exerts cytotoxic effects on patient myeloma cells and myeloma cell lines (Aparicio et al., 
1998, Derenne et al., 1999, Jagdev et al., 2001). In addition, ZA inhibits BMSC mediated release of IL-6 
which otherwise promotes myeloma cell growth (Derenne et al., 1999).  The availability of ZA in bone 
prior to the arrival of tumour cells may have resulted in a direct cytostatic effect of the tumour cells 
upon arrival. But, if ZA treatment was introduced after tumour cell homing to the bone, the myeloma 
cells would have already interacted with the cells of the BM microenvironment thereby evading 
treatment (Cheung and Van Ness 2001, Landowski et al., 2003). Furthermore, ZA treatment was 
shown to inhibit tumour-associated angiogenesis in vivo (Croucher et al., 2003a). However, the exact 
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mechanism by which ZA exerts this anti-tumour effect only when the animals were treated prior to the 
homing of myeloma cells in bone is not yet clear and warrants further investigation.  
Data from the current study provides strong clinical rationale to support the early use of bone 
modifying agents such as ZA which may be beneficial for both the prevention of tumour-induced bone 
disease as well as reduction in tumour burden. The present study showed that ZA treatment 
significantly extended disease-free survival and was not dependent on whether ZA treatment was 
initiated prior or at the time of tumour cell injection. Similar results were shown in both in vivo 
preclinical studies and human trials (Croucher et al., 2003a, Morgan et al., 2010b). 
The present study is the first to show that anti-tumour effect of ZA in MM is dependent on the time of 
initiation of treatment. In this model, it is clearly shown that only ZA treatment initiated prior to 
tumour cell injection inhibited tumour burden (day 21) whereas treatment initiated after tumour cell 
injection did not, although both treatment strategies effectively suppressed bone remodelling. 
Moreover, both treatment strategies did not affect the process of tumour expansion from single cells to 
the formation of myeloma colonies during the early stages (day 10) of disease. The fact that no 
reduction in late stage tumour burden, despite effective suppression of osteoclastic bone resorption 
following ZA treatment, post tumour cell injection shows that the 5TGM1 model may not be 
dependent of the so called ‗vicious cycle‘ for tumour expansion. Therefore, it is evident that the anti-
tumour effect observed with ZA (pre-treatment) under this experimental condition is clearly due to the 
early induction of treatment prior to the tumour cell arrival in bone. However, the mechanisms 
responsible are not understood from the current experiment. Moreover, in the 5TGM1 model, 
development of osteolytic disease was seen as early as 10 days without any measurable alterations in 
bone remodelling such as an increase in osteoclastic bone resorption or a decrease in osteoblastic bone 
formation. However, it is well established that myeloma induced bone lesions are due to tumour-
induced uncoupling of bone remodelling. This suggests that bone histomorphometry and serum levels 
of bone turn-over markers used in the present study may not have been sensitive enough to detect 
minor changes in bone remodelling and may need to be investigated further. 
Future directions 
In this study, the murine model of myeloma was developed by injecting 2 X 10
6
 5TGM1-eGFP-DID cells 
into young (aged 6-12 weeks) C57BL/KaLwRij mice. The use of young mice in these experiments posed 
a major setback as MM is primarily a disease of the elderly. Young rodents are frequently used for the 
development of animal model of bone metastasis owing to high bone remodelling, active blood flow 
and a tortuous capillary network in the metaphysis of the long bones which promotes tumour cell 
retention and development (Rosol et al., 2003). However, Glick et al., (2013) showed that old mice 
(aged 18-20 months) supported the growth of myeloma better than young mice (aged 2-3 months) 
using 5T33MM cells injected in to wild type C57BL/6. Moreover, bone remodelling in young is high 
when compared to older rodents and this difference in the remodelling frequency may very well 
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influence the bioavailability of bone-modifying agents such as ZA. Therefore, using older mice will be a 
better option for myeloma model development as it will be a better reflection of the clinical scenario 
with stable bone remodelling as MM is a disease of the elderly.  
For the first time, subpopulations of ‗quiescent‘ myeloma cells close to bone surfaces were identified 
during the late stages of tumour development. This suggests that within the BM specific niches exist 
which may render tumour cells dormant. It will therefore be interesting to characterise the ‗quiescent‘ 
myeloma cells and define the niche they reside in the BM. For this purpose, the quiescent myeloma 
cells can be separated from the BM by fluorescently activated cell sorting (as the quiescent population 
were DID labelled) and analysed to determine whether these quiescent cells express cell surface markers 
similar to the HSC‘s and therefore whether they hijack the HSC niches which will render them in a 
quiescent state. To test the hypothesis that myeloma cells compete with HSCs to occupy endosteal 
niches, in vivo competitive engraftment assays between the myeloma cells and the HSCs can be 
performed to determine the cell type that preferentially localises to the BM endosteal niche. (Shiozawa 
et al., 2011). Alternately, as HSC endosteal niches are made up of cells of the early osteoblastic lineage, 
using a conditional osteoblast knockout mouse (Col2.3Δ-TK), it would be possible to ablate the 
osteoblasts and see whether this affects the homing of the myeloma cells to bone Similar works were 
performed in a prostate cancer model by Shiozawa et al., (2011). Finally, in the present study, it has 
been clearly shown that the quiescent myeloma cells resided closer to bone. It will be therefore 
interesting to define the location and components of these niches within the BM. As the cells are DID 
labelled, immunohistochemical techniques can be used to identify neighbouring cells such as osteoclasts, 
osteoblasts or HSCs by appropriate fluorophore labelled antibodies. Similar techniques were used by 
Iriuchishima et al., (2012) who showed that myeloma cells form complexes with osteoclasts and 
osteoblasts in the endosteal region of the long bone. 
In this study a novel multiphoton microscopy method was developed to visualise fluorescently tagged 
myeloma cells in bone. This technique can be further extended to determine whether ZA can directly 
inhibit myeloma cell growth in vivo. Although several studies have shown that ZA directly inhibit 
myeloma cell growth in vitro, whether ZA can be internalised by myeloma cells in bone is not known. 
Roelofs et al., (2010) demonstrated the fluorescently labelled RIS are internalised into bone resorbing 
osteoclasts. Similar experiments may be helpful to determine whether ZA can be internalised by 
myeloma cells in the BM. 
Finally, this thesis has clearly shown that ZA has anti-myeloma activity in the 5TGM1 murine model of 
myeloma if initiated prior to tumour cell injection. Previously, results from several preclinical and 
human clinical trials also suggested that ZA possessed anti-myeloma activity. In clinical scenarios, ZA is 
used as an adjunct along with standard myeloma chemotherapy. The effect of ZA in combination with 
other standard chemotherapeutic agents can be tested to see whether a combination treatment will 
evoke a better anti-tumour response in MGUS.    
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